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ABSTRACT
ALARMING IMMUNITY: A WAKE UP CALL FOR CD8 T CELLS
USING GENETIC ADJUVANTS
(IL-33 AND ISG15)
Daniel Villarreal
David B Weiner

There exists a paramount need for effective vaccines against cancer, TB, malaria, HIV,
HCV, and other chronic infections. The hope for long-term control of these important
diseases ultimately may depend upon development of potent T cell-based therapeutic
vaccines. However, current, licensed vaccines or capable vaccine platforms have not
made a substantial impact on treatment of these conditions, likely due in part to poor
CD8 T cell immune induction. Thus, identification of novel adjuvants to be deployed to
induce effective T responses is an important area of research in T cell based vaccines.
While multiple adjuvants have been readily identified which impact CD4 T cells, it has
been a challenging task to identify adjuvants that can amplify CD8 T cell responses. In
this regard, Interleukin 33 (IL-33) and Interferon Stimulated Gene 15 (ISG15) have
emerged as immunomodulatory molecules facilitating the generation of TH1-mediated T
cell immunity; however, their ability to function as vaccine adjuvants to enhance CD8 T
cell immunity was not previously explored. Here we used a DNA-vaccination approach to
investigate the effect of IL-33 and/or ISG15 on vaccine-induced CD8 T cell immune
responses. My studies showed that both IL-33 and ISG15 served as effective vaccine
adjuvants to enhance the antigen-specific, polyfunctional, and cytolytic effector CD8 T
cell responses in vivo. Importantly, I demonstrate for the first time the efficacy of both
v

IL-33 and ISG15 as DNA vaccine adjuvants in driving viral or tumor protective immunity.
Consideration of our findings, combined with a further understanding of the functional
roles of these molecular adjuvants in immune expansion, likely will aid in the
development of therapies for augmenting T cell based responses against many
infectious diseases and cancers.
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CHAPTER 1

GENERAL INTRODUCTION

“If I have seen further it is by
Standing on the shoulders of giants.”
—Isaac Newton

1

Vaccination is one of the greatest triumphs of modern medicine. Immunization
eradicated smallpox in 1976 and has nearly eradicated polio from this world (1,2). In
addition, the substantial reduction of the number of incidences of measles, mumps,
diphtheria, and tetanus worldwide are examples of the incontrovertible success of
vaccines in the prevention and protection against infectious pathogens (2). Many of the
aforementioned vaccines are based on live attenuated or whole-killed organisms, as
they mimic a live infection without causing disease. These traditional vaccines
occasionally have well-known safety issues such as reversion, incomplete inactivation of
virus and/or transmission of virus to immunocompromised individuals that deem them
inappropriate for certain populations. Thus, alternative vaccine formulations, such as
subunit, conjugate, toxoid and DNA vaccines, which contain only target proteins, are
used to reduce the drawbacks concerning traditional vaccines. However, these
alternative vaccine approaches are often poorly immunogenic as a result of its limited
antigenic targets. Therefore, the addition of adjuvants has become a key method for
enhancing the protective immunity generated by current vaccination.

Adjuvants
Adjuvant is derived from the Latin word adjuvare which means to help. It was first
termed by Ramon Gaston, a French veterinarian, who defined it as a substance that
enhanced immune responses to an antigen (3). Subsequently, Gleeny and colleagues
would be the first to report the critical role adjuvants played in the effectiveness of
vaccines. Gleeny et al. demonstrated the adjuvant activities of aluminum compounds,
observing a 1,000 fold increase in antibody production when using an alum precipitated
diphtheria toxoid vaccine (4,5). Since then, aluminum based adjuvants (aluminum
hydroxide, aluminum phosphate, aluminum sulfate (alum)) have been used successfully
2

in vaccines for over 80 years for promoting the enhancement of antibody responses.
Today, alum adjuvants can be found in several vaccines, such as Gardasil (HPV), DTaP,
HBV, Haemophilus influenza B (HIB) and pneumococcal vaccines (Table 1) (6).
Adjuvants currently licensed to be used in human vaccines in the US and/or Europe
include aluminum-based salts, oil-in-water emulsions (MF59, AS03) and AS04
(monophosphoryl lipid A preparation (MPL) with aluminum salt) (Table 1.1). Due to the
attractive property of adjuvants to promote and modulate vaccine immunogenicity they
have become an increasingly important ingredient in novel vaccines being developed
today.
Adjuvants, in the context of vaccines, are defined as substances that enhance
and/or shape antigen (Ag)-specific immune responses. For new vaccines in
development, adjuvants are increasingly used to promote types of immunity not
effectively generated by the nonadjuvanted antigens. A variety of compounds have been
examined as adjuvants including mineral salts, emulsions, microparticles, saponins,
microbial products, liposomes and cytokines (7,8). Based on their proposed mechanism
of actions, adjuvants can be divided into two classes: delivery systems and
immunostimulatory adjuvants (7,9). Delivery systems concentrate and present vaccine
antigens to antigen presenting cells (APCs) and help colocalize antigens and immune
potentiators to increase specific immune responses (7,10). Immunostimulants, such as
cytokines or bacterial components, activate immunity directly or through pathogen
recognition receptors (PRRs), respectively, to increase the immune responses to
antigens (7). Despite the wide use of adjuvants in vaccines, the underlying mechanisms
by which they potentiate immune responses are not well characterized. However,
available evidence suggest that adjuvants induce immune responses by a combination
of the following mechanisms: (i) activation, maturation and migration of APCs to the
3

draining lymph nodes, (ii) induction of cytokines ad chemokines; (iii) enhancement of
cellular recruitment of important immune modulating cells at the site of injection; (iv)
increase antigen uptake and presentation to APC; (v) activation of PRRs and
inflammasomes (11). Both delivery systems and immune potentiators serve to augment
vaccine-induced Ag-specific responses in vivo. Clearly, since adjuvants can affect the
immune responses in different manners, inducing humoral vs cellular immunity, wellinformed and rational selection of adjuvants will contribute to development of effective
new specific vaccine formulations.

Major Benefits of Adjuvants
Adjuvants can have a variety of other beneficial advantages besides the
traditional role of being used to improve the immunogenicity of vaccine immune
responses (Figure 1.1). First, adjuvants can enable the use of lower vaccines doses,
greatly expanding the supply when large-scale vaccination is urgent in the case of a
major pandemic outbreak of infection (12). Second, vaccines can benefit from suitable
adjuvants by inducing a more rapid immune response and thus reducing the number of
immunizations to achieve effectiveness (13-15). This approach would be beneficial for (i)
vaccine delivery in parts of the world where compliance can be an issue and (ii) for the
development of biodefense vaccines against potential bioterrorism weapons where a
single-shot vaccine would be critical. A third advantage of adjuvants would be
broadening the repertoire (breadth and/or specificity) of antibody responses, which could
be crucial to the success of vaccines targeting pathogens that undergo antigenic drift or
strain variation (16-18). Finally, a major role for the inclusion of adjuvants would be to
aid in the development of new effective therapeutic T cell inducing vaccines. These are
4

practical applications by which adjuvants can be specifically used to improve future
vaccines for unmet needs.

Importance for T Cell-Based Vaccine Adjuvants
Although widespread use of vaccines with adjuvants has had an extraordinary
impact on global health, there remain many infectious and other diseases for which
vaccines are not available. The difficult challenge remains in developing adjuvants that
generate effective CD8+ T cell responses for chronic viral infections and for therapeutic
treatment of cancers. Historically given that most vaccines confer protection through
humoral immunity (19), it led to the development of adjuvants focused at inducing and/or
enhancing antibody responses. As a consequence, a major limitation of the currently
licensed vaccine adjuvants are ineffective at inducing CD4 T helper 1 (TH1), especially
CD8 T cell immune responses (20,21), which are required for either controlling or
preventing the onset of chronic infections and cancer. Therefore, they are not optimal for
many of the challenges in vaccination today. And given that there are still no effective
vaccines against Tuberculosis (TB), Malaria, HIV, or for cancer therapy, developing
adjuvants that can generate potent and durable protective T cell immunity will have a
profound clinical impact for a variety of diseases. This underscores the critical need to
develop vaccines with appropriate adjuvants capable of evoking the desired potent and
durable Ag-specific CD8 T cell immunity.

5

CD8 T cells
The goal of successful vaccination is the induction of the potent CD8 memory Tcell populations to rapidly control infection or disease. CD8 T cells are an important
component of the immune response to infection and cancer (22-25). CD8 T cells (as
known as cytotoxic T lymphocyte, CTL, cytolytic T cell, Tc, or killer T cells) mediate their
effector functions through production of cytokine such IFNγ and TNFα and/or secretion
of perforin or granzyme (23,26). After infection or immunization, Ag-specific CD8 T cells
respond in 3 distinguishable phases: expansion, contraction and memory (23,27,28).
When naïve CD8 T cells are primed they undergo clonal expansion when its TCR comes
in contact with its cognate peptide-bound MHC class I molecule presented by APCs.
After activation it culminates in a higher frequency of antigen-specific CD8 T cells that
can enter the blood and migrate to the site infection inducing rapid effector function
capable of killing infected cells. CD8 T cell activation is also dependent on a second
signal, which is the engagement of the CD28 molecule on the T cell with the
costimulatory molecule CD80 and CD86 expressed on APCs. In addition, simultaneous
external influences, such as the presence of inflammation and cytokines (e.g. IL-2, IL-12,
IL-7, IL-15) are also essential for T cells to undergo full T cell proliferation and
differentiation into Ag-specific memory T cells (29-32) (Figure 1.2). After pathogen
clearance, the Ag-specific CD8 T cells undergo contraction, where the bulk of the
effecter T cells die. However, a small number of effector cells survive, leading to
established long-loved CD8 memory T cell subsets, which are the basis for protective
immunity against infection and diseases (33). Thus, given that CTLs can survive long
term in the absence of antigen and provide protection against recurrent infections
(26,34,35), enhancing the quantity and quality of memory CD8 T cells is the ultimate
6

goal for improving the efficacy of most vaccines.

DNA Vaccines
In recent years, improved DNA vaccines have now reemerged as a promising lead
candidate for therapeutic intervention due to their ability to potently induce CD8 T cell
immunity in humans (15,36-38).
The DNA vaccine platform first came into the spotlight in the early 1990s, when it
was reported that the delivery of plasmid DNA into the muscle induced an immune
response against encoded viral antigens (39-41). In 1993, Wang et al. were the first to
show immune responses against a chronic viral infection (40). Subsequently, Margaret
Liu et al. (39) and Harriet Robinson et al. (41) both independently reported that injecting
plasmid DNA encoding influenza A nucleoprotein intramuscularly generated both
humoral and cellular immune responses against influenza virus antigens in mice.
Subsequently, David Weiner and colleagues at the University of Pennsylvania would
show that DNA plasmids carrying HIV antigens engendered the induction of both Agspecific antibodies and cytotoxic T lymphocytes (CTLs) (42). These findings introduced
the potential of DNA as an immunization platform.
DNA vaccination has been suggested as an ideal therapeutic strategy due to
numerous advantages over competing platforms. For example, DNA vaccines are nonlive and non-replicating and thus unable to revert into virulent form, unlike live vaccines.
Furthermore, DNA vaccines are highly customizable and hence, multiple antigens can
be encoded within a single DNA plasmid. This allows for a much greater breadth in the
host immune response and better protection as different epitopes can elicit different
types of immune responses (43). In addition, individuals receiving DNA vaccines are
unlikely to harbor anti-plasmid vector immunity, as seen with adenovirus vectors. For this
7

reason, DNA therapeutic vaccinations can be delivered repeatedly without initiating an
immune response against the DNA plasmid (44,45).

Moreover, DNA vaccines are

simple and inexpensive to construct, can easily be produced in large quantities, are
more temperature-stable than conventional vaccines, and can be easily stored and
transported (45). Finally, DNA encoded antigens can be processed via both MHC class I
and MHC class II pathways. Thus, DNA vaccines can drive the diverse induction of TH1,
TH2 and CD8 T cell responses, unlike recombinant protein vaccines that mainly drive TH2
skewed responses. These advantages may help contribute to the successful delivery
and administration of therapeutic vaccines to infected individuals in developing nations.
The success of DNA vaccines in preclinical studies quickly lead to clinical trials,
and the idea of using DNA to immunize people immediately gained widespread
recognition. The first DNA vaccine studies in humans were conducted over 15 years
ago. The goals of the various studies were to evaluate and demonstrate the safety,
tolerability and immune potency of the DNA vaccines. In the first Phase I clinical trial, a
DNA vaccine for HIV-1 infection was evaluated for both therapeutic and prophylactic
applications (46). Soon other DNA vaccine trials would follow, including trials that tested
DNA-based vaccines against other HIV antigens, HBV, and malaria (47-49). These
introductory studies established that DNA vaccines were tolerable in humans, and that
they could enhance T cell proliferation and CTL activity (50,51), although the immune
responses elicited were weaker than expected based on preclinical data. Although ‘firstgeneration’ DNA vaccines failed to demonstrate a robust level of vaccine-specific
immunity in humans, extensive research continued to develop new modifications and
improvements to the technology to enhance DNA efficacy.
To date, a plethora of approaches have been conducted to significantly improve
the immunogenicity elicited by DNA vaccines, and as a result has sparked great
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excitement and interest in the DNA platforms to be examined for therapeutic approaches
and vaccines for unmet needs. These efforts have included optimization of the vaccine
vectors (e.g. RNA/codon optimization) and antigens encoded by the plasmids (e.g.
consensus sequences) to enhance antigen expression and cellular/humoral crossreactivity (45,52); and in vivo electroporation (EP), a promising delivery method that
improves the expression and presentation of antigens expressed by DNA vectors (45).
EP is a simple, direct approach that involves the application of short electrical pulses to
the vaccine delivery site. This transiently increases cell membrane permeability allowing
for increased plasmid uptake and increased expression in the target tissue of mice, pigs
and rhesus macaques (45,53-56). Although the mechanism for DNA delivery by EP is
not fully understood, the procedure has improved plasmid transfection efficacy by a
factor of 100 fold or greater and as result, has increased immunogenicity of DNA
vaccines in both small (mice, guinea pigs, and rabbits) and large animal models (pigs,
rhesus macaques, and chimpanzees) (56-64). DNA vaccination in combination with EP
is a novel, safe, and effective strategy that elicits a strong, broad, and long-lasting
humoral and cellular immune responses. EP is advantageous as a vaccine delivery
approach because it can broadly activate CD8 cytotoxic T cells (CTL) that eliminate cells
infected with intracellular pathogens. Thus, EP has been successfully used to enhance
both cellular and humoral responses in small animal models and humans (55,56,65,66).
More recently, Bagarazzi M.L., et al. (38), have published exciting data on EP
administration with a DNA-HPV vaccine that opens many exciting new avenues for this
combined technology approach to treat or prevent against many human pathogens.
Bagarazzi and colleagues (38) reported that a therapeutic DNA vaccine co-administered
with EP on its own in humans could produce long-lived CD8 T cells with cytolytic activity.
The results also show that DNA delivered by EP is safe and tolerable (38). Finally, the
9

inclusion of molecular cytokine adjuvants to enhance, modulate and skew a desired
immune response has become a promising way for significantly enhancing the efficacy
of the DNA vaccine platform.

Cytokines
The human immune system is constantly in a perennial battle against infectious
agents that cause disease and often, death. Therefore, to resolve such conflicts the
immune system has developed countless strategies to effectively vanquish pathogenic
intruders. One essential tactic is the release of chemical messengers known as
cytokines. Cytokines are a group of proteins that promote copious biological functions
that help regulate and generate the immune system (e.g. inducing maturation of APCs,
differentiation of TH1 and TH2 cells, and inducing NK cells and CTLs) (67). Cytokine
activity is highly pleiotropic as many cells can produce one to several cytokines therefore
influencing many phenotypic traits of immune cells (68,69). They facilitate inflammatory
and proliferative responses, differentiation, and crosstalk between immune cells; cells
which perform the real-time fight against harmful pathogens that enter the body (68,70).
Because of their crucial role in triggering the innate and adaptive immune responses for
fighting off infections, certain cytokines, such as IL-2, TNFα, IL-15 and GM-CSF, have
been used as vaccine adjuvants to increase memory response against some infectious
diseases and cancer (68,71,72). Therefore, cytokines are promising vaccine adjuvants
for boosting the immune responses for the prevention, control, and treatment against
infectious pathogens and cancers.
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DNA Co-delivery with Molecular Adjuvants
One important approach with regard to increasing the potency of DNA based
vaccines is the ability to manipulate the immune response through co-administration of
cytokine genes. Genetic molecular adjuvants are normally administered as plasmids
encoding a specific cytokine, chemokine, or costimulatory molecule. Indeed, the addition
of immune modulatory adjuvants as part of a vaccine cocktail has been demonstrated to
boost the adaptive immune response (73). A number of groups have shown that cellmediated responses can be modulated both quantitatively and qualitatively through coimmunization with cytokine-expressing plasmids (Table 1.2). Specifically, it was
demonstrated that co-immunization with TH1 type cytokines (e.g. IL-12, IL-18) can
enhance cellular immunity and bias the immune response toward a TH1 type response,
while TH2-type (e.g. IL-4) cytokines can boost antibodies responses and promote a TH2type bias immune response (74,75). In choosing an adjuvant that provides a TH1 or TH2
biased response, it is important to consider which type of response may be more helpful
in contributing to protection. For example, Tuberculosis (TB) and Leishmania major
require a TH1-type response for effective immunity, while other parasitic and microbial
infections require a TH2-type response (76-78). This ability to modulate or enhance the
immune response in a defined manner has great promise to improve vaccine design and
development.
The exact mechanism by which DNA molecular adjuvants induces an immune
response is not fully understood. However, it is assumed first that after injection of DNA
plasmids encoding the antigen of interest and cytokine adjuvant, local APCs, myocytes,
monocytes or keratinocytes are transfected (45). Once cells are transfected, the plasmid
encoded antigens and cytokine genes are expressed. In the case of the antigen, it is
processed, and peptides are presented in the context of Class I or Class II MHC
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molecules by DCs, affording these cells to stimulate CD4 and CD8 T cells in the
secondary lymphoid organs (Figure 1.3). Meanwhile, as the antigen presentation by
DCs is perpetuating an immune response, the transfected cells are subsequently
producing the selected cytokine to help shape and augment the desired immune
responses (Figure 1.3).
The inclusion of different cytokines is actively being studied as a way to induce
and shape both innate and adaptive immune responses. For example, one of the most
studied and tested cytokine adjuvants has been IL-12. IL-12 a cytokine produced by DCs
supports the differentiation of Ag-specific CD4 T cells to produce TH1 cytokines as well
as prompts the expansion of Ag-specific CD8 T cells to express cytotoxic molecules,
such as granzyme B, perforin, and IFNγ (79). Kim J.J. et al. were the first to investigate
the role of co-delivery of IL-12 with DNA vaccines, observing an increase in specific CTL
responses when mice where coimmunized with a HIV-1 DNA vaccine plus an IL-12
plasmid (81). Moreover, IL-28, a cytokine that belongs to the Interferon III/lambda (IFNγ)
family cytokines has also been shown to play a role in the adaptive immune response
(82,83). Its inclusion as an immunoadjuvant during small animal and NHP vaccination
led to augmented Ag-specific TH1-biased responses, as well as an increased cytotoxic
potential in CD8 T cells (84-86). Finally, granulocyte macrophage colony-stimulating
factor (GM-CSF), a cytokine secreted white blood cell growth factor has also been used
a molecular adjuvant and has been shown to enhance both cellular and humoral
responses in mice and non-human primates (87-90). This indicated that our search for
improving effective vaccine-induced CD8 T cell responses for diseases where vaccines
are still needed such as HIV, TB, malaria and even cancer, may lie in the discovery of
novel molecular cytokine adjuvants.
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While certain immunoadjuvants have been shown to enhance the potency of TH1
vaccine-induced responses, it has been a challenge to find adjuvants that can enhance
polyfunctional CD8 T cell responses. Every year new insights into the biological
functions of cytokines or cytokine-like molecules are being discovered, with many still
waiting to be discovered. However, recently, two novel immunomodulatory molecules,
IL-33 and ISG15, have been demonstrated to drive Th1-type cell-mediated viral and/or
tumor immunity (91-93). Therefore, this led us to explore the use of Interleukin 33 and
Interferon stimulating gene 15 as effective vaccine adjuvants to boost a TH1 and CTL
immune responses, a desired result for effective vaccination against cancer and chronic
infections.

Interleukin 33 (IL-33)
Interleukin 33 (IL-33) was first described in 1999 by Onda H and colleagues who
identified it as DVS27—a 30-kDa protein highly expressed in canine vasospastic
cerebral cells (94). Six years later, through computational sequence comparison,
Schmitz and colleagues revealed that the C-terminal end of IL-33 contained a β-sheet
trefoil-fold structure characteristic of the Interleukin 1 (IL-1) family (95). IL-33 then
became the 11th identified IL-1 family member. Subsequently, IL-33 was recognized as
the functional ligand for the orphan IL-1 receptor ST2 (also called IL-1R-like-1) (95). ST2
is selectively expressed on the cell surface of TH2 cells and not on TH1 cells (95).
Therefore, IL-33 has been studied primarily for its role in the context of TH2 immunity and
TH2-related diseases such as asthma, atopic dermatitis, and anaphylaxis (95,97,98).
However, recent studies are beginning to show that IL-33 cytokine activities far exceed
the realm of TH2 immunity by promoting TH1 immune responses and influencing the
development of antiviral CD8 T cells (Figure 1.4) (91).
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While historically isolated from keratinocytes, epithelial cells, and endothelial
cells, IL-33 is now known to be released from a variety of tissue types as a proinflammatory cytokine (97-99). Specifically, IL-33 functions as an alarmin by signaling
tissue damage to local immune cells after exposure to pathogens, tissue damage, or
death by necrosis (Figure 1.5) (99). IL-33 is predominantly expressed at the epithelial
barrier as the first line of defense against pathogenic threats. Through its cognate
receptor ST2, IL-33 activates a variety of cells: hematopoietic cells, mast cells,
eosinophils, basophils, Natural Killer (NK) cells, Natural Killer T (NKT) cells, CD8 T cells,
TH2 lymphocytes, and non-hematopoietic cells (99). In addition, IL-33 signaling can be
negatively regulated by a soluble form of ST2 that lacks transmembrane domain, which
behaves as a decoy receptor (97,98,103) (Figure 1.5).
IL-33 exists in two biologically active isoforms: full-length IL-33 (proIL-33) and
mature IL-33 (mtrIL-33). These two isoforms can operate in at least two spaces—nuclear
and extracellular (100,101), highlighting IL-33 dual-function cytokine properties. The
nuclear space is the exclusive domain of proIL-33 and it is able to concentrate there via
its amino terminus that contains a non-classical nuclear-localization sequence and a
short chromatin-binding motif (99). This is where IL-33 is usually found; however, when
released by inflammation or stimulation, proIL-33 is often digested into mtrIL-33, a form
with a lower molecular weight (18-kDa). Unlike proIL-33, mtrIL-33 is not capable of
localizing into the nucleus because it lacks the N-terminal nuclear-localization sequence.
Currently, the nuclear function of proIL-33 is unclear, but recent studies have suggested
it may play a role in transcriptional repression and chromatin compaction (100,102).
Extracellular proIL-33 and mtrIL-33, on the other hand, are known to bind to their
cognate receptor ST2, activating the MyD88-signaling pathway which induces the
production of various cytokines and chemokines or causes cell differentiation,
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polarization, and activation, depending on the target cell (Figure 1.5) (103,104). While
one might assume that they induce similar effects because they bind to the same ST2L,
Luzina et al. demonstrated that proIL-33 can promote inflammation differently from
mtrIL-33 in an ST2-independent fashion (Figure 1.5) (105). This study showed that
compared to proIL-33, mtrIL-33 produced a strong TH2-skewing cytokine profile (105).
However, the processing and release of IL-33 appears cell-type specific and how proIL33 is digested into mtrIL-33 is still a matter of debate (99).

IL-33’s Role in Antiviral and Antibacterial Immunity
Multiple groups have shown that IL-33 activity is primarily associated in driving
TH2-immune responses, particularly in augmenting cytokine levels of IL-4, IL-5 and IL-13
(98). However, it is now beginning to surface that IL-33 has functions that surpass TH2
immunity as it can contribute to the development of TH1-type immune responses and
promote CD8+ T cell responses (99).
Given its ability to direct these TH1-type immune responses, it is reasonable to
suggest IL-33 may also be essential in inducing protective immunity against viral
infections. Some of the 1st studies to implicate IL-33’s pro-TH1 cytokine activities
observed its biological target on NKT cells (106,107). These studies showed that
exposure to IL-33 privileged the production of IFNγ by NKT cells in response to TCR
engagement and in the presence of IL-12. More recently, several studies have shown
that this activity was not restricted to NKT cells. Yang et al. showed that CD8+ T cells
can also express ST2 and respond to IL-33 (108). They reconfirmed the notion that IL-33
synergizes with TCR and/or IL-12 signaling to augment IFNγ production in effecter CD8
T cells (108). Consistent with these findings, Bonilla et al. showed that following LCMV
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infection in mice, roughly 20% of activated Ag-specific CD8 T cells expressed ST2 (91).
Subsequently, Sesti-Costa et al, demonstrated in a Coxsackie virus infection model, that
mice treated with recombinant IL-33 (rIL-33) increased IFNγ and TNFα secretion by CD8
T cells and NK cells, which correlated with viral clearance of Coxsackie virus (109).
These studies provide evidence that IL-33 can drive protective antiviral CD8 T cell
responses in vitro and in vivo.
On the hand, studies on IL-33’s protective role against bacterial infections have
been limited and are only beginning to be appreciated. Li et al showed in a mouse model
of S. aureus skin infection, delivery of rIL-33 improved antibacterial defense by activation
of nitric oxide in macrophages (110). Moreover, a recent study by Lee et al. reported a
positive correlation between IL-33 and IFNγ levels in patients with TB pleurisy (111).
Clearly, IL-33 likely has protective antibacterial properties, however, more studies are
needed to understand its role during bacterial infections. Together, these studies give
insight into IL-33’s new biological activity to direct TH1 and effector CD8 T cells and its
essential role in driving protective immunity against viral and bacterial pathogens.

IL-33’s Role in Antitumor Immunity
There is a plethora of studies about the pleiotropic cytokine activities of IL-33 and
its role in inflammation and its association with allergy and autoimmune diseases
(97,98). However, its role in antitumor immunity and antitumor growth is only beginning
to surface. Several recent studies have highlighted the important role of IL-33 in
experimental mouse tumor models and have shown that IL-33 can drive antitumor CD8
T cell responses. Gao et al. used B16 melanoma and Lewis lung carcinoma (LLC)
metastatic models to show that transgenic expression of IL-33 inhibited tumor growth
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and metastasis in mice (92). Transgenic expression of IL-33 and delivery of recombinant
IL-33 increased the infiltration of CD8 T cells and NK cells into the tumor and also
increased their cytotoxicity both in vitro and in vivo (92). This study provides further
evidence that IL-33 promoted the proliferation and activation of CD8 T cells and NK cells
by activating the intracellular molecule nuclear factor-κb (NF-κb) and suggests a
mechanism by which IL-33 might promote CD8 and NK activation and expansion. In
addition, Gao et. al. recently also reported that tumoral expression of IL-33 can inhibit
tumor growth and modify the tumor microenvironment by promoting the function of CD8
T and NK Cells (112). Interestingly, recent reports have reported that increase levels of
IL-33 in human cancers may have a correlation with better diseases prognosis in HPV
cervical cancer (113) or associated with hepatocellular carcinoma prolonged patient
survival (114). Together, these studies demonstrate the notion that IL-33 increases the
formation of Ag-specific CD8 T cells and reveals that IL-33 has immunotherapeutic
implications in driving immune responses against cancer.

Interferon Stimulated Gene 15 (ISG15)
Interferon stimulated gene 15 (ISG15) was identified in 1984 by Ernest Knight Jr
and colleagues as a 15kDa protein induced by type 1 interferons (IFNs) (115). Three
years later, Haas and colleagues, showed a resemblance between ISG15 and ubiquitin
(116). The crystal structure of ISG15 showed its similarity to ubiquitin by revealing that
ISG15 consisted of two ubiquitin-like domains, located at its N-terminal and C-terminal
ends of the protein (117). ISG15 is synthesized as a 17kDa precursor that is cleaved at
its C-terminal domain to yield the mature form of ISG15 (118). Unlike ubiquitin which is
highly conserved, ISG15 varies between species (119). However, similar to ubiquitin, the
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mature form contains the ubiquitin-like C-terminal LRLRGG motif that is essential for
covalently attaching itself to the lysine residues of target proteins by an E1-E2-E3
enzyme process called ISGylation (Figure 1.6) (117). This enzymatic cascade that is
similar to, yet distinct from that of ubiquitin conjugation has been studied in great detail
and has been reviewed elsewhere (93,119-121). Several proteomic strategies have
been conducted to catalogue ISGylated proteins, identifying more than 300 candidates
(122). However, how ISGylation affects their cellular distribution and function remains to
be elucidated (123). ISG15 is one of the most highly induced transcripts after type 1
IFNs

stimulation

or

other

stimuli,

such

as

exposure

to

viral

infections,

lipopolysaccharides, and TNFα stimulation (93). These types of stimuli activate
transcription factors in IFNs signaling, mainly IRF3 and ISGF3 (119-123), which in turn
upregulate expression of ISG15 (Figure 1.6). For instance, in Type I IFN receptor R1
knockout mice, ISG15 production significantly decreases upon treatment with Gramnegative bacteria lipopolysaccharide (LPS) or viral infections (93), suggesting that
induction of Type I IFN secretion triggers ISG15 expression. Therefore, ISG15 is
essential for the control of certain viral and bacterial infections.

Antiviral and Antibacterial Activity of ISG15
Frist, given that IFNs play an important role during viral infections, and second,
that ISG15 and its ISGylation are strongly induced by Type 1 IFNs, many studies have
explored their contribution to antiviral activities (93,125). Briefly, several in vitro
challenges have shown that ISG15 can regulate viral growth or titers of Dengue, West
Nile, HIV, Ebola, Japanese encephalitis and Influenza A virus (93). For instance, the
delivery of small interfering RNA knockdown of ISG15 in wild-type murine cells or human
airway epithelia cells were found to increase the titers of dengue virus and influenza A
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viral titers, respectively (93). Moreover, increase lethality has been observed in ISG15-/mice after infection with Influenza A and B viruses, herpes simplex virus type 1, Sindbis
virus and Chikungunya (93). ISGylation does not usually cause substrate degradation
like ubiquitin (119,123), but can function to regulate protein levels, signaling pathways,
vesicular trafficking, and numerous other undefined regulative roles (119). While, it is
known that ISG15 conjugates to hundreds of target proteins, how ISG15 conjugation
mediates a broad range of protection still remains to be fully elucidated (93,126).
Although a number of studies have shown ISG15 antiviral protective properties, no
studies have evaluated ISG15’s biological role during bacterial infection or its protection
in vivo. ISG15 mediated protection against bacterial infection is largely unknown and
future studies are warranted.

Antitumor Activity of ISG15
ISG15 has also been implicated in host defense pathways that serve antitumor
functions. To initiate the process of ISG15 conjugation (ISGylation), ISG15 must first
utilize the E1 enzyme (UBE1L) (Figure 1.6) (93). Without this enzyme ISGylaton of
specific target proteins cannot occur. UBE1L has been demonstrated not to be detected
in all human lung cancer cells lines (122-124), implicating a tumor-suppressive role of
ISGylation and suggesting the potential role of ISG15 in facilitating tumor control or
immunity. Human leukemia cells have also been found to lack functional E1 enzymes
and inducing ectopic expression of UBE1L restore ISGylation and enhanced IFN
signaling (127). Moreover, ISG15 has also been reported to be induced during cancer
chemotherapies, as studies have shown that ISG15 was upregulated following
camptothecin treatment of colorectal and breast cancer cells (122-124). Collectively,
these studies potentially demonstrate that reduced ISGylation may be linked to a
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malignant phenotype, and enhanced ISGylation correlated with the therapeutic response
to anticancer signals. In contrast, a few studies have also demonstrated that
overexpression of ISG15 or ISGylation positively correlated with tumorgenesis (122124). This relationship is complex and a universal consensus on the relationships
between ISG15 and tumor development is still missing. A similar yin and yang role in
human cancers have also been reported for other cytokine mediators such as IL-2 and
HGMB1 (128,129). A better understanding of the potential function of ISG15 in tumor
immunity or in the tumor microenvironment requires future studies. Nevertheless, given
ISG15’s ability to be induced by a diverse stress of stimuli, suggests that it may serve
broader functions beyond the innate immune response.

Free ISG15 Modulates Immune Responses
In addition to its conjugated form, ISG15 can also exist in a free unconjugated
form both intracellularly and extracellularly (Figure 1.6). Both forms of free ISG15 could
influence cellular functions. For instance, intracellular free ISG15 has been shown to
control the ability of Ebola VLPs to egress from cells in vitro (93,130). Over expression of
ISG15, independent of the conjugation cascade, consequently decrease Ebola VP40
VLP release (93,130). More interestingly, the secreted ISG15 form can act as cytokine
and modulate the immune responses (125). ISG15 is synthesized in many cells and has
been shown to be secreted by monocytes, lymphocytes and neutrophils in vitro (126).
The underlying mechanism of how ISG15 is secreted from the cell remains unknown.
The secretion of free ISG15 was first described in the early 90s by Ernest Knight Jr and
Beverly Cordova demonstrating secretion of ISG15 from human lymphocytes and
monocytes (131). Subsequently, Ernest Knight Jr and colleagues would report on its
function to induce secretion of IFNγ from peripheral blood mononuclear cells (PBMCs)
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(132). Five years later, in 1996, Ernest C. Borden and colleagues would confirm the
immunoregulatory properties of ISG15 to induce IFNγ production from PBMCs (133).
Although given these exciting results of ISG15 cytokine-like properties, no further studies
on free ISG15 would be made for almost two decades. In 2012, Casanova and
colleagues would reconfirm the cytokine-like role for ISG15 by demonstrating that
ISG15-deficiency was associated with a loss of IFNγ, which in turn led to increased
susceptibility to mycobacterial disease in both mice and humans (134). They
reestablished that ISG15 can induce IFNγ production in PBMCs and also demonstrated
that NK cells upregulate IFNγ production in respond to recombinant ISG15. These
collected studies support the ability of free ISG15 to function as an immunomodulatory
molecule to regulate IFNγ production and that ISG15 contributes to host protection
against infectious disease through both conjugation-dependent and –independent
modes of action. Therefore, given that ISG15 has been implicated in the regulation of
IFNγ and NK cells, both which are important mediators of viral and tumor immunity, it is
conceivable that ISG15 could be used as a vaccine adjuvant to help fight pathogenic
infections or even cancer. The mechanism by which all three forms of ISG15 exert
antiviral or antitumor effects is an important area of research that remains poorly
understood.
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Goals of this Thesis
CD8 T cells play a crucial role in mediating protection against cancers and to a
variety of chronic infections, including HIV, tuberculosis (TB) and malaria. An overall
shortcoming of currently licensed vaccines, especially non-live vaccines, is their inability
to generate effective CD8 T cell responses. One way to improve the quantity and quality
of immune responses during vaccination is to incorporate adjuvants, which have been
shown to help increase their immune potency. However, it has been a challenge to
discover adjuvants that can amplify the induction of CD8 T cell responses. This
highlights the need to develop new vaccine adjuvants capable of inducing potent and
durable CD8 T cell immunity in human-kind.
Different vaccine platforms have been studied, but the development of DNAbased vaccines in conjunction with immunomodulatory ‘cytokine’ adjuvants has emerged
as particularly promising for inducing Ag-specific CD8 T cell-mediated immune
responses (15). Recently, two immunomodulatory molecules have been demonstrated to
play a role in inducing TH1-type cell-mediated immunity: cytokine IL-33 and cytokine-like
molecule ISG15 (91-93). Therefore, in this thesis, I tested the hypothesis that both IL-33
and ISG15 delivered as molecular adjuvants can increase the CD8 T cell potency of
DNA vaccines. Specifically, I proposed that IL-33 and ISG15 can act as vaccine
adjuvants to enhance the CD8 T cell immunity against intracellular chronic pathogens
and tumors. I used different disease models to study the efficacy of IL-33 and ISG15 as
DNA vaccine adjuvants. Additionally, this thesis aims to give further insight into the
biological function of IL-33 and ISG15 to modulate the cell-mediated immune responses.
Overall, I believe that identifying new molecular adjuvants that elicit effective vaccineinduced CD8 T cell immunity may be critical for the elimination of many challenging
diseases including TB, HIV, malaria and cancers.
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FIGURES

Table 1.1. Licensed adjuvants in humans

Ab, antibodies; MPL, monophosphoryl lipid A; Th1, CD4 T helper 1; Th2, CD4 T helper 2
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Figure 1.1. Major benefits of adjuvants. These are all factors by which idea adjuvants
can be used to improve future vaccines against many challenging diseases where no
effective vaccines still exist.
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Figure 1.2. CD8 T cell priming and activation. When innate cells interact with
pathogen-associated molecular patterns (PAMPs), damage-associated molecular
patterns (DAMPs) or some inducible signal, the immune system is initiated (Signal 0).
Dendritic cells uptake protein antigen, process it into smaller peptide fragments and load
them onto MHC Class I or II molecules. These mature DCs with highly upregulated
costimulatory molecules due signal 0, then migrate to the draining lymph nodes where
their MHC-peptide complex can be recognized by the T cells expressing the matching
cognate T cell receptor (TCR) (Signal 1). For proper activation of CD8 T cells they
require a second signal, provided by binding to costimulatory molecules CD80 and CD86
on APC by CD28 (Signal 2). As a result, CD8 T cells secrete effector cytokines and
cytotoxins, which can directly kill pathogen infected cells or tumor cells. In addition,
proinflammatory and cytokines are also essential for proper activation, differentiation and
expansion of memory CD8 T cell subsets or can further amplify costimulatory molecules
(Signal 3).
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Figure 1.3. Proposed mechanism of DNA vaccination with molecular adjuvants. (1) Vaccine
formulation containing two separate DNA plasmids, one that contains the antigen target and the other that
contains the immune adjuvant gene, is administered in the muscle followed with electroporation. After
immunization, myocytes (2a), resident antigen presenting cells (APCs) (2b), and other cells (e.g.
keratinocytes, monocytes) (2c), are transfected with the plasmids, leading to protein and cytokine
production. The protein processed and/or released by transfected cells are presented in the context of MHC
class II (3a) or MHC class I (2b) molecules which stimulate CD4 and CD8 T cells, respectively. Peptides can
also be presented on MHC class I by cross-presentation due to APCs engulfing apoptotic or necrotic bodies
(4). Meanwhile, the transfected cells are simultaneously secreting the gene (e.g. cytokines or chemokines)
adjuvant which in turn facilitates the recruitment of many various immune cells to the site. All these events
lead more effective maturation and activation of immune cells. Mature antigen-loaded APCs then migrate to
the draining lymph nodes (5) to interact with antigen-specific B and T cells (6) to activate both B (antibody
secreting) and T cell (effector CD8) responses (7). These activated lymphocytes can now migrate to the
inflammatory sites to provide protection against infectious diseases (8). At the infection site these activated
lymphocytes could be restimulated and further expanded at the site of immunization by transfected cells
(2c). In addition, the secretion of the selected adjuvant by transfected cell at site can lead to further
enhancement of immunological parameters, perpetuating proper expansion and differentiation of memory T
cells, thus leading to the proper establishment of immunological memory. Therefore, upon reinfection the
established surveillance memory system could rapidly and effectively respond.
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Figure 1.4. Interleukin 33 effects on innate and adaptive immune cells. Interleukin
33 (IL-33) can be secreted by neutrophils, macrophages, DCs, fibroblasts, but it is
mainly secreted by epithelial and endothelial cells and is released in response to
external stimuli or passively secreted due to tissue damage or cell neurosis. IL-33 has
pleiotropic activities that act on a variety of innate and adaptive immune cells. The key
effects they have on some of these cell types are indicated. DC, dendritic cell; IFNγ,
interferon-gamma; NKT, natural killer T; TH2, T helper 2; TH1, T helper 1
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Figure 1.5. The basic biology of interleukin 33. In its normal state interleukin 33 (IL33) resides in the nucleus of cells. Tissue damage or some inducible signal leads to the
release of IL-33 from cells such as fibroblasts, epithelial cells, endothelial cells, and
smooth muscle cells. IL-33 can be released or secreted as two biological active forms:
full-length IL-33 (proIL-33) and/or as processed proIL-33 into mature IL-33 (mtrIL-33). As
a cytokine-alarmin, IL-33 signals through a heterodimer complex which consists of ST2
and IL-1 receptor accessory protein (IL-1RAcP). The binding of IL-33 to its cognate
receptor results in recruitment of MyD88 and TRAF6, which then leads to the activation
of the transcription factor nuclear factor-kB (NK-kB) and mitogen-activated protein
kinase (MAPK) pathways. This signaling perpetuates an immune response, inducing
gene expression which leads to cytokine and chemokine synthesis. Through a poorly
defined mechanism proIL-33 can induce immune responses independent of its ST2
receptor. In addition, ProIL-33 not only acts as a secreted cytokine, but can also act as a
nuclear binding factor. ProIL-33, which contains a nuclear localization and chromatin
binding motif at its N-terminus, can migrate into the nucleus, and bind to acidic residues
of dimeric histones (H2A-H2B). However, proIL-33’s role in the nucleus is still not fully
understood. Moreover, soluble ST2 can act as a decoy receptor to negatively regulate
IL-33 signaling.
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Figure 1.6. The ISGylation machinery and schematic roles of ISG15. ISG15 is
strongly induced by type I interferons (IFNs), which initiates several initial signaling
pathways to induce expression of ISG15. The first step, ISG15 is activated by UBE1L
enzyme (E1) in an ATP-dependent manner. ISG15 is then transferred to UbcH8 (E2)
and subsequently conjugates to target substrate proteins through the aid of E3 ligases
(HERC5, EFP, HHAR1). The isopeptidase USP18 (deconjugating enzyme) reverses the
coupling by removing ISG15 from target proteins. The ISGylation pathway can therefore
be recycled. However, ISG15 can also exist as free intracellular ISG15 or as secreted
extracellular free ISG15. The biological role of free intracellular ISG15 remains unknown.
Secreted free ISG15 is known to have immunomodulatory properties, however, how it is
secreted or how cells may respond to ISG15 (may bind to unknown receptors) remains
to be determined. IFN, interferon; ISG, IFN-stimulated gene. Figure was adapted from
Joen YJ, et al 2010.
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CHAPTER 2
ALARMIN INTERLEUKIN 33 ACTS AS A VACCINE ADJUVANT INDUCING POTENT
ANTIGEN-SPECIFIC TUMOR IMMUNITY
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“Two roads diverged in a wood, and I—
I took the one less traveled by,
And that has made all the difference”
-Robert Frost

39

ABSTRACT
Interleukin 33 (IL-33) has emerged as a cytokine that can exhibit pleiotropic properties.
Here we examine IL-33 for its immunoadjuvant effects in an HPV-associated cancer
immune therapy model in which cell-mediated immunity is critical for protection. It is
known that two biologically active forms of IL-33 exist: full-length IL-33 and mature IL-33.
The potential ability of both isoforms to influence the adaptive immune responses and
act as a vaccine adjuvant has not been well defined. We show that both isoforms of IL33 are capable of enhancing potent antigen specific effector and memory T cell immunity
in vivo in a DNA vaccine setting. We also show that while both forms of IL-33 drove
robust IFNγ responses, neither form drove high secretion of IL-4 or any elevation of IgE
levels. Further, both isoforms augmented vaccine-induced polyfunctional CD4 and CD8
T cell responses, with a large proportion of CD8 T cells undergoing cytolytic
plurifunctional degranulation. Therapeutic studies indicated that vaccination either IL-33
isoform in conjunction with an HPV DNA vaccine caused rapid and complete regression
of established tumors in vivo. Moreover, we show that IL-33 can significantly expand the
magnitude of antigen-specific CD8 T cell responses and elicit effector-memory CD8 T
cells. Overall, our results support the development of these two IL-33 isoforms as
immunoadjuvant candidates in future vaccination against pathogens and in the context
of anti-tumor immune-based therapy.
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INTRODUCTION
Adjuvants are critical components of most clinical vaccines and are used to
enhance adaptive immune responses to antigen (1). Adjuvants can help shape the
quantity and quality of immune responses (1). However, currently available FDAlicensed adjuvants are poor inducers of CD4+ T helper 1 (TH1) and even worse at
treating CD8 T cell responses (2,3). It is important to identify a new generation of potent
vaccine adjuvant(s) that can drive and specifically direct these desired responses. Thus,
the inclusion of different molecular adjuvants, such as cytokines, is actively being
studied as a way to increase the efficacy of vaccines. Different vaccine platforms have
been studied, but the development of DNA-based vaccines in conjunction with cytokine
adjuvants, has emerged as a particularly promising for inducing anti-viral and anti-tumor
cell-mediated immune responses (4,5). Indeed, the potency of DNA-based vaccines coadministered with molecular cytokine adjuvants as part of a vaccine cocktail has been
demonstrated to boost the adaptive immune response (5). Recently IL-12 as a vaccine
molecular adjuvant has been shown to augment the T cell immunity induced by a DNA
vaccine in humans (4). IL-12 was particularly effective in expanding CD4 and CD8
immunity but less effective, in driving strong B cell immunity. Building on this important
recent success is an area of great importance. We therefore employed a DNA
vaccination approach to investigate the inclusion of Interleukin 33 (IL-33) to further
enhance, both arms of the adaptive immune responses.
IL-33 is a member of the IL-1 family of cytokines that is constitutively expressed
in the nucleus of epithelial and endothelial cells (6,7). IL-33 is classified as an alarminlike molecule, whose release during cell injury signals tissue damage to local immune
cells (7). Alarmin IL-33 has been shown to have pleiotropic cytokine activities such as
mediating diverse pro-inflammatory responses (9,10), activation and recruitment of
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antigen-presenting cells (11), enhancing adaptive immunity (12,13), and wound healing
(14). To date, IL-33 has been studied primarily in the context of T helper type 2 (TH2)
immune responses associated with modulating inflammatory disorders such as asthma
and atopic dermatitis (6,15,16-18). More recently though, IL-33 has been reported to
activate CD8 T cells and influence the development of protective anti-viral CD8 T cells
against infections in mice (12). However, the role of IL-33 in the induction of vaccineinduced, antigen-specific TH1 and CD8 T cell immunity remains to be determined. Two
different biologically active forms of IL-33 exist: full-length IL-33 (proIL-33) and mature
IL-33 (mtrIL-33) (18). ProIL-33 is thought to be the most biologically active form
promoting inflammation, while the function of mtrIL-33 in modulating immune responses
remains more elusive (7,15,18). Therefore, we investigated whether the two isoforms of
IL-33 (proIL-33 and mtrIL-33) can function as vaccine adjuvants to augment adaptive
immune responses (both TH1 and CD8 T cell responses) and induce anti-tumor immunity
using a murine model for HPV-associated cancer.
In this study, we demonstrate that IL-33 can act as a potent cell-mediated
adjuvant using the DNA vaccine platform. Its adjuvant activity skews towards the TH1
axis, and not to the TH2 axis. We show that IL-33 can be effective as an adjuvant in
either form – its uncleaved “pro” form or its “mature” state, a shorter form that results
from cleavage by cellular enzymes (10,17,19). Both IL-33 isoforms when combined with
an HPV16 E6/E7-encoded DNA vaccine enhance the adaptive effector and memory
immune responses, but pro IL-33 was more potent at also expanding the humoral
immune response. We show that both immunoadjuvant IL-33 isoforms induce potent
anti-tumor immunity and regression of established TC-1 tumor-bearing mice. Using the
P14 LCMV DbGP33 transgenic mouse model, we show that immunoadjuvant IL-33 can
significantly expand the magnitude of Ag-specific CD8 T cell responses and elicit potent
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effector-memory CD8 T cells. Our findings reveal that IL-33 can be an effective adjuvant
to drive CD4 immunity, humoral immunity and to generate effective CD8 mediated
protective immunity against cancer and potentially have application in treatment of
chronic viral infections.
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METHODS
Plasmid Construction
The GenBank sequence NM_001164724.1 (accession no: Q8BVZ5.1) for mouse IL-33
was used to synthesize full-length (proIL-33) and mature IL-33 (mtrIL-33) (aa 109-266)
plasmid DNA constructs. Each construct had highly efficient immunoglobulin E (IgE)
leader sequence inserted at the 5’end of the gene. The constructs were commercially
synthesized and optimized as described previously (20). Plasmid expressing HPV 16
ConE6E7 was prepared as previously described (21). The GP33 construct was provided
by Dr. Rafi Ahmed of Emory University, Atlanta GA, USA and used as described (22).

Transfection and Expression of Plasmids
ProIL-33 and mtrIL-33 construct expression was confirmed by Western Blot and
Immunofluorescence microscopy in Human Rhabdomyosarcoma (RD) cells. RD cells
were cultured in 6-well plates and transfected with the constructs (pVAX as control)
using LipofectamineTM2000 (Invitrogen) following the manufacturer’s protocol. Fortyeight hours later cells were lysed using modified RIPA cell lysis buffer and cell lysate
was collected. Western blot analysis was performed with an anti-IL33 monoclonal
antibody (R&D systems) and visualized with horseradish peroxidase (HRP)-conjugated
anti-rat IgG (Cell Signaling) using an ECL western blot analysis systems (GE
Amersham). In addition, supernatants were also collected at 48 hours after transfection
and cytokine secretion was examined by mouse/rat IL-33 Quantikine ELISA kit (R&D
Systems) according to manufacturer’s protocol. An indirect immunofluorescence
microscopy assay was also utilized to confirm expression of both IL-33 isoforms. Briefly,
RD cells were plated on two-well chamber slides (BD Biosciences) and grown to 70%
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confluence overnight in a 37 incubator with 5% CO2. The cells were transfected with 1ug
of IL-33 constructs and the control plasmid pVAX (1 ug/well) using TurboFectinTM8.0
Transfection Reagent (OriGene) according to the manufacturer’s instructions. Forty-eight
hours later the cells were fixed on slides using ice cold methanol for 10 min. The cells
were stained with anti-IL-33 mouse monoclonal antibody (R&D Systems, Minneapolis,
MN) and subsequently incubated with Alexa 555-conjugated anti-rat secondary antibody
(Cell Signaling). Slides were mounted using Fluoromount G with Dapi (Southern
Biotechnology). Images were analyzed by florescence microscopy (Leica DM4000B,
Leica Microsystems Inc, USA) and quantification was conducted using SPOT Advanced
software program (SPOTTM Diagnostic Instruments, Inc).

Animals
Female 8-week-old C57BL/6 mice were purchased from Jackson Laboratory (Bar
Harbor, ME, USA). The P14 mice bearing the DbGP33-specific T-cell receptor were a
kind gift from Dr. John Wherry of the University of Pennsylvania. To generate the “P14
chimera” mice, 1.6x105 naïve T-cell receptor transgenic T cells were adoptively
transferred into naïve B6 mice. All animals were conducted and maintained in
accordance with the National Institutes of Health and the University of Pennsylvania
IACUC guidelines.

Immunization/EP of mice
Mice were immunized three times at three-week intervals in the tibialis anterior muscle.
In vivo Electroporation (EP) was delivered, with the CELLECTRA adaptive constant
current EP device (Inovio Pharmaceuticals, Blue Bell, PA), at the same site immediately
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following vaccination as described (20). The mice (n=4-5) were immunized with either
5µg pVAX1 or 5µg ConE6E7 alone or with various amounts of proIL-33 and mtrIL-33
constructs, depending on the experiment. The GP33 construct was administered at 5µg.
All studies were repeated twice.

ELISpot assays
Spleens were harvested 8 days following the final immunization as previously described
(20). After spleens were harvested and processed both IFNγ and IL-4 ELISpot assays
were performed to determine antigen-specific cytokine secretion from immunized mice
as described previously (20,21,22). A set of peptides (15 amino acid residues
overlapping by 8 amino acids) representing the entire consensus E6/E7 fusion protein
sequence of HPV16 was synthesized from GenScript. This set of peptides was
combined into two pools, spanning the length of the E6 and E7 antigens as previously
described (21). Concavalin A (Sigma-Aldrich, St. Louis, MO) at 5µg/ml was used as
positive control and complete culture medium was used as negative control. Spots were
enumerated using an automated ELISPOT reader (Cellular Technology, Shaker Heights,
OH).

Flow Cytometry
Lymphocytes were isolated and processed from the spleen and peripheral blood as
previously described (20, 23, 24). Splenocytes were added to a 96-well plate
(1x106/well) and were stimulated with pooled HPV-16 E6/E7 pooled peptide for 5-6
hours at 37C/5% CO2 in the presence of Protein Transport Inhibitor Cocktail (Brefeldin A
and Monensin) (eBioscience) according to the manufacturer’s instructions. The Cell
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Stimulation Cocktail (plus protein transport inhibitors) (phorbol 12-myristate 13-acetate
(PMA), ionomycin, brefeldin A and monensin) (eBioscience) was used as a positive
control and R10 media as negative control. In cultures being used to measure
degranulation, anti-CD107a (FITC; clone 1D4B; Biolegend) was added. All cells were
then stained for surface and intracellular proteins as described previously (20). Briefly,
the cells were washed in FACS buffer (PBS containing 0.1% sodium azide and 1% FCS)
before surface staining with flourochrome-conjugated antibodies. Cells were washed
with FACS buffer, fixed and permeabilized using the BD Cytofix/Ctyoperm TM (BD, San
Diego, CA, USA) according to the manufacturer’s protocol followed by intracellular
staining. The following antibodies were used for surface staining: LIVE/DEAD Fixable
Violet Dead Cell stain kit (Invitrogen), CD19 (V450; clone 1D3; BD Biosciences) CD4
(FITC; clone RM4-5; Ebioscience), CD8 (APC-Cy7; clone 53-6.7; BD Biosciences),
CD44 (A700; clone IM7; Biolegend); KLRG1 (FITC; clone 2F1; eBioscience). Major
histocompatibility complex class I peptide tetramer to LCMV-GP33 was used as
described previously (4,5). For intracellular staining the following antibodies were used:
IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone MP6-XT22; ebioscience), CD3
(PerCP/Cy5.5; clone 145-2C11; Biolegend). All data was collected using a LSRII flow
cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland,
OR) and SPICE v5.2 (free available from http://exon.niaid.nih.gov/spice/). Boolean
gating was performed using FlowJo software to examine the polyfunctionality of the T
cells from vaccinated animals. Dead cells were removed by gating on a LIVE/DEAD
fixable violet dead cell stain kit (Invitrogen) versus forward scatter (FSC-A)
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Antigen-specific Antibody Determination
The measurement of IgG antibodies specific for viral genes E6 and E7 was performed
by ELISA (enzyme linked immunosorbent assay) in both immunized and controlled mice.
The plates were coated with 1ug/ml of each protein (ProteinX Lab) and incubated
overnight at 4 degrees. After washing, plates were blocked with 10% fetal bovine serum
(FBS) in 1x phosphate-buffered saline (PBS) for 1 hour at room temperature. Plates
were then washed again and serum was added at a 1:25 dilution in 1% FBS + PBS +
0.05% Tween-20 and incubated at room temperature for 1 hour. After another wash,
goat anti-mouse IgG HRP (Santa Cruz) at a 1:5000 dilution was added to each well and
incubated for 1 hour at room temperature. Following a final wash, the reaction was
developed with the substrate 3,3’,5,5’-tetramethylbenzidine (Sigma-Aldrich) and stopped
with 100ul of 2N sulfuric acid/well. Plates were read at 450nm on Glomax MultiDetection System (Promega). All serum samples were tested in duplicate. The amount
of antigen specific IgE was also determined using a similar ELISA protocol using the
secondary rat anti-mouse IgE HRP antibody (Southern Biotech).

Total IgE was

determined using GenWay’s mouse IgE kit. The manufacturer’s protocol was followed
with serum dilutions at 1:50. All serum samples were tested in duplicate.

Tumor Cell line
TC-1 cells were purchased from ATCC and cultured as previously described (26). The
TC-1 cell line was a graciously given gift from Dr. Yvonne Paterson of the University of
Pennsylvania, Philadelphia, PA, USA. The TC-1 cell line is well characterized,
constitutively expresses E6 and E7, and is highly tumorigenic (26, 27). TC-1 cells were
prepared and mixed with Matrigel (BD Bioscience) for subcutaneous (s.c.) tumor
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implantation.

In vivo tumor treatment (regression) study
Female B6 mice were separated into four groups of 10 mice each and 5 x 104 TC-1 cells
were s.c. implanted into the flanks of each wild-type female B6 mice. On days 4, (after
tumor implantation and when tumors reached 3mm), each group of mice was immunized
i.m./EP with pVAX, ConE6E7, ConE6E7 proIL-33 and ConE6E7 mtrIL-33, respectively
and boosted on day 11 and 18. Mice were monitored twice a week for tumor growth and
were measured as described previously (21,27).

Statistical analysis
Student’s t-test was applied for comparison of the quantitative data of the cellular
immune response and tumor diameters. In this study, p < 0.05 were regarded as
statistically significant.
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RESULTS
Construction and expression of IL-33 isoforms
Two IL-33 adjuvants constructs (pro-IL33 and mtrIL-33) were designed and
generated to test our working hypothesis (Figure 2.1A). To determine the expression of
both IL-33 isoforms, human rhabdomyosarcoma (RD) cells were transfected separately
with each construct, and expression was assessed by Western immunoblotting. A
~20kDA protein was observed for mtrIL-33 and a ~30kDA and ~20kDA protein size was
observed for proIL-33, in cell lysates harvested 48 hours after transfection using an antiIL33 monoclonal antibody (mAb) for detection (Figure 2.1B). For a comparative control,
no protein band could be detected in the negative pVAX control. To examine the
cytokine secretion of both isoforms, cell supernatants were obtained 48 hours after
transfection in RD cells and the detection of cytokine secretion into the extracellular
environment were carried out by enzyme-linked immunosorbent assays (ELISAs). As
shown in Figure 2.1C, supernatants from mtrIL-33 and proIL-33 transfected RD cells
contained mtrIL-33 and proIL-33 at concentrations of roughly 20,000 pg/ml and 600
pg/ml, respectively. Finally, the expression for both IL-33 isoforms was further confirmed
using immunoflourescent staining using an anti-IL33 mAb. ProIL-33 can act both as a
secreted cytokine and as a nuclear binding factor (19). ProIL-33 nuclear localization is
mediated by the nuclear localization signal in its N-terminus, which also contains a
chromatin-binding motif (Figure 2.1A). However, the cleavage of proIL-33 into mtrIL-33
yields a truncated IL-33 that lacks the nuclear localization signal found in proIL-33. As
projected, high nuclear expression with some cytoplasmic expression was observed in
the proIL-33 transfected cells (Figure 2.1D, bottom). This is an important observation
which supports previous findings showing that proIL-33 cytokine can also be expressed
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and found in the cytoplasm (27). In contrast, only high cytoplasmic expression was
visualized in the mtrIL-33 transfected cells shown in Figure 2.1D, middle.

IL-33 adjuvant isoforms enhance potent HPV-specific cellular immune responses
following vaccination
A quantitative ELISpot assay was used to determine the number of antigenspecific IFNγ secreting cells in response to stimulation with the E6 and E7 peptide pool.
As we have reported, electroporation (EP) improves the immunogenicity or potency of
DNA vaccines by increasing antigen expression (28,29), thus we performed
ConE6E7/EP intramuscular (i.m.) vaccination in C57BL/6 (B6) mice (n=5) with a dosage
of 5µg alone or in combination with either mtrIL-33 or proIL-33 at various doses followed
by EP. One week after final immunization we monitored the degree of immune
responses by isolating splenocytes for further analysis (Figure 2.2A). As shown in
Figure 2.2B, the critical role of IL-33 to drive TH1-polarized immune responses is clearly
demonstrated. Co-immunization with both adjuvant cytokine-encoding plasmids induced
higher numbers of E6- and E7-specific IFNγ secreting T cells at all doses when
compared with ConE6E7 alone-vaccinated mice (~500 SFU per million splenocytes). As
noted in Figure 2.2B, the optimal dose of either the mtrIL-33 or proIL-33 (7µg) resulted
in a total 4 and 3.5-fold increases in IFNγ responses, respectively. Due to earlier reports
suggesting that IL-33 was a key cytokine in the induction and support of a TH2 response
(6,15,16), we assessed whether IL-33 induced the prototypical TH2 cytokine, Interleukin4 (IL-4) via IL-4 ELISpot. Our data reveals that neither form of IL-33 drove a robust
secretion of IL-4 (Figure 2.2C). Instead, IL-33 as an adjuvant skewed towards the TH1
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biased axis, and not the TH1 cytokine associated immune responses as originally
described (18).

IL-33 enhances HPV antigen-specific CD4 and CD8 T cell immunity
We next characterized the antigen (Ag)-specific phenotype and cytokine
production profile of memory T cells generated, using the 7µg dose that induced the
optimal adjuvant affect as shown in Figure 2.2B. Given the importance of multifunctional
CD4 and CD8 T cell immunity in the elimination of HPV16-infected cells (5, 30-33), we
measured the ability of vaccine-induced Ag-specific T cell populations to secrete IFNγ
and TNFα, in response to ex vivo E6/E7 pooled peptide stimulation in the spleens. Our
gating strategy for intracellular cytokine flow-cytometry analysis is depicted in Figure
2.3A. Compared with ConE6E7 vaccination alone, the ConE6E7 co-administered with
mtrIL-33 and proIL-33 elicited higher frequency of HPV-specific CD4 T cells producing
either total IFNγ (mtrIL-33: 0.21%; proIL-33: 0.25%), total TNFα (mtrIL-33: 0.25%; proIL33: 0.39%) and dual IFNγ/TNFα (mtrIL-33: 0.12%; proIL-33: 0.15%) (Figure 2.3B-E). In
terms of CD8 T cells, we observed that vaccination with both IL-33 isoforms elicited
substantially higher frequencies of HPV-specific CD8 T cells producing total IFNγ (mtrIL33: 3.68%; proIL-33: 3.50%), total TNFα (mtrIL-33: 3.11%; proIL-33: 3.13%) and dual
IFNγ/TNFα (mtrIL-33: 2.83%; proIL-33: 2.75%) (Figure 2.4A-C). The same trend was
seen with the frequency of Ag-specific CD8+ T cells secreting IFNγ alone and TNFα
alone (Figure 2.4D). Overall, both immunoadjuvant IL-33 isoforms produced similar
amounts of Ag-specific CD4 and CD8 T cell responses, with cytokine production
mediated mainly by CD8 T cells. The high frequencies of effector cells secreting antiviral cytokines are indicative of the adjuvant effects of IL-33 to enhance vaccine potency.
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Given the importance of cytotoxic CD8 T lymphocytes (CTLs) functionality as
critical components in protection (34), we characterized the cytotoxic potential of vaccine
induced CD8 T cells undergoing degranulation. CD8 T cells isolated from mice
vaccinated with adjuvant showed a higher frequency of the degranulation marker,
CD107a (mtrIL-33: 4.4%; proIL-33: 4.9%), compared to mice that received the ConE6E7
constructs alone (Figure 2.4E). More interestingly, the HPV-adjuvanted vaccines elicited
substantially higher frequencies of plurifunctional effector CD8 T cells co-expressing
CD107a/IFNγ/TNFα (mtrIL-33: 2.5%; proIL-33: 2.5%), compared to the ConE6E7
construct alone (Figure 2.4F). These results indicate the adjuvant potential of IL-33 to
induce functional effector cytotoxic CTLs, which have a phenotype suggesting the cells
ability to clear HPV16 infected cells.

IL-33 role in the induction of humoral responses
Identifying potent adjuvants that not only mediate protective cell-mediated
immune responses, but can also induce humoral immune responses, will be ideal for
enhancing effective prophylactic and therapeutic vaccines against a variety of microbial
infections. Thus, to determine whether mtrIL-33 and proIL-33 influence the level of
circulating HPV E6- & E7-specific antibodies, we analyzed humoral responses by ELISA
using collected sera obtained one-week post final vaccination. As shown in Figure 2.5A,
only co-immunization with proIL-33 significantly induced E7-specific total IgG compared
to other immunized groups. No E6-specific antibodies were induced or detected (data
not shown). In addition, because reports have indicated that IL-33 plays a role in allergic
responses we examined E7-specific IgE and total IgE responses in the sera. As
illustrated in Figure 2.5B and 2.5C, the adjuvant effects of mtrIL-33 and proIL-33 did not
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drive enhanced levels of IgE responses compared to control vaccinated groups. This is
consistent with the low induction of IL-4 responses shown in Figure 2.2C, as IL-4 is
known to drive IgE class-switch (35). These results supported that IL-33 adjuvant effects
in a DNA vaccination setting do not induce TH2-associated responses. Interesting, only
the combination of HPV and proIL-33 increased Ag-specific IgG humoral responses,
indicating its role as an effective adjuvant to enhance both Ag-specific cell-mediated and
humoral responses.

IL-33 immunoadjuvants induce potent anti-tumor immunity and regression of
established TC-1 tumor-bearing mice
A strong frequency of anti-HPV CD4 TH1 and CD8 T cell immunity has been
considered a critical characteristic of an effective therapeutic T cell-based vaccine
designed to control and eliminate established pre-existing HPV infections and
associated lesions (32,36). Given the results that IL-33 acts as a cell-mediated adjuvant
eliciting potent HPV Ag-specific TH1-and CD8-biased T cell immune responses, we
performed an in vivo tumor therapy study to determine the therapeutic efficacy of IL-33
immunoadjuvants in TC-1 tumor bearing mice. HPV16 E6/E7-expressing TC-1 tumors
(5x104) cells were implanted in naïve B6 recipient mice. Four days after TC-1 cell
implantation, tumors were measured (tumors had reached an average size of 3 mm) and
groups of mice (n=10) were immunized with pVAX, ConE6E7 (5µg) alone, or ConE6E7
co-administered with 7µg of mtrIL-33 or proIL-33, followed with two boosts at one week
intervals as outlined in Figure 2.6A. As shown in Figure 2.6B, tumor growth was
substantially rejected in the mtrIL-33 and proIL-33-adjuvanted groups compared with
controls. The IL-33 groups remained tumor free until day 42, with the exception of one
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mouse in the mtrIL-33-adjuvant group. Meanwhile, only 6 mice in the ConE6E7vaccinated group were tumor free after 42 days and in the control group all mice had
died by day 28. Furthermore, as shown in Figure 2.7, both IL-33 isoforms can maintain
and elicit anti-tumor memory responses similar to ConE6E7. Clearly, ConE6E7 can
easily prevent E6/E7 tumor growth, but have difficulties curing in a tumor therapy study,
however the inclusion of IL-33 makes a substantial difference (Figure 2.6B). Thus, our
data illustrates that HPV-specific T cell immunity induced by both immunoadjuvants
provides substantial protective anti-tumor immunity by further delaying or rapidly
inducing complete regression of established TC-1 tumors.

IL-33 adjuvant expands Ag-specific CD8 T cell responses and elicits potent
CD62L-KLRG1+ effector-memory CD8 T cell responses after vaccination
Given the increase of Ag-specific CD8 T cell responses and the remarkable
display of complete tumor regression elicited by immunoadjuvant proIL-33, we examined
whether the 100% protective efficacy of proIL-33 was due to its ability to rapidly expand
the effector memory CD8 Ag-specific T cell responses. To achieve this goal, we took
advantage of the P14 (DbGP33-specific T cell receptor (TCR)) mouse model, which is a
great model for tracking populations of T cell subsets. Therefore, to investigate CD8 T
cell expansion during vaccination with proIL-33, we transferred ~150,000 Ly5.1+ naïve
P14 TCR transgenic CD8 T cells into (n=4/group) naïve wild type recipients to make
“P14 chimeric mice” that were subsequently vaccinated with GP33 alone and GP33
coimmunized with proIL-33. The frequency of the Ag-specific CD8+ T cells responses
was monitored in the blood during the course of a prime and boost DNA vaccination with
or without proIL-33 adjuvant (Figure 2.8). As shown in Figure 2.8A and Figure 2.8B,
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the GP33-proIL-33 adjuvanted group dramatically increased the frequency of P14
CD8+Ly5.1+ T cells in the blood, compared to the non-adjuvanted group. This
significantly increased frequency (~5-fold) of Ly5.1+ CD8+ T cells peaked at ~14 dpv
(days post vaccination) compared to the GP33 immunized group which reached its peak
at ~21 dpv. Furthermore, seven days after homologous boosting (48 days after initial
vaccination), proIL-33 immunoadjuvant markedly increased the frequency of Ag-specific
CD8+ T cells compared to control group (Figure 2.8B).
Several studies have suggested that effector CD8 T cells are the optimal subset
for protective immunity and pathogen control (37-39). It has been proposed that a
predominant CD62L-KLRG1+ effector-memory T cell response may be a vital prognostic
for the efficacy of therapeutic cancer vaccines (40). Thus, starting at 14 dpv we
examined the phenotype of the effector CD8 T cells within the vaccine-induced P14specific CD8 T cell population based on the cell surface expression markers: Ly5.1,
CD62L and KLRG1 (Figure 2.8C).

As shown in Figure 2.8C, the percentages of

CD62L-KLRG1+ effector memory cells were significantly higher in the proIL-33 adjuvant
group compared to the GP33-only vaccinated group. Secondary memory cells showed a
greatly expanded population of KLRG1+ T cells in both groups after homologous DNA
boosting, 48 days after initial immunization. The effector-memory responses remained
significantly higher in the proIL-33-adjuvanted group compared to GP33-alone group.
Together, these results support the notion that IL-33 increases the formation of Agspecific CD8 T cells and that IL-33 can enhance clonal expansion of the effector memory
pool (12).
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FIGURES

Figure 2.1. Expression and secretion of mtrIL-33 and proIL-33 DNA vaccine
constructs. (A) Schematic representation of IL-33 protein and the IL-33 adjuvant
constructs encompassing the proIL-33 and mtrIL-33 under the CMV promoter. All
constructs contain an IgE leader sequence. The N-terminus domain of IL-33 contains a
chromatin-binding motif (CBM) and nuclear localization signal (NLS). (B) Expression of
mtrIL-33 and proIL-33 constructs in RD cells as examined by Western blot analysis.
Labeled lanes show proteins detected by anti-IL33 mAb. Smaller band represents mtrIL33, while the larger band represents proIL-33. (C) Secretion of IL-33 from transfected
RD cells was confirmed via ELISA. Data shows the means with standard error of the
means (SEM) for two replicate assays. (D) Detection of expression of mtrIL-33 and
proIL-33 via Immunofluorescence microscopy
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Figure 2.2. Immunoadjuvants IL-33 isoforms enhance strong HPV16 E6- and E7specific IFN-γ immune responses, but no IL-4 responses. (A) DNA vaccine
immunization schedule for adjuvant study. C57BL/6 (B6) mice (n=5 per group) were
immunized at weeks 0, 3, and 6 with HPV16 consensus E6/E7 (ConE6E7) construct with
or without adjuvant via intramuscular/EP and spleens were harvested one week post
final immunization to assess the cellular immune responses. (B) The induction of a Th1
response is shown by the frequency of HPV16 E6 and E7-specific IFNγ spot-forming
units (SFU) per million splenocytes determined by IFNγ ELISpot assay. (C) Antigenspecific IL-4 responses measured by IL-4 ELISpot assay. Experiments were performed
independently at least two times with similar results.
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Figure 2.3. Cytokine frequencies of specific CD4 T cells induced by
immunoadjuvants mtrIL-33 and proIL-33. (A) Depicted is the gating strategy used for
identifying Ag-specific T cell populations. (B) Column graphs depicting E6/E7-specific
CD4+ T cells releasing the cytokines IFNγ (C) TNFα and (D) double-positive producing
cells (and pVAX control). (E) Column graph shows plurifunctional subpopulations of
single- and double-positive CD4 T cells releasing the cytokine IFNγ and TNFα. Pie
charts show the relative proportion of each cytokine subpopulation to Ag-specific
stimulation. Experiments were performed independently at least two times with similar
results with five mice per group.
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Figure 2.4. Cytokine frequencies of specific CD8 T cells induced by
immunoadjuvants mtrIL-33 and proIL-33. (A) Column graphs depicting E6/E7-specific
CD8+ T cells releasing the cytokines IFNγ (B) TNFα and (C) double-positive producing
cells (and pVAX control). (D) Column graph shows plurifunctional subpopulations of
single- and double-positive CD8 T cells releasing the cytokine IFNγ and TNFα. Pie
charts show the relative proportion of each cytokine subpopulation to Ag-specific
stimulation. Dot plots, representative of four mice is also shown in (D), depicting double
positive cytokine expressing CD8 cells after stimulation with pooled E6/E7 peptide. (E)
Antigen-specific cytolytic degranulation T cells were measured by degranulation marker
expression, CD107a. (F) Cytokine profile of the cytolytic phenotype. Experiments were
performed independently at least two times with similar results with five mice per group.
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Figure 2.5. Humoral responses of ConE6E7 with and without mtrIL-33 and proIL-33
adjuvants. Blood collected from control (pVAX) and immunized mice (n=4) was
analyzed for humoral responses via ELISA one week after last immunization. (A)
Specific total IgG antibodies against HPV16 E7 (B) Specific IgE antibodies against
HPV16 E7. (C) Total IgE antibodies detected in the serum. Experiments were repeated
two times with similar results.
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Figure 2.6. Vaccination with IL-33 adjuvants induces regression of established TC1 tumors. (A) Schematic illustration of the time line of therapeutic study regimen. (B)
Groups of B6 mice (10 mice/group) were s.c. challenged with 5x104 TC-1 tumor cells.
Tumors were measured twice a week in two dimensions with electronic calipers and
data are presented with the average of these values over time for each individual
mouse. Mice were sacrificed when tumor diameter reached approximately 2.0 cm.
Tumor measurements for each time point are shown only for surviving mice. pVAX
immunized mice served as negative control.
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Figure 2.7. Protective efficacy maintained by mtrIL-33- and proIL-33-adjuvanted
ConE6E7. In a prophylactic study, groups of B6 (10 mice/group) were immunized (three
times at three week intervals) with ConE6E7 with or without 7µg of mtrIL-33 or proIL-33
and challenged with 5x104 TC-1 cells one week after last immunization to assess the
anti-tumor effects. All vaccination groups prevented tumor growth upon TC-1
implantation.
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Figure 2.8. Immunoadjuvant IL-33 expands the frequency and effector memory
phenotype of the Ag-specific CD8 T cells. P14 chimera mice (n=4) were vaccinated
twice (on day 0 and day 41) containing GP33 with or without proIL-33. (A) Displayed are
representative fluorescent intensity plots of GP33/Ly5.1-specific CD8 T cells responses
in the blood of vaccinated mice at days 14, 21 and 31 after first vaccination and day 48
(day 7 after second immunization). Numbers indicate the percentage of Ag-specific
CD8+ T Cells within the total CD8+ T cell populations. (B) Kinetics of Ly5.1+ expression
on P14-specific CD8 T cells in PBMC following DNA vaccination with a prime at day 0
and a boost at day 41. (C) Distribution of effector memory CD8+ T cell from immunized
mice at day 14, 21, 31 after first vaccination and day 48 (day 7 after second
vaccination). Data are representative of two independent experiments with four mice per
group.
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DISCUSSION
In this study, we provide insight on the TH1-and CD8-biased adjuvant activity of
two isoforms of IL-33-encoding plasmids in a DNA vaccine setting. We demonstrate that
IL-33 elicits bonafide Ag-specific TH1cell-mediated immune responses to a consensus
HPV16 E6/E7 antigen, but neither IL-4, nor any elevation of IgE levels as previously
described. Clearly both isoforms elicited strong HPV16 Ag-specific polyfunctional CD4
and CD8+ T cells secreting both anti-viral IFNγ and/or TNFα cytokines, and also induced
an increase in the Ag-specific cytolytic effector CD8 T cells undergoing plurifunctional
degranulation. More importantly, both IL-33 isoforms were shown to be strong adjuvants
when used in conjunction with a therapeutic HPV DNA vaccine to generate robust antitumor immunity, facilitating successful tumor regression in established TC-1 tumorbearing mice.
The major significant difference between proIL-33 and mtrIL-33 was that proIL-33
was able to increase E7-antigen specific IgG levels. However, because mtrIL-33 induced
90% tumor regression, it suggested that T cells mediated the anti-tumor protection, not
B-cell responses. Full length IL-33’s dual function property, to act not only as a cytokine,
but also as a nuclear transcription factor, may explain the increase in antibody
responses by proIL-33. Its nuclear localization may have additive effects on modulating
the humoral immune responses. However, the specific transcriptional targets of nuclear
IL-33 are still unclear. We are currently pursuing understanding its precise role in the
nucleus and its association with modulation of immunogenicity. Although the importance
of this finding is not yet clear, the data suggests that proIL-33 could also be useful in
vaccine strategies aiming to achieve enhanced antibody responses and cellular
immunity. This is an area of further investigation.
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The specific roles in the protective responses against HPV infection and
associated cancers have been attributed to CD8 T cell immune responses, and
therefore, are the focus for achieving effective immunity by therapeutic treatments
against tumors (5,21, 28, 32). Our results reveal that the cytokine secreting T cell
responses induced by IL-33 were mainly mediated by eliciting a high frequency of Agspecific CD8+ T cells co-expressing CD107a/IFNγ/TNFα. While Bonilla et al. similarly
demonstrated that IL-33 can drive plurifunctional CD8 T cell responses in a viral infection
model (12), we further demonstrated that the delivery of IL-33 as an immunoadjuvant
can indeed enhance plurifunctional CD8 T cell responses, further expanding the pool of
information we now know about IL-33. Consistent with this enhanced polyfunctional antiHPV effector CD8 and CD4 T cell immunity, mice vaccinated with IL-33 demonstrated
remarkable ability to induce anti-tumor immunity and tumor regression in established
TC-1 tumor bearing mice (Figure 2.6B). The significantly improved vaccine efficacy
offered by IL-33 suggests its potential utility as a vaccine adjuvant. Recently, Luzina et
al. demonstrated that mtrIL-33 induced TH2 responses in vivo via a mouse model of
pulmonary infection (18). In contrast, we show in vivo that not only proIL-33, but also
mtrIL-33, a cleaved form of proIL-33 has pleiotropic properties, and can modulate the
immune responses towards a TH1 and CD8 T cell response. It seems that IL-33 may not
be a classical TH2 cytokine as originally suggested, but under certain conditions can
promote TH1 and CD8 type immunity. It is likely that other immune cells may have
accounted for the observed enhancement in TH1 immunity and tumor regression. For
instance, IL-33 has been shown to activate Natural Killer (NK) cells (6,41). However, it is
unlikely that NK cells could have accounted for the observed enhancement in CD8 T cell
immunity or tumor regression. The HPV E6-E7 vaccine encodes a nuclear antigen that is
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not lipid based and not targetable by Fc-Receptor bound antibodies directing NK
immunity and can only be a target of CD8 T cells. Furthermore, much prior work in the
TC-1 tumor challenge model, including work conducted by our lab, has established that
this model is CD8+ T cell dependent for protection (26,32,42-44). Nevertheless, further
studies will be needed to elucidate under what conditions IL-33 promotes TH1 and CD8 T
cell immunity, and the IL-33 regulatory networks connecting the innate with the adaptive
immune response.
It is known that IL-33 exhibits pleiotropic properties and could promote responses
other than TH1, such as activating CD8 T cells (12,13,27). Thus, to investigate the ability
of IL-33 to modulate the CD8 T cells we used the P14 mouse model to monitor the
expansion of LCMV DbGP33/Ly5.1+ cells in the P14 chimeras after immunizing mice with
a cognate viral Ag. We show in vivo that IL-33 can modulate the expansion of CD8 T
cells in a vaccine setting and observed that inclusion of the IL-33 adjuvant significantly
expanded the magnitude of Gp33/Ly5.1+-specific CD8 T cell responses in the blood
(Figure 2.8). These data demonstrate the overall superiority of immunoadjuvant IL-33 in
enhancing the Ag-specific CD8 T cells in a DNA vaccine. In addition to implying that IL33 plays an important role in the expansion of CD8 T cells, it also suggests that IL-33
mediated antitumor immunity and tumor regression in the TC-1 tumor therapy study was
probably CD8 T cell related (Figure 2.6). Moreover, as shown in Figure 2.8, the peak of
CD8 expansion (14 dpv) seemed to correlate with the complete tumor regression
mediated by prolL-33, which was 17 days post first vaccination (Figure 2.6B). From the
increased expansion of CD8 effector T cells elicited by the effects of IL-33 adjuvant
properties, we can postulate their important role in providing tumor protection as shown
in Figure 6B. Subsequently, we also demonstrate that a boost vaccination can further
expand the formation of Ag-specific CD8 T cells after a prime vaccination suggesting the
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potential recall of the established memory CD8 T cell pool (Figure 2.8B). The reasons
behind the ability of IL-33 to expand the frequency of CD8 T cells are not yet entirely
clear (12,13,41,45). However, further studies are needed to elucidate these
mechanisms.
From a therapeutic point of view, the goal of successful vaccination is the
induction of the most potent subsets of CD8 memory T cell populations to rapidly control
infection. Recently, reports have begun to show that the effector-memory KLRG1+CD8+
T cell population can mediate potent protective immunity against certain pathogens (3739) and might be optimal for immediate regression of established subcutaneous (s.c.)
tumors (40). Mice immunized with IL-33 demonstrated robust expansion of activated
effector memory CD8+ T cells in the periphery (Figure 2.8C), suggesting trafficking of
activated CD8+ T cells to the site of Ag stimulation. Our findings support the concept that
vaccine-induced effector-memory CD8 T cell responses might be important memory
CD8+ T cell subsets for an effective therapeutic vaccine against tumors (40). The high
frequency of Ag-specific effector-memory cells in the periphery is consistent with the
observation that effector-memory T cells can migrate to the site of infection and initiate
immediate effector function (46). Furthermore, these results are in agreement with
Bonilla et al., reporting IL-33 is important for primary effector CD8 T cell responses (12).
However, they show that IL-33 may not play a role in memory responses, while our
findings suggest that in certain cases it may play an important role. The reasons for the
differences between the two studies are currently unknown, but may be due to
differences in model systems. We also demonstrate that secondary memory cells after
boost showed a greater formation of CD62L-KLRG1+ cells in the periphery (Figure
2.8C). Together, these results indicate that the increase in the frequency and phenotype
of the IL-33-adjuvanted vaccine-induced Ag-specific P14 CD8 T cells after a prime and
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boost vaccination may be a prediction of the protective correlates of immunity behind the
therapeutic efficacy of immunoadjuvant IL-33 against the established TC-1 tumors
(Figure 2.6B). We are currently investigating the ability of IL-33 to generate central
memory immunity, since central memory T cells are important subsets of memory CD8 T
cells that also mediate optimal protective immunity against pathogens (47,48). Overall,
understanding the mechanism of action by which IL-33 influences the expansion and
development of heterogeneous CD8 T cell populations in vaccines is an important area
for further investigation. Altogether, these results support evidence that IL-33 acts as a
potent adjuvant capable of inducing and modulating potent Ag-specific cell-mediated
immunity in a variety of pathogens.
In summary, we provide insight into the biological function of proIL-33 and mtrIL33 and its effects on modulating the adaptive immune responses in vivo, inducing potent
Ag-specific anti-viral and anti-tumor TH1 and CD8 T cell immunity, which resulted in
effective tumor regression. This study provides evidence that immunoadjuvant IL-33
elicits its affects by enhancing the formation of the Ag-specific effector CD8 T cells and
markedly amplifying the effector-memory CD8 T cells responses. These findings, we
believe, establish the validity of IL-33 as a new adjuvant for consideration in the context
of immune-therapies, in particular, for cancer vaccine therapies.
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CHAPTER 3
MOLECULAR ADJUVANT IL-33 ENHANCES THE POTENCY OF A DNA VACCINE IN
A LETHAL CHALLENGE MODEL
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ABSTRACT
Identifying new molecular adjuvants that elicit effective vaccine-induced CD8 T cell
immunity may be critical for the elimination of many challenging diseases including
Tuberculosis, HIV and cancer. Here, we report that co-administration of molecular
adjuvant IL-33 during vaccination enhanced the magnitude and function of antigen (Ag)specific CD8 T cells against a model Ag, LCMV NP target protein. These enhanced
responses were characterized by higher frequencies of Ag-specific, polyfunctional CD8
T cells exhibiting cytotoxic characteristics. Importantly, these cells were capable of
robust expansion upon Ag-specific restimulation in vivo and conferred remarkable
protection against a high dose lethal LCMV challenge. In addition, we demonstrate the
ability of IL-33 to amplifying the frequency of Ag-specific KLRG1+ effector CD8 T
cells. These data show that IL-33 is a promising immunoadjuvant at improving T cell
immunity in a vaccine setting and suggest further development and understanding of this
molecular adjuvant for strategies against many obstinate infectious diseases and cancer.
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INTRODUCTION
There is still a great need for effective vaccines against many chronic infectious
including HIV, HCV, Tuberculosis and malaria. For these pathogens, it is known that T
cell-mediated immunity is critical in either controlling, preventing or delaying the onset of
disease (1). Thus, a crucial step in vaccine development for these infections requires
producing cytotoxic TH1 versus humoral TH2 responses. Currently, licensed vaccines
such as inactivated and recombinant protein or non-live vaccines predominately drive
humoral immune responses (2). An overall shortcoming of these vaccines, especially
non-live vaccines, is their inability to generate both effective TH1 and CD8 T cell
immunity, thus hindering their beneficial role in limiting or preventing diseases that
require adaptive cellular immune responses (2,3). One way to improve the quality of
immune responses during vaccination is to incorporate immunoadjuvants, which have
been shown to help increase their TH1 immune potency (2). However, it has been a
challenge to discover immunoadjuvants that can amplify the induction of CD8+ T cell
responses. Notably, IL-33 has emerged as a proinflammtory cytokine capable of
promoting both potent TH1 and cytotoxic CD8 T cell immunity (4,5,6). Therefore, IL-33
has great potential to act as a potent molecular adjuvant in vaccines designed to boost
CD8+ T cell immune responses.
IL-33 is a member of the IL-1 cytokine family, which is released by necrotic cells
or activated innate immune cells during trauma or infection (6,7). Therefore, it is
considered to serve as the first line of defense against pathogens, by providing an
endogenous “danger signal” that triggers inflammation and promotes cell-mediated
immune response. Originally studied in the context of TH2 immunity associated with
inflammatory disorders (6,7), evidence has begun to unveil IL-33’s unappreciated ability
to induce TH1 and CD8 T cell-mediated immunity (4-6). We have recently reported that
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IL-33 can act as novel immunoadjuvant to induce both potent TH1 and effective CD8 T
cell responses in an anti-tumor DNA vaccine (5). Here we expanded the scope of these
initial studies to evaluate the capacity of IL-33 to serve as a vaccine adjuvant to enhance
and modulate cell-mediated responses against various models of infection that require
CD8 T responses.
In the present study, we use the well-studied lymphocytic choriomeningitis virus
(LCMV) model to investigate IL-33’s ability to facilitate the induction of antiviral and
protective immunity and further elucidate its biological function on memory CD8 T cell
expansion and differentiation in a vaccine setting. We hypothesize that IL-33 would have
the capacity to improve the efficacy of DNA vaccines against a viral challenge, providing
optimal effector function and protection. Here we show that the administration of IL-33
coadministered with a DNA vaccine against LCMV induces robust antigen-specific IFNγ
responses, enhances antigen (Ag)-specific polyfunctional CD8+ T cell immune
responses, increases the cytotoxic phenotype of the CD8 T cells, and provides
substantial protective immunity against a high-dose lethal LCMV challenge. We also that
inclusion of IL-33 can significantly amplify and expand the Ag-specific effector memory
CD8 T cell responses. Furthermore, we provide evidence of IL-33’s ability to also
enhance cell-mediated immune responses when co-delivered with an HIV DNA vaccine.
These findings significantly highlight the important role of IL-33 as a potential future
vaccine adjuvant with applicability in the treatment of a variety of chronic viral diseases
that require potent TH1-type immunity for their prevention or control.
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METHODS
Constructs
The DNA constructs encoding mature IL-33 (mtrIL-33), HIV (ConC) and LCMV-GP
construct has been described (5-10). All constructs had highly efficient immunoglobulin
E (IgE) leader sequence inserted at the 5′end of the gene. The constructs were
commercially synthesized and optimized as described previously (10).

Animals
All animals were conducted and maintained in accordance with the NIH and the
University of Pennsylvania Institutional Animal Care and Use Committee guidelines.
Female C57BL/6 (H-2b) 8-week-old mice were purchased from Jackson Laboratory (Bar
Harbor, ME).

Animal immunizations
Mice were immunized once intramuscularly (i.m.) in the tibialis anterior muscle. In vivo
electroporation (EP) was delivered, with the CELLECTRA adaptive constant current EP
device (Inovio Pharmaceuticals), at the same site immediately following vaccination as
previously described (5,10). The mice were immunized with either 10 μg pVAX1 or 10 μg
pLCMV-NP with or without 11 μg of mtrIL-33 construct. Three weeks after initial
immunization, mice were sacrificed and splenocytes were harvested to measure immune
responses. The LCMV-GP (GP) construct was administered at 10 μg. For the HIV
immunizations, mice were immunized three times at two-week intervals with 10 μg of
each construct (ConC) with or without 11 μg of mtrIL-33. One week after immunization,
the mice were sacrificed and splenocytes were harvested to monitor immune responses.
All studies were repeated at least two times.
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LCMV Viral Challenge
For lethal challenge studies, immunized mice were challenged intracranial (i.c.) 21 days
after initial vaccination with either 20xLD50 or 40xLD50 of LCMV Armstrong as previously
described (11) in 30 μl of virus diluent (PBS with 20% FBS and 1X Anti-Anti (Invitrogen,
Carlsbad,CA)). All mice LCMV challenged were housed in a BSL-2 facility and were
observed daily for 21 days.

ELISPOT assay
For mice vaccinated with DNA all spleens were processed and IFNγ ELISpot assays
were performed to determine the antigen-specific cytokine secretion. Spleens were
collected in RPMI 1640 medium (supplemented with 10% FBS, 1X AntibioticAntimycotic, and 1X β-ME) and splenocytes were isolated by mechanical disruption of
the spleen using a Stomacher machine (Seward Laboratory Systems, Bohemia, NY).
The resulting mashed spleens were filtered using a 40µm cell strainer, treated with ACK
lysis buffer for 5 minutes to lyse the RBCs, washed in PBS and then resuspended in
RPMI medium for use in ELISpot or Flow Cytometry assay. The IFNγ ELISPOT assays
were conducted as previously described in detail (5,10,11). The measurement of LCMVspecific

T

cell

responses

were

assessed

by

stimulating

splenocytes

with

immunodominant LCMV epitope from the H-2b background (DbNP396-404 (NP396)) or
(DbGP33-41 (GP33)) (Invitrogen). The HIV-specific T cell responses were measured by
using pooled peptides (15-mers overlapping by 9 amino acids; 2.5 µg/ml final
concentration). All peptides were synthesized from GenScript. Concavalin A (SigmaAldrich, St. Louis, MO) was used as positive control and complete culture medium was
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used as negative control. Spots were enumerated using an automated ELISPOT reader
(Cellular Technology, Shaker Heights, OH).

Flow cytometry
Lymphocytes were isolated and processed from the peripheral blood as previously
described (5). Cells were stained with CD8, CD44, CD62L, KLRG1, and MHC class I
peptide tetramer to LCMV-GP33 (KAVYNFATC) (Beckman Coulter) as described
previously (5). Intracellular cytokine staining was performed after 5 hr of ex vivo
stimulation with either LCMV epitope DbNP396-404 or DbGP33-41 peptide, HIV and Ag85B
pooled peptides depending on the study as described (5,10). The following antibodies
were used for surface staining: LIVE/DEAD Fixable Violet Dead Cell stain kit
(Invitrogen), CD4 (FITC; clone RM4-5; ebioscience), CD8 (APC-Cy7; clone 53-6.7; BD
Biosciences); CD44 (A700; clone IM7; Biolegend). For intracellular staining the following
antibodies were used: IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone MP6XT22; ebioscience), CD3 (PerCP/Cy5.5; clone 145-2C11; Biolegend); IL-2 (PeCy7;
clone JES6-SH4; ebioscience). All data was collected using a LSRII flow cytometer (BD
Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR) and SPICE
v5.2 (free available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed
using FlowJo software to examine the polyfunctionality of the T cells from vaccinated
animals.

Bone Marrow Dendritic Cell Maturation
Bone marrow was harvested from femurs and tibias of female C57BL/6 mice age 6-8
weeks. Following RBC lysis, bone marrow cells were cultured in 40 ng/mL recombinant
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murine GM-CSF and incubated at 37° C, 5% CO2. Media was refreshed on days 3 and
6. On day 8, immature BMDCs were harvested by pipetting floating and loosely adherent
cells. BMDCs were subsequently treated for 24 hours with 100 ng/mL recombinant IL33 or vehicle-sham (PBS) control.

Following treatment, BMDCs were harvested by

scraping and analyzed by flow cytometry against CD40, CD80, CD86, or isotypematched control antibodies.

Luminex
Cytokines and chemokines were quantified in supernatant collected from BMDC treated
with or without 100ng/ml of rIL-33 (R&D Systems) at 24 hours, using a custom Millipore
cytokine assay (Millipore, Billerica, MA) according to manufacturer’s instructions. The
panel of cytokines and chemokines included: IL-1a, IL-1b, IL-2, IL-6, IL-12, TNFa, IP-10,
MIG and RANTES. Samples were read on a Bio-Plex 200 system with Bio-Plex Manager
Software (Bio-Rad).

T cell proliferation assay
Splenocytes isolated from immunized B6 mice 21 days after initial immunization were
labeled with Cell Tracer violet Violet (Molecular Probes) and pulsed with 10 μM peptide
for 5 days. CD8 T cell proliferation was determined using flow cytometry to assess Cell
Trace Violet dilution.

Statistical Analysis
Group analyses were completed by matched, two-tailed, unpaired t-test and survival
curves were analyzed by log-rank Mantel-Cox test. For non-equally distributed samples
nonparametric Mann-Whitney test was performed (Figures 3.2E and 3.2F). All values
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are mean ± SEM and statistical analyses were performed by GraphPad Prism (La Jolla,
CA).
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RESULTS
IL-33 elicits protection against a lethal LCMV challenge
The LCMV infection model has been extensively used to understand the role of
virus-specific CD8+ T cell responses in the context of vaccine-elicited protection (12-14).
Considering our recent novel finding that IL-33 can act as an immunoadjuvant to induce
both anti-viral and anti-tumor CD8 T cell immunity (5), we used the intracranial (i.c.)
LCMV challenge model to further study the protective efficacy of IL-33. Three groups of
C57BL/6 mice (B6) (n = 10) were vaccinated by electroporation (EP) one time with 10 µg
of pLCMV-NP (NP) construct with or without 11 µg of mature IL-33 (mtrIL-33) construct.
The empty vector pVAX was used as a negative control. The LCMV NP structural
protein is recognized as a critical component and target for protective LCMV immunity
since it is not a target for neutralizing antibodies (11). All animals were challenged 21
days post-vaccination (dpv) with a lethal 20xLD50 dose of LCMV Armstrong (Figure 3.1a)
(11,14-16). Vaccinated animals with NP plus mtrIL-33 showed complete protection while
the NP alone group achieved only 60% protection (Figure 3.1b). On the other hand, all
control pVAX vaccinated animals succumbed to infection. After showing that mice
immunized using mtrIL-33 as an adjuvant exhibited 100% survival rate, we next sought
to determine whether vaccinated mice with adjuvant could confer protection against an
even higher lethal dose of LCMV challenge. Therefore, mice where challenged with a
40xLD50 dose of LCMV Armstrong (11), 21 days post-single vaccination (Figure 3.1c).
Notably, animals receiving one immunization of NP plus mtrIL-33 yielded a significant
80% protection, while the NP alone group only conferred 10% protection against this
highly lethal dose of LCMV (Figure 3.1c). These data show that IL-33 elicits protection
against a lethal LCMV challenge.
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IL-33 significantly increases LCMV-specific CD8 T cell responses
Considering that CD8 T cell responses are essential for facilitating control
against LCMV (11-16), we hypothesized that the IL-33 adjuvanted vaccine induced CD8
T cells mediated antiviral protection. Thus, to better characterize the protective immune
correlates driven by mtrIL-33, groups of mice (n = 4-5) were immunized once with NP
either with or without mtrIL-33. The magnitude of NP-specific immune responses was
measured 21 dpv in response to peptide re-stimulation (2.5 µg/ml) using the
immunodominant epitope in the H-2b background: DbNP396-40 (NP396) (11). Compared to
NP alone-vaccinated mice, we found that co-immunization with mtrIL-33-encoding
plasmid elicited stronger NP-specific T cell responses by greater than 2.5 fold (Figure
3.2a); IFN-γ ELISPOT counts were ~2,500 spot-forming cells [SFCs] per 106 splenocytes
in the IL-33 vaccinated mice versus ~980 SFC/106 splenocytes for the NP alone group.
Next, we assessed the phenotypic and functional profile of vaccine-induced CD8+ T cells
in response to NP396 peptide re-stimulation (2.5 µg/ml final peptide concentration).
Twenty-one days after vaccination there was a significant difference among vaccine
groups in the frequency of CD8 T cells producing effector cytokines (Figures 3.2b,c).
The NP vaccine coadministered with mtrIL-33 elicited a higher percentage of Ag-specific
CD8 T cells producing all three cytokines (Figure 3.2b), and a significant number of the
CD8 T cells were polyfunctional (Figure 3.2c). Compared with the NP alone vaccinated
group, the NP+mtrIL-33 vaccinated group elicited substantially higher frequencies of NPspecific CD8 T cells producing either IFNγ alone (NP, 1.3%; NP+mtrIL-33, 2.3%), dual
IFNγ+TNFα+ (NP, 0.76%; NP+mtrIL-33, 1.63%), or triple-positive IFNγ+TNFα+IL-2+ (NP,
0.20%; NP+mtrIL-33, 0.43%) in the spleens 21 dpv (Figure 3.2c). Collectively, the
enhanced Ag-specific CD8+ T cell response induced by IL-33 is indicative of IL-33’s
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ability to provide substantial protection against LCMV challenge. We next characterized
the cytotoxic potential of vaccine-induced CD8 T cells. CD8 T cells isolated from mice
vaccinated with IL-33 showed a significantly higher frequency of antigen-specific
(IFNγ+CD107a+:

2.5%)

degranulation

compared

to

NP

alone-vaccinated

mice

(IFNγ+CD107a+: 1.2%) (Figure 3.2d). We next evaluated the proliferative capacity of the
CD8 T cells by monitoring Cell Trace Violet dilution in splenocytes isolated from mice 21
dpv rechallenged in vitro with NP396 peptide re-stimulation. Figure 3.2e shows that
mtrIL-33 vaccinated mice underwent significantly higher Ag-specific proliferation of CD8
T cells, being ~2 fold greater than NP control group. Notably, there was an enrichment of
effector memory CD8 T cells (CD44+CD62L-) in the adjuvant-vaccinated group (Figure
3.2f). There was no significant difference in the central memory CD8 T cell
(CD44+CD62L+) population (data not shown). Taken together, the inclusion of IL-33
elicits robust levels of NP-specific T cell immunity, especially enhancing CD8 T cell
immune responses.
To better understand the biological function of IL-33 on the induction of Agspecific CD8+ T cells during the course of vaccination, we further characterized IL-33’s
ability to expand the Ag-specific effector memory CD8 T cell population. To achieve this
goal, we took advantage of the well-studied DbGP33-41 MHC class I tetramer to follow Agspecific CD8 T cells as they develop after initial priming. Mice were vaccinated once with
a LCMV glycoprotein LCMV-GP (GP) DNA vaccine and the frequency of DbGP33specific CD8+ T cells was monitored in the peripheral blood during the course of
vaccination either with or without mtrIL-33 (Figure 3.4a). Delivery of IL-33 expanded the
number of DbGP33 tetramer-specific CD8 T cells in the peripheral blood (Figure 3.3a).
In peripheral blood lymphocytes (PBLs), the frequency of GP33-specific CD8 T cell was
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significantly 2-fold higher at 18 and 21 dpv compared with the nonadjuvanted group
(Figure 3.3a). Similarly, the inclusion of IL-33 also increased the number of GP33specific CD8+ T cells in the spleen 21 dpv (Figure 3.3b) and the Ag-specific CD8 T cells
secreting IFNγ, undergoing degranulation, and expressing the transcription factor T-bet
(Figures 3.3c-f). Additionally, all mice were boosted with the GP construct alone (21
days after initial immunization) to quantify the Ag-specific recall responses. Compared to
control group, the IL-33 vaccinated group significantly increased the Ag-specific CD8+ T
cells. Notably, the IL-33 immunized group GP33 tetramer-specific T cells were ~3-fold
higher starting 3 days post-boost vaccination (d24) compared to the NP-vaccinated
group (Figure 3.3a). The significant difference in the amplification of the GP33-specific
CD8 T cells was still observed 10 days after DNA boost (d31). Consistent with figure
3.2, the current data further confirms IL-33’s ability to induce the quality of Ag-specific
CD8 T cells which seemed to correlate with IL-33’s adjuvant effect to mediate its antiviral
protection as shown in Figure 3.1. Finally, since it has been demonstrated that effectorphenotype memory CD8 T cells (Teff) can mediate clearance of blood-borne pathogens
(17-22), we next evaluated the ability of IL-33 to induce the differentiation of Teff cells
based on expression markers: CD44 and KLRG1 (Figure 3.4b). The administration of
mtrIL-33 resulted in a significant expansion in the percentages of CD8+KLRG1+ Teff cells
in the PBLs, compared with the GP-only vaccinated group (Figure 3.4c). We also
evaluated the recall response of DbGP33 tetramer-specific CD8+KLRG1+ T cells after
DNA-GP boosting, 21 days after initial immunization and observed marked expansion of
GP33-specific memory CD8+KLRG1+ T cells in both groups after boosting; however, the
proportion of CD8+KLRG1+ T cells remained significantly higher in the mtrIL-33 adjuvant
group (Figure 3.4c). In summary, IL-33 significantly increased LCMV-specific CD8 T cell
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immunity against two separate viral proteins and enhanced effector-memory
CD8+KLRG1+ T cell subset differentiation.

IL-33 promotes DC maturation in vitro
It is well known that antigen presented by activated DCs and the type of
production of polarizing cytokines they secrete can promote different fates on T cell
development (23). We next investigated whether IL-33 could induce DC maturation by
assessing the up-regulation of certain surface expression markers and their induction of
proinflammatory cytokines, all of which may influence adaptive immunity. Mouse bone
marrow-derived dendritic cells (BMDC) incubated with 100 ng/ml of recombinant IL-33
(rIL-33) for 24 hours up-regulated the expression of co-stimulatory CD80 and CD86 and
CD83 (marker for DC maturation) molecules (Figure 3.5a). Moreover, to characterize
the cytokines induced by the effect of IL-33, we employed a multiplex cytokine array
consisting of a panel of TH1 cytokines (IL-12), TH2 cytokines (IL-4), anti-inflammatory
cytokines (IL-10), and pro-inflammatory cytokines (IL-1a, IL-1b, IL-6, TNF-α). In addition,
we included cytokines and chemokines associated with activation and chemoattraction
of T cells: RANTES (CCL5), IP-10 (CXCL10) and MIG (CXCL9). As shown in figure
3.5b, rIL-33 stimulated DC production of a variety of proinflammatory cytokines and
chemokines. Additionally, DCs incubated with rIL-33 showed no detectable production
anti-inflammatory suppressive cytokine IL-10 and of the prototypical TH2 cytokine IL-4
(data not shown). Therefore, the biological function of IL-33 exhibits the capacity to
induce phenotypic maturation of DCs, which have the potential to drive proinflammatory
cytokines and chemokines that may facilitate a polarized TH1/CD8+ T cell protective
response.
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IL-33 augments HIV-specific T cell-mediated responses
To determine whether mtrIL-33 adjuvant can enhance the vaccine potency for
other pathogens requiring both TH1 and CD8 T cell responses, we assessed the Agspecific T cell-mediated responses of mtrIL-33 co-delivered with a HIV DNA vaccine
antigen (Figure 6.6). B6 mice (n = 5) were vaccinated three times i.m. at two week
intervals with 10 µg HIV Consensus clade C (ConC) alone or in combination with 11 µg
of mtrIL-33 followed by EP. One week after final immunization Ag-specific immune
responses were measured using cells derived from the spleen. Consistent with findings
in the LCMV model (Figures 3.2a-c), the inclusion of mtrIL-33 enhanced the numbers of
HIV-specific IFNγ secreting T cells (ConC, ~3,800 SFC) when compared with nonadjuvanted groups (ConC, ~2,300 SFC) (Figure 3.6a). Furthermore, we characterized
the cytokine-producing phenotype of the T cell population after immunization with the
HIV DNA (Figures 3.5b,c). In mice, the Ag-specific TH1 response after HIV vaccination
with mtrIL-33, consisted of significantly high frequency of polyfunctional double-positive
(IFNγ+TNFα+) and TNFα- and IFNγ-single-positive CD8 T cells in the spleen (Figure
3.6B). Regarding CD4 T cells, the Ag-specific TH1 response after HIV plus IL-33
vaccination, consisted of high frequency of polyfunctional triple-positive (IFNγ+TNFα+IL2+), double-positive (IFNγ+TNFα+) and IFN-γ single-positive CD4 T cells in the spleen
(Figure 3.6C). Overall, these findings significantly highlight the important role of IL-33 as
an effective immunoadjuvant to be incorporated into future vaccines targeting an array of
microbial infections.
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FIGURES

Figure 3.1. IL-33-elicited protection against lethal LCMV challenge. (a) Mice (n =
10/group) were immunized one time i.m. using EP with 10 µg of empty vector control
plasmid (pVAX) or 10 µg of LCMV-NP with or without 11 µg of mtrIL-33. At day 21 postvaccination, mice were either challenged intracranial (i.c.) with (b) 20xLD50 armstrong
LCMV or (c) 40xLD50 armstrong LCMV and animal survival was monitored for 21 days
post challenge. Experiments were performed at least two times in independent
experiments and data are representative of the result. *, P < 0.05; **, P < 0.01.
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Figure 3.2. IL-33 induces potent antigen-specific effector CD8 T cells. C57BL/6
mice (n = 4-5) were immunized once by i.m. followed by EP with 10 µg of NP with or
without 11 µg of mtrIL-33. Splenocytes were harvested 21 days post vaccination to
assess the cellular immune responses. ELISpot and ICS assays were stimulated for 18
hours and 5 hours, respectively, with a final concentration of 2.5 µg/ml
Mice that
received 10 µg pVAX only served as a negative control. (A) The ability of T cells to
produce IFNγ in response to DbNP396 epitope (CD8) was determined by IFNγ ELISpot
assay. (B) Flow cytometry was used to determine the total cytokine (IFNγ, TNFα and IL2) frequencies of the DbNP396-specific CD8 T cells induced by mtrIL-33. (C) Column
graph shows multifunctional subpopulations of single-, double- and triple-positive CD8 T
cells releasing the cytokines IFNγ, TNFα and IL-2. (D) The antigen-specific cytolytic
degranulation T cells induced by mtrIL-33 adjuvant were measured by degranulation
marker expression, CD107a and producing IFNγ. Dot plots show representative
examples of each mouse group. (E) Splenocytes from mice were labeled with cell tracer
violet and stimulated with DbNP396 peptide. Cell tracer signals on CD8 T cell population
were detected by flow cytometry to measure proliferation. (F) After proliferation the % of
effector CD8 T cells upon stimulation with NPDb396-specific peptide (2.5 µg/ml) was
assessed. Dot plots show representative figure of CD62L-CD44+ CD8 T cells after
stimulation. Data shows the SEM of two independent experiments repeated at least two
to three times. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with NP.
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Figure 3.3. IL-33 amplifies the percentage of antigen-specific CD8 T cells. C57BL/6
mice (n = 4-8) were immunized once with 10 µg LCMV-GP (GP) construct with or
without mtrIL-33 and the Ag-specific CD8 T cell population was monitored during the
course of vaccination. (A) Kinetics DbGp33(Tet+)-specific CD8 T cells in the blood
following DNA vaccination with a prime at day 0 and boost with GP alone (red arrow) on
day 21 post vaccination (dpv). The cells are gated on live CD8+CD44+ T cells. (B-F) At
day 21, spleens (n =4 per group) were harvested and antigen-specific responses were
monitored ex vivo with GP33 peptide. (B) Frequency of DbGP33 CD8+ T cells at 21 dpv.
(C) IFN-γ ELISpot assay used to measure the GP-specific T cells producing IFN-γ on 21
dpv. (D) Frequency of GP-specific IFN-γ+CD8+, (E) CD107a+CD8+, and (F) T-bet+CD8+ T
cells at 21 dpv. Data shows the SEM of two independent experiments repeated at least
two times. *, P < 0.05; **, P < 0.01; no statistical difference in Fig 3 B, C, E.
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Figure 3.4. IL-33 enhances the expansion of CD8+KLRG1+ effector-memory T cells.
(A) Vaccine immunization schedule in mice. B6 mice (n = 4-8) were immunized once
with 10 µg of GP plasmid with or without 11 µg of mtrIL-33 construct and boosted with
only GP (red arrow) at 21 days after initial vaccination. Ag-specific responses in the
blood were monitored as indicated. (B) Gating strategy used to identify the
DbGp33+CD44+KLRG1+CD8+ T cell population in the blood following vaccination (C)
Kinetics of the CD8+KLRG1+ T cell population after DNA vaccination. Experiments were
repeated two times. Population were gated on DbGp33+CD8+CD44+KLRG1+ *, P < 0.05;
**, P < 0.01; ***, P < 0.001.
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Figure 3.5. IL-33 promotes phenotypic and functional maturation of DCs. (A)
Mouse bone marrow dendritic cells (BMDCs) were incubated in medium in the absence
(sham-PBS) or presence of 100 ng/ml recombinant IL-33 (rIL-33) for 24 hours before
measurement of the indicated DC surface marker expression by flow cytometery (red,
isotype-matched control). The data shown represent the results of one experiment
repeated twice. (B) Supernatants were obtained after BMDCs were incubated in the
absence or presence of 100 ng/ml for the measurements of the indicated cytokines.
Shown is the SEM of duplicate wells of one experiment representative of two. *, P <
0.05; **, P < 0.01; ***, P < 0.001
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Figure 3.6. IL-33 enhances potent HIV-specific cell-mediated immune responses.
B6 mice (n = 5/group) where immunized three times i.m. at two week intervals with 10
µg of HIV Consensus Clade C (ConC) alone or in combination with 11 µg of mtrIL-33.
One week after last immunization mice were sacrificed and spleens were processed to
monitor the vaccine induced immune responses. (A) IFNγ ELISpot was performed to
detect antigen specific cells secreting IFNγ after vaccination. (B &C) Multiparameter flow
cytometry was used to determine the percentages of both the polyfunctional CD8 and
CD4 T cell cytokine profiles. The column chart shows the percentage of HIV-specific T
cells displayed as triple, double and single positive secreting cytokines. Pie charts show
the relative proportion of each cytokine subpopulation. Experiments were performed at
least two times with similar results. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared
with ConC group.
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DISCUSSION
Interleukin 33 is a pleiotropic cytokine whose properties extend beyond TH2
responses. We show here that IL-33 is capable of inducing and modulating TH1
responses (6). However, the biological role of IL-33 as an adjuvant in vaccines remains
to be further elucidated. The mature form of IL-33 delivered as an adjuvant remarkably
augments LCMV-specific cell-mediated antiviral immunity and provides substantial
protection against a high-dose lethal LCMV challenge.
The LCMV model of infection is well established with great applicability to
investigations regarding vaccine-induced immunity. In a previous study, we showed that
mice immunized once with a LCMV-NP DNA vaccine yielded 67% protection after a
20xLD50 lethal dose of LCMV challenge (11). Therefore, we sought to investigate
whether the inclusion of IL-33 after one immunization would increase its protective
efficacy since a high frequency of LCMV-specific CD8+ T cells is considered a critical
characteristic against an LCMV infection (12-16). Here, the coadministration of IL-33 not
only increased the magnitude of IFNγ spot-forming NP396-specific CD8 T cells, but also
improved their polyfunctionality, increased the cytolytic phenotype of the CD8 T cells,
and their effector memory differentiation. As measured by IFNγ ELISpot for the specific
CD8 T cell epitope DbNP396-40, the inclusion of IL-33 induced a 2.5-fold greater response
compared to NP-alone immunization. IL-33 also induced greater responses compared
with our previous LCMV-NP DNA vaccine study, where 25 μg of pLCMV-NP
administered i.m. twice at two week intervals only elicited ~1400 SCFs per 106
splenocytes (11). Nevertheless, although our IL-33 adjuvant approach matched the
immunogenicity of the 35 μg of LCMV-NP dose that elicited 100% protection eventually
after three immunizations (11), our IL-33-assisted DNA vaccination conferred 100%
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protection only after one immunization (Figure 3.1). Furthermore, we show that IL-33
enhanced the polyfunctional CD8+ T cell populations secreting IFNγ+TNFα+IL2+,
IFNγ+TNFα+ and IFNγ+ and elicited a greater Ag-specific CD8 cytolytic degranulation
(Figure 3.2). We find this data in accordance with our previous findings that IL-33 can
increase the Ag-specific cell-mediated immune response when coadministered with a
DNA vaccine (5) and with others (4,6). The reasons behind the role of IL-33 to enhance
the frequency of CD8 T cells are not entirely clear. Nevertheless, recently Luzina et al.
have shown in a vaccine delivery approach that mature IL-33 (the same isoform used in
our vaccine) effect is ST2-dependent (24). Moreover, substantial research has shown
the ST2 is important for IL-33 action as mice deficient in ST2 are entirely unresponsive
to IL-33 (25). Therefore, the ability of CD8 T cells to respond to IL-33 is a possible
explanation for the augmentation, as activated differentiated CD8 T cells can upregulate
their cognate binding receptor ST2 (4,26) and therefore lead to more memory cells
capable of responding to rechallenge. More importantly, consistent with the markedly
enhanced cytotoxic CD8 T cell activity and the higher levels of NP396-specific effector
memory CD8 T cells, the challenge studies using two different lethal doses of LCMV
(Figure 3.1) validate IL-33’s potent adjuvant properties, ultimately to improving antiviral
vaccine efficacy (4,5).
The inclusion of adjuvants in vaccine formulations has long been a method of
improving vaccine efficacy, but how adjuvants alter the phenotype and differentiation of
T cells still remain unknown. Current studies have shown that the characteristic profiles
of Ag-specific T cell responses can be correlated with superior disease protection
(18,19,27-29). Therefore, to examine the biological function of mtrIL-33 to expand and
differentiate the CD8 T cells, we coadministered mtrIL-33 with an LCMV-GP DNA
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vaccine to monitor the DbGP33 tetramer-specific T cells after immunization. In
accordance with our previous data (5), we show that mtrIL-33, similar to full-length IL-33,
can significantly amplify GP33+CD8+ T cell responses in the peripheral blood in a
vaccine setting. Nevertheless, although not significant, a similar trend was observed
whereby the frequency of GP33+CD8+ T cells in the spleen was higher in the IL-33
vaccinated group (Figure 3.3B). These results substantiated IL-33’s cytokine property to
mediate the expansion of CD8 T cells. In addition, we show that IL-33 also induced
significant expansion of Ag-specific CD8+KLRG1+ T cells in the periphery (Figure 3.4c),
as previously reported (4,5). These results can be explained by the ability of IL-33 to
induce the trafficking of effector–memory T cells out of the spleen and into the periphery
(Figure 3.4c), migrating to the site of infection to initiate immediate effector function (3032) and protective immunity as illustrated in figure 3.1. Moreover, the significant higher
recall responses of the Ag-specific CD8 T cells 8 days after boosting (Figures 3.3a and
3.4c) was due to higher basal levels of responses which likely correlated with IL-33’s
adjuvant effect. We find these results in accordance with Olson et al demonstrating that
this population can expand after boosting (18). These findings further support the notion
that effector-memory CD8 T cell responses can mediate potent protective immunity
against certain pathogens (18,19). CD8+KLRG1+ T cells are usually considered as shortlived effector cells (22), and together, with recent reports demonstrating vaccines
eliciting persistent effector-memory CD8 T cells may be essential for developing
effective viral and cancer vaccines (27-29), suggest IL-33 as a suitable adjuvant for
therapeutic vaccines. However, IL-33’s role as a suitable adjuvant for preventative
vaccines cannot be negated. On the contrary, new reports have suggested that KLRG1
expressing CD8 T cells may be capable of surviving long-term (18,19,30). And given that
in this study IL-33 was administered in a prophylactic setting may also qualify IL-33’s
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utility as a preventative vaccine adjuvant. Nevertheless, because preventive vaccines
should induce long-lasting Ag-specific responses, we are currently pursuing the role of
IL-33 to induce central memory CD8 T cells.
One molecular mechanism behind IL-33’s potential to drive the formation and
differentiation of effector memory CD8 T cells is likely due to its ability to significantly
increase T-bet expression in CD8 T cells in vivo (Figure 3.3f). Joshi and colleagues
have shown that overexpression of T-bet is enough to induce the formation of KLRG1+
effector cells and that CD8 T cells lacking T-bet are impaired in forming these cytolytic
effector cells (32). Therefore, our data further support the notion that an increase in Tbet is associated with effector CD8 T cell differentiation and their ability to have CTL
phenotype. This finding also supports previous data showing that in vitro IL-33 can
increase T-bet expression (26). Binfeng Lu and colleagues also reported that IL-33
promoted the effector CD8 T cells synergistically with TCR and IL-12 signaling (26).
Therefore, given that the expression of T-bet in T cells is known to be induced by a
combination of T-cell receptor and IFNγ signaling, could explain one underlining
molecular mechanism by which IL-33 promotes effector-memory CD8 T cells (22,32,33).
Nevertheless, further studies are needed to further elucidate these mechanisms and
how IL-33 alters the transcriptional programs to induce memory T cell differentiation.
Interestingly, IL-33 was also associated with inducing the chemokines, CXCL9
(MIG) and CXCL10 (IP-10). These two chemokines have been reported to play a critical
role in (1) recruiting T cells into the inflammatory sites, (2) vaccine-induced T-cell
infiltration into the tumor, and (3) driving effective TH1/CD8 T cell responses (34-43). To
the best of our knowledge, this is the first time these two cytokines have been reported
to be associated with IL-33. This provide further insight to one of the many potential
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roles behind IL-33’s ability to elicit robust effector T cell generation and trafficking in the
periphery that may have correlated with IL-33’s protective role in viral immunity as
established in this study. Furthermore, this provides further insight to our previous
finding on how IL-33’s may have induced complete tumor regression in a therapeutic
HPV-tumor model (5). In fact, MIG and IP-10 have been shown to inhibit tumor growth
by recruiting effector T cells to tumors (44-46). Therefore, these cytokines critical roles
for attracting T-cells to the site of infection, may explain IL-33’s functional role on the
impact of CD8 T cells observed in our study, recruiting the right type of immune cell
infiltration necessary to facilitate viral immunity. We are currently investigating IL-33
roles on DC maturation and function during vaccination in vivo. Indeed, this data
prompts further questions about how IL-33 acts on innate and adaptive immunity and
how it bridges both arms of the immune system in vivo.
The goal of incorporating immunoadjuvants in vaccines is to regulate, modulate,
and enhance the desired adaptive responses to prevent disease acquisition and/or
progression. Therefore, understanding the biological functions and immunological
mechanisms of immunoadjuvants can allow us to better understand correlates of
vaccine immunogenicity, ultimately resulting in the design of better vaccines. Here we
demonstrate that the administration of IL-33 serves as potent adjuvant improving
vaccine efficacy by augmenting the frequencies of effective Ag-specific CD8 T cells,
ultimately leading to significant antiviral protection in a widely used challenge model.
This report also reveals new critical insight into the biological properties of IL-33 to
perpetuate the differentiation of Ag-specific memory CD8 T cells during vaccination.
Consideration of these findings may facilitate the development of better vaccine as well
as to improve immune responses against cancer.
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CHAPTER 4

ALARMIN IL-33 ELICITS POTENT TB-SPECIFIC CELL-MEDIATED RESPONSES
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ABSTRACT
Tuberculosis (TB) still remains a major public health issue despite the current available
vaccine for TB, Bacille Calmette Guerin (BCG). An effective vaccine against TB remains
a top priority in the fight against this pandemic bacterial infection. Adequate protection
against TB is associated with the development of TH1-type and CD8 T cell responses.
One alarmin cytokine, interleukin 33 (IL-33), has now been implicated in the
development of both CD4 TH1 and CD8 T cell immunity. In this study, we determined
whether the administration of IL-33 as an adjuvant, encoded in a DNA plasmid, could
enhance the immunogenicity of a TB DNA vaccine. We report that the co-immunization
of IL-33 with a DNA vaccine expressing the Mycobacterium Tuberculosis (Mtb) antigen
85B (Ag85B) induced robust Ag85B-specific IFNγ responses by ELISpot compared to
Ag85B alone. Furthermore, these enhanced responses were characterized by higher
frequencies of Ag85B-specific, multifunctional CD4 and CD8 T cells. Vaccination with IL33 also increased the ability of the Ag85B-specific CD8 T cells to undergo degranulation
and to secrete IFNγ and TNFα cytokines. These finding highlights IL-33 as a promising
adjuvant to significantly improve the immunogenicity of TB DNA vaccines and support
further study of this effective vaccine strategy against TB.
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INTRODUCTION
Tuberculosis (TB) continues to be one of the most devastating infectious
diseases existing worldwide and a major threat to global health. The causative agent of
TB, Mycobacterium tuberculosis (Mtb), infects as many as 8.8 million new individuals per
year with active TB and is responsible for over 1.4 million deaths annually (1). Against
this threat, the BCG vaccine remains the only currently licensed TB vaccine approved for
human use. While BCG has shown to have adequate efficacy against pediatric forms of
TB, a major drawback has been its inability to protect against adult pulmonary TB (2,3).
The current lack of an effective vaccine necessitates the urgent development of novel
vaccine strategies against TB.
Recently, DNA-based vaccines have shown promise as a therapeutic platform for
treating established HPV infections, because of their ability to evoke both humoral and
cell-mediated immunity (4). Furthermore, the delivery of DNA vaccines, along with
molecular cytokine adjuvants, by electroporation has greatly improved the effectiveness
of DNA vaccines (5). Together these features make DNA vaccines an ideal approach for
the development of an efficacious TB vaccine. In the past several decades only a few
adjuvants have been approved for human use; however, these adjuvants mainly induce
humoral immunity and CD4 T cell responses with relatively little CD8 T cell responses
(6,7). Given the trending evidence that an important feature for an effective vaccine
against Mtb will require both CD4 TH1 and CD8 T cell responses (8-10), it will be
imperative that new vaccine adjuvants tested induce optimal activation of both CD4 and
CD8 T cells.
Alarmins are a unique group of endogenous molecules that initiate host defenses
by inducing inflammation, activating wound healing, and perpetuating immune
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responses (11-13). Alarmins comprise a multitude of molecules, many of which have yet
to be described. However, there are several identified alarmin cytokines, which are
known to differentially induce specific types of immune responses. For instance, both IL1a and HGMB1 cytokines have been associated with promoting the generation of TH1
immune responses (14,15). Specific to this paper, Interleukin 33 (IL-33), a relatively new
member of the IL-1 pro-inflammatory cytokine family, has been associated with TH2driven responses (16,17). Although earlier studies have shown that IL-33 plays a role in
TH2 immune responses, new confounding evidence also characterizes IL-33 as a potent
TH1-polarizing alarmin (18-21). Current studies show that IL-33 can contribute to the
development of TH1-like CD4 and CD8 T cell immunity against infectious diseases and
cancer (20,21). We, ourselves, recently demonstrated that IL-33 could serve as an
immunostimulatory molecule to generate effective immune responses by inducing potent
CD4 TH1 and CD8 antiviral and antitumor immunity in a DNA HPV16 vaccine setting
(21). Moreover, a recent study by Lee et al. reported a positive correlation between IL-33
and IFNγ levels in patients with TB pleurisy (22). Here, we investigated whether
administration of IL-33 expressed as a DNA vaccine construct could increase the
immunogenicity of an anti-TB DNA vaccine. We found that the co-immunization of IL-33
with a TB antigen 85B (Ag85B) DNA vaccine enhanced the potency of the Ag85Bspecific CD4 TH1 and CD8 T cell responses. This data encourages further studies
investigating the potential use of IL-33 as an effective immunoadjuvant for future TB
DNA vaccine studies and for protection in preclinical challenge models.
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METHODS
DNA Construct Designs
The DNA constructs encoding mature IL-33 (mtrIL-33) and the TB Ag85B construct was
designed as previously described (21,23). All constructs had highly efficient
immunoglobulin E (IgE) leader sequences inserted at the 5′ end of the gene. The
constructs were commercially synthesized and optimized as described previously
(21,23).

Animals
All animals were conducted and maintained in accordance with the NIH and the
University of Pennsylvania Institutional Animal Care and Use Committee guidelines.
Female C57BL/6 8-week-old mice were purchased from Jackson Laboratory (Bar
Harbor, ME).

Animal Immunizations
C57BL/6 mice (n = 4 per group) were immunized twice, two weeks apart,
intramuscularly (i.m.) in the tibialis anterior muscle. In vivo electroporation (EP) was
delivered, with the CELLECTRA adaptive constant current EP device (Inovio
Pharmaceuticals), at the same site immediately following vaccination as previously
described (21,23). The mice were immunized with either 10 μg pVAX1 or 10 μg Ag85B
with or without 11 μg of mtrIL-33 construct. One week after final immunization, mice
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were sacrificed and splenocytes were harvested to measure immune responses. All
studies were repeated at least twice.

ELISPOT Assay
All spleens were processed and IFNγ ELISpot assays were performed to determine
antigen-specific cytokine secretion. Briefly, spleens were collected in RPMI 1640
medium (supplemented with 10% FBS, 1X Antibiotic-Antimycotic, and 1X β-ME) and
splenocytes were isolated by mechanical disruption of the spleen using a Stomacher
machine (Seward Laboratory Systems, Bohemia, NY). The resulting mashed spleens
were filtered using a 40µm cell strainer, treated with ACK lysis buffer for 5 minutes to
lyse RBCs, washed in PBS and then re-suspended in RPMI medium for use in ELISpot
or Flow Cytometry assay. The IFNγ ELISPOT assays were conducted as previously
described in detail (21,23). Ag85B-specific T cell responses were measured by
stimulating splenocytes with pooled peptides (11-mers overlapping by 8 amino acids; 2.5
µg/ml final) spanning the entire TB Ag85B antigen (Invitrogen). All peptides were
synthesized from GenScript. Concavalin A (Sigma-Aldrich, St. Louis, MO) was used as
positive control and complete culture medium was used as negative control. Background
staining from cells stimulated with medium alone has been subtracted. Spots were
enumerated using an automated ELISPOT reader (Cellular Technology, Shaker Heights,
OH).
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Intracellular Cytokine Staining Flow Cytometry
Intracellular cytokine staining was performed after 5 hours of ex vivo stimulation with
Ag85B pooled peptides as described (21-24). In cultures being used to measure
degranulation, anti-CD107a (FITC; clone 1D4B; Biolegend) was added during time of
stimulation to capture the degranulation induced by exposure to antigen stimulation by
Ag-specific cells. The cells were then fixed and stained as described elsewhere (21-24).
The following antibodies were used for surface staining: LIVE/DEAD Fixable Violet Dead
Cell stain kit (Invitrogen), CD4 (V500; clone RM4-5; BD Biosciences), CD8 (APC-Cy7;
clone 53-6.7; BD Biosciences). For intracellular staining the following antibodies were
used: IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone MP6-XT22; ebioscience),
CD3 (PerCP/Cy5.5; clone 145-2C11; Biolegend), and IL-2 (PeCy7; clone JES6-SH4;
ebioscience). All data was collected using a LSRII flow cytometer (BD Biosciences) and
analyzed using FlowJo software (Tree Star, Ashland, OR) with SPICE v5.3 (free
available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed using
FlowJo software to examine the polyfunctionality of the T cells from vaccinated animals.
For flow cytometry, cells were gated on singlets using SSC-H by SSC-A followed by
gating on LIVE-DEAD, CD3+CD4+CD8- T and CD3+CD8+CD4- T cells to examine the
CD4 and CD8 T-cell populations.
Statistical Analysis
Group analyses were completed by matched, two-tailed, unpaired student’s t-tests to
analyze statistical significance of all quantitative data produced in this study. A P<0.05
was considered statistically significant. All values are mean ± SEM and statistical
analyses were performed using GraphPad Prism (La Jolla, CA).
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RESULTS
IL-33 enhances TB Ag85B-specific IFNγ responses after in vivo vaccination
We have previously shown that IL-33 delivered as an immunoadjuvant can
induce TH1 responses in a DNA vaccine setting (21). Therefore we examined whether
IL-33 could increase vaccine potency when co-administered with a DNA vaccine
encoding the TB antigen 85B (Ag85B). To this end, C57BL/6 mice were immunized
intramuscularly with 10μg of Ag85B with or without 11μg of IL-33, immediately followed
by electroporation (EP) (Figure 4.1A). One week after final immunization the magnitude
of Ag85B-specific IFNγ production was measured by IFNγ ELISpot assay. As shown in
figure 4.1B, the addition of IL-33 increased the Ag85B-specific IFNγ T cell-secreting
responses. Compared to the Ag85B alone-immunized group (~333 SFC per million
splenocytes), the IL-33 vaccinated group resulted in a 3-fold increase (~1062 SFC per
million splenocytes) in the frequency of Ag85B-specific responses (Figure 4.1B). These
results suggest that IL-33 functions as an effective adjuvant to augment the TB antigenspecific responses during DNA vaccination.

IL-33 significantly increases TB Ag85B-specific CD4 and CD8 splenic T cell
responses
Next we were interested in whether IL-33 could enhance both the CD4 and CD8
T cell responses to Ag85B, so we carefully characterized the phenotype and cytokine
profile of the 85B-specific T cells generated. To that end, one week after last
immunization (Figure 4.1A), splenocytes were stimulated ex vivo with Ag85B pooled
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peptides and the production of IFNγ, TNFα, and IL-2 by CD4 and CD8 T cells was
analyzed by intracellular cytokine staining (ICS). Compared to Ag85B vaccination alone,
the IL-33 adjuvant group induced significantly higher percentages of Ag85B-specific CD4
T cells, many of which were multifunctional (Figure 4.2D). These T cells were described
by total IFNγ (Ag85B: 0.8%; mtrIL-33: 1.6%), TNFα (Ag85B: 0.9%; mtrIL-33: 1.6%), and
IL-2 cytokine production (Ag85B: 0.30%; mtrIL-33: 0.51%) (Figures 4.2A-C). As shown
in figure 4.2D, vaccination with Ag85B co-administered with IL-33 elicited substantially
higher frequencies of TB-specific CD4 T cells producing dual IFNγ+TNFα+ (Ag85B:
0.43%; mtrIL-33: 0.95%) or triple-positive IFNγ+TNFα+IL-2+ (Ag85B: 0.24%; mtrIL-33:
0.47%) in the spleens (Figure 4.2D). In terms of CD8 T cells, we saw a similar trend with
the vaccinated IL-33 group, which induced higher percentages of TB-specific CD8 T
cells producing total IFNγ (Ag85B: 0.19%; mtrIL-33: 1.12%), total TNFα (Ag85B: 0.29%;
mtrIL-33: 1.1%), and total IL-2 cytokine responses, although IL-2 responses were not
significant (Figures 4.3A-C). However, we found that

immunization with IL-33

predominately elicited higher frequencies of TB-specific CD8 T cells producing dual
IFNγ+TNFα+ (Ag85B: 0.12%; mtrIL-33: 0.92%)(Figure 4.3D). The administration of IL-33
produced similar amounts of Ag-specific CD4 and CD8 T cell responses with the
majority of T cell subsets simultaneously secreted both IFNγ and TNFα. Subsequently,
we analyzed the cytotoxic ability of the vaccine-induced CD8 T cells to undergo
degranulation, which was measured by staining with antibody to CD107a, a marker for
degranulation. Compared to Ag85B alone-vaccinated mice (IFNγ+CD107a+: 0.2%), the
CD8 T cells isolated from mice vaccinated with IL-33 showed significantly higher
percentages of Ag-specific CD8+CD107a+ T cells secreting IFNγ (IFNγ+CD107a+: 1%)
(Figure 4.4A). The IL-33 immunized mice also elicited substantially higher polyfunctional
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CD8 T cells co-expressing CD107+IFNγ+TNFα+ (Ag85B: 0.11%; mtrIL-33: 0.91%),
compared with the control groups (Figure 4.4B). Altogether, the inclusion of IL-33 can
elicit robust levels of TB-specific TH1 driven cell-mediated immune responses.

113

FIGURES

Figure 4.1. IL-33 enhances TB-specific IFNγ cellular immune responses in
immunized mice. (A) Immunization schedule in mice. C57BL/6 mice (n = 4) were
immunized twice, with a two-week interval between immunizations, with 10 µg Ag85B
construct with or without 11 µg of IL-33 construct. (B) The total magnitude of IFNγ
responses induced by isolated mice splenocytes (n = 4) stimulated ex vivo with Ag85B
pooled peptides for 24 hours and measured by IFNγ ELISpot assay. The Data shows the
SEM of one experiment repeated at least two times. **, P < 0.01
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Figure 4.2. IL-33 augments cytokine production by Ag85B-specific CD4 T cells
following DNA immunization. Cytokine-recall responses to TB Ag85B antigen were
measured one week after last immunization by ICS and flow cytometry. A-C, column
graphs depict the total TB-specific CD4 T cells expressing IFNγ (A), TNFα (B) and IL-2
(C). (D) Polyfunctional flow cytometry was used to determine the percentages of
multifunctional CD4 T cell cytokine profiles. The bar chart shows the percentage of
Ag85B-specific CD3+CD4+ T cells displaying triple, double, or single release of the
cytokines IFNγ, TNFα, and/or IL-2+. Pie charts show the proportion of each cytokine
subpopulation to Ag-specific stimulation. Experiments were performed independently at
least twice and data represent the mean ± SEM of four mice per group. *, P < 0.05
compared with Ag85B non-adjuvanted group.
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Figure 4.3. Induction of enhanced cytokine production of Ag85B-specific CD8 T
cells following DNA immunization with IL-33. Cytokine-recall responses to TB Ag85B
antigen were measured one week after last immunization by ICS and flow cytometry. AC, column graphs depict the total TB-specific CD8 T cells expressing total IFNγ (A),
TNFα (B) and IL-2 (C). (D) Polyfunctional flow cytometry was used to determine the
percentages of multifunctional CD8 T cell cytokine profiles. The bar chart shows the
percentage of Ag85B-specific CD3+CD8+ T cells displaying triple, double, or single
release of the cytokines IFNγ, TNFα, and/or IL-2. Pie charts show the proportion of each
cytokine subpopulation to Ag-specific stimulation. Experiments were performed
independently at least twice and data represent the mean ± SEM of four mice per group.
***, P < 0.001; **, P < 0.01; *, P < 0.05 compared with Ag85B non-adjuvanted group.
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Figure 4.4. IL-33 promotes Ag85B-specific cytotoxic degranulating CD8 T coexpressing IFNγ and TNFα. (A) Ag85B-specific, cytolytic-degranulation CD8 T cells
were measured by degranulation marker expression, CD107a and IFNγ. Figure (B)
shows the frequency of polyfunctional CD8 T cells co-expressing CD107a. Data
represent the SEM of 4 mice per group. The experiment was repeated twice with similar
outcome. **P < 0.01, *P < 0.05 using Student’s t-test.
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DISCUSSION
It has been established that the development of an acquired cellular immune
response (both TH1-type CD4 and CD8 T cells) is paramount for the control of Mtb
infection. These T cell populations secrete essential cytokines (IFNγ+ and TNFα+), which
stimulate infected macrophages to kill intracellular bacteria (25-27). Additionally it has
been shown that knockout mice that have been genetically altered to eliminate IFNγ+ or
TNFα+ production are more susceptible to mycobacterial infection (25-27). Therefore,
the development of new molecular adjuvants to drive these preferable anti-TB immune
responses may potentially lead to a more effective vaccine against TB.
The data presented here demonstrates that IL-33 delivered as a molecular
adjuvant can evoke significant Ag85B-specific cell-mediated immune responses in a TB
DNA vaccine setting. We show that co-administration of IL-33 with Ag85B DNA EP
immunization markedly increases the magnitude of Ag-specific IFNγ responses by
ELISpot. The inclusion of IL-33 induced a ~3-fold greater response compared with to
Ag85B-alone immunization (Figure 4.1B). We find this in accordance with previous data
showing that administration of IL-33 along with vaccine antigen can increase the
vaccine-induced TH1 responses (20,21). Furthermore, we show that IL-33 can increase
the total splenic CD4 T cells and CD8 T cells secreting IFNγ and TNFα after Ag85B
peptide pool stimulation (Figures 4.2-4.3). Given the importance of multifunctional
vaccine-induced anti-TB protective CD4 T cell responses to prevent disease after
exposure and to control Mtb in a latent state (28,29), we assessed the polyfunctionality
of the CD4 T cells (Figure 4.2). The Ag85B vaccine co-administered with IL-33 elicited a
significant enhancement of the polyfunctional CD4 T cell population simultaneously
secreting both IFNγ+TNFα+ and IFNγ+TNFα+IL-2+ cytokines (Figure 4.2D). The triple
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positive IFNγ+TNFα+IL-2+ and double positive IFNγ+TNFα+ T cell phenotypes normally
represent effector memory and central memory T cells (30), indicating the induction of
memory CD4 T cell immune responses. Within the cytokine-producing CD8 T cells, the
proportional distribution of polyfunctional T cell subsets followed the order of IFNγ+TNFα+
being greater than IFNγ+ (Figure 4.3D). IL-33 not only improved the polyfunctionality of
the CD8 T cells, but also increased their antigen-specific cytolytic phenotype activity as
demonstrated by the co-expression of CD107a+IFNγ+TNFα+ (Figure 4.4B). Moreover, IL33 significantly enhanced the vaccine-induced total CD4 T cells secreting IL-2 responses
(Figure 4.2C), a cytokine that is secreted predominately by Ag-stimulated CD4+ T cells
(31-33). IL-2 also plays a crucial role in driving CD8 T cell differentiation, proliferation,
and activation and therefore enhancing the Ag-specific CD8 effector functions (Figure
4.3 & 4.4), such as cytolytic activity and cytokine production (8,9). Altogether, the data
highlight adjuvant effects of IL-33 to augment vaccine potency of both CD4 and CD8 T
cells, which would be indispensable for protective immunity against TB (8-10).
These results are in agreement with our previously published data that
demonstrated that IL-33 could enhance both CD4 TH1 and CD8 T cell responses with
cytolytic properties (21). Furthermore, this finding is consistent with the recent reports
that IL-33’s role extends beyond TH2 immunity; IL-33 can promote TH1 and CD8 type
cell-mediated immunity given the appropriate cytokine milieu and microenvironment (1621). Recent reports suggest that IL-33 can be a potent inducer of CD8+ T cells, as only
activated effector CD8 T cells can up-regulate the IL-33 cognate receptor, ST2, and in
synergy with IL-12 can selectively enhance the expression of IFNγ responses (20). The
mechanism by which IL-33 promotes TH1 CD4 and CD8 T cell differentiation is still
unknown. In our study, it is possible that the co-induction of type 1 cytokine IFNγ could
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be related to our selected antigen, Ag85B, which is a potent TH1 antigen (34,35).
Therefore, the favored TH1 cytokine milieu perpetuated by our selected TB antigen may
have induced a favorable immune environment that allowed IL-33 to foster a greater TH1
cell-mediated immune response. Further studies are needed to understand exactly how
IL-33 induces type-1 TH1 IFNγ+ responses in the context of an in vivo immune setting. In
addition, studies are needed to understand how IL-33 bridges the innate with the
adaptive immune response to evoke a pro-TH1 cell-mediated response.
Overall, in this study we further validate IL-33 as a future potent TH1- and CD8mediated immunoadjuvant in a DNA vaccine setting. IL-33 may be an effective strategy
for increasing the efficacy of future DNA vaccines against Mtb. Since Mtb infection
targets the lungs, current studies are evaluating the ability of IL-33 to induce
polyfunctional antigen-specific T cells in the lungs. Furthermore, although IL-33 can elicit
desired cell-mediated responses, it can also be detrimental to subjects at risk for HIV.
The immune activation induced by IL-33 could pave the road for more efficient
acquisition of HIV infection. Thus, challenge studies will be important to confirm the
protective nature of IL-33 as a vaccine adjuvant in a relevant challenge system.
Experiments are currently under way to test the protective efficacy of IL-33 against Mtb
both as a standalone and as a prime-boost immunization regimen in combination with
BCG.
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CHAPTER 5
UBIQUITIN-LIKE MOLECULE ISG15 ACTS AS AN IMMUNE ADJUVANT TO
ENHANCE ANTIGEN-SPECIFIC CD8 T CELL TUMOR IMMUNITY

“This day is full of glorious victory,
Echoes of conquest whisper from afar
In every wave of the remembering sea.”
-H. Begbie
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Abstract

ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral
activity. ISG15 is also secreted and known to function as an immunomodulatory
molecule. However, ISG15’s role in influencing the adaptive CD8 T cell responses has
not been studied. Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant,
inducing HPV E7-specific IFNγ responses as well as the percentage of effector-like
memory, polyfunctional, and cytolytic CD8 T cell responses. Vaccination with ISG15
conferred remarkable control and/or regression of established HPV-associated tumorbearing mice. T cell depletion coupled with adoptive transfer experiments revealed that
ISG15 protective efficacy was CD8 T cell-mediated. Importantly, we demonstrate that
ISG15 vaccine-induced responses could be generated independent of ISGylation,
suggesting that responses were mostly influenced by free ISG15. Our results provide
more insight into the immunomodulatory properties of ISG15 and its potential to serve as
an effective immune adjuvant in a therapeutic tumor or infectious disease setting.
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Introduction
The induction of cytotoxic CD8 T cells is believed to be essential in tumor control, and,
thus, a necessary goal for any therapeutic cancer vaccine. Nevertheless, insufficient
generation of CD8 effector T cells has led to the failure of several therapeutic cancer
vaccines to produce clinical regression of solid tumors (1-3). For such vaccines, the
incorporation of adjuvants can assist in generating potent and durable tumor immunity
(4,5), but most of the effects of adjuvants have been limited to TH1 CD4 expansion with
poor CD8 T cell killing function induced. Thus identifying adjuvants capable of amplifying
CD8 T cell antitumor immunity is very important for therapeutic antitumor vaccines.
Interferon-stimulating gene 15 (ISG15) is one of the first and most abundant
proteins induced by type I interferon stimulation (6). ISG15 is an ubiquitin-like protein,
which plays a major role in antiviral defense (6). Its ubiquitin-like C-terminal (LRLRGG)
motif is necessary for its conjugation to a variety of intracellular proteins in a process
known as ISGylation (6) producing “conjugated” ISG15. When not in its conjugated form,
free or “unconjugated” ISG15 can exist intracellularly or extracellularly. For decades, free
ISG15 has been implicated in the production of IFNγ (7-9).

Recently, a new study

confirmed this cytokine-like role for ISG15 by demonstrating that ISG15- deficiency was
associated with a loss of IFNγ, which in turn led to increased susceptibility to
mycobacterial disease in both mice and humans (10). Although these studies have
established the ability of ISG15 to function as an immunomodulatory molecule, its ability
to influence CD8 T cell immune responses and act as a vaccine adjuvant remains
unknown. Here we sought to investigate the role of ISG15 as an adjuvant to enhance
tumor-specific CD8 T cell immunity using a human papilloma virus (HPV)-associated
tumor murine therapeutic model.
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Here we report that ISG15 can act as an effective CD8 T cell-mediated adjuvant
when co-delivered with a HPV16 DNA vaccine via in vivo electroporation (EP). The
inclusion of ISG15 substantially increased E7-specific IFNγ responses as well as the
percentage of effector-like memory, polyfunctional, and cytolytic CD8 T cells.
Importantly, we report that the augmentation of ISG15’s functional CD8-mediated tumor
immunity achieved control and/or regression of tumors in established HPV-associated
tumor-bearing mice. We also show that the therapeutic efficacy of ISG15 correlates with
the increase in magnitude and phenotype of tetramer-specific, effector-memory CD8 T
cells. Finally, we demonstrate that ISG15 delivered as an immunoadjuvant generates
responses independent of conjugation as an LRLRGG-mutant ISG15 also induced
potent CD8 T cell responses. We conclude that ISG15 may be a valuable tool to improve
the immunogenicity of vaccines against cancer as well as to treat persistent infections.
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METHODS
DNA construction and expression
The GenBank accession no. Q64339 for mouse ISG15 was used to synthesize the DNA
construct encoding wild-type ISG15 (wtISG15). Mutated ISG15 (mutISG15) is a variant
of wtISG15 with point mutations at its C-terminal conjugation site (LRLRGG to
AAAAGG). All constructs contained highly efficient immunoglobulin E (IgE) leader
sequence inserted at the 5’ end of the gene. The constructs were commercially
synthesized and optimized as described previously (5,11). HPV16 plasmid containing
the E6 and E7 antigens was prepared as previously described (15). In vitro expression
of both ISG15 constructs was confirmed by Western Blot (WB) analysis using. Human
rhabdomyosarcoma (RD) cells were maintained in Dulbecco’s modified Eagle’s medium
(Life Technologies, Grand Island NY USA) and supplemented with 10% heat-inactivated
fetal calf serum as well as penicillin and streptomycin. After plating 3.0 x105 cells per
well, transfection was performed using Neofectin (NeoBiolab Cambridge MA) following
the manufacture’s protocol. Cells were transfected with 2ug of each DNA construct
including pVAX1 empty vector backbone as a negative control. Following 48 hour
incubation, cell supernatants were collected and cells were washed with cold PBS. After
centrifugation, cells were lysed using cell lysing buffer (Cell Signaling Technology
Danvers, MA) and EDTA free protease inhibitor cocktail (Sigma-Aldrich St. Louis, MO).
Cell lysate was run on a 10% Tris-Acetate gel with MES buffer (Life Technologies Grand
Island NY USA) and transferred onto a PVDF membrane (Millipore, Darmstadt,
Germany). The membrane was block using Odyssey blocking buffer (Licor, Lincoln,
Nebraska) for three hours at room temperature followed by probing with rabbit antimouse ISG15 (Cell Signaling Technology Danvers, MA) and mouse anti-human β-actin
(Sigma-Aldrich St. Louis, MO) as a loading control at 4 degrees overnight. After washing
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with PBS-Tween, secondary goat anti-mouse IRDye 680RD and goat anti-rabbit IRDye
800 CW (Li-cor, Lincoln, Nebraska) were added for 1 hour at room temperature. The
membrane was then washed and imaged on the Odyssey CLX (Licor, Lincoln,
Nebraska). In addition, supernatants were also collected at 48 hours after transfection
and cytokine secretion was examined by using a CircuLex mouse ISG15 ELISA kit (MBL
International), according to manufacturer’s protocol. Optical density was measured at
450nm using a Bioteck EL312e Bio-Kinetics reader (Biotek US, Winooski, VT). All
supernatants were tested in duplicate with two separate supernatant sample per a
plasmid.

Animals
All animals were conducted and maintained in accordance with the NIH and the
University of Pennsylvania Institutional Animal Care and Use Committee guidelines.
Female C57BL/6 (H-2b) 8-week-old mice and H2b B6.129S7-Rag1tm1Mom/J mice (Rag1
KO) were purchased from Jackson Laboratory.

Animal immunizations
All mice were immunized intramuscularly (i.m.) in the tibialis anterior muscle. In vivo
electroporation (EP) was delivered, with the CELLECTRA adaptive constant current
electroporation device (Inovio Pharmaceuticals), at the same site immediately following
immunization as previously described (11). The mice were immunized with either 5μg
pVAX1 or 5μg of HPV16 construct with or without 11μg of wtISG15 and mutISG15. All
studies were performed at least twice.
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ELISPOT assay
Spleens were harvested and processed 7 days following the final immunization as
previously described (5,11). After spleens were harvested and processed, an IFNγ
ELISpot assay was performed to determine antigen-specific cytokine secretion from
immunized mice as described previously in detail (5,11-12). HPV16 Ag-specific T cell
responses were measured by stimulating splenocytes with E6 or E7 pooled overlapping
peptides (2.5 µg/ml final concentration of peptide). The E7 overlapping pooled peptides
contained the CD8 T cell immunodominant HPV16 DbE749-57 epitope (RAHYNIVTF).

Flow cytometry
Lymphocytes were isolated and processed from the spleen and peripheral blood as
previously described (5,11,13). Lymphocytes were stained with CD8, KLRG1, and MHC
class I peptide tetramer to HPV16 H-2DbE749-57 (RAHYNIVTF) (MBL International) as
described previously (5,14). Intracellular cytokine staining was performed after 5 hrs of
ex vivo stimulation with the HPV16 E7 peptide DbE7 (RAHYNIVTF) (2.5 µg/ml final
concentration of peptide) or E7 pooled overlapping peptides to assess CD4 T responses
(12). In cultures being used to measure degranulation, anti-CD107a (FITC; clone 1D4B;
Biolegend) was added during time of stimulation to capture the degranulation induced by
exposure to stimulation by Ag-specific cells (5). The cells were then fixed and stained as
described elsewhere (5,15). The following antibodies were used for surface staining:
LIVE/DEAD Fixable Violet Dead Cell stain kit (Invitrogen), CD4 (FITC; clone RM4-5;
ebioscience), CD8 (APC-Cy7; clone 53-6.7; BD Biosciences), NK1.1 (FITC; clone
PK136; biolegend); CD49b (FITC; clone DX5; ebioscience). For intracellular staining the
following antibodies were used: IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone
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MP6-XT22; ebioscience), CD3 (PerCP/Cy5.5; clone 145-2C11; Biolegend); IL-2 (PeCy7;
clone JES6-SH4; ebioscience). All data was collected using a LSRII flow cytometer (BD
Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR) and SPICE
v5.3 (free available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed
using FlowJo software to examine the polyfunctionality of the T cells from vaccinated
animals.

Tumor cell line
The TC-1 cell line was a graciously given gift from Dr. Yvonne Paterson of the University
of Pennsylvania, Philadelphia, PA. TC-1 cell line is a well-characterized lung epithelial
immortalized cell line, constitutively expresses E6 and E7, and is highly tumorigenic
(16,17). The TC-1 cells were purchased from American Type Culture Collection and
cultured as previously described (5).

In vivo therapeutic study
B6 mice were separated into four groups of 10 mice each and 5x104 TC-1 cells were
subcutaneously implanted into the right flank of each mouse. On day 4, after tumor
implantation, each group of mice was immunized by intramuscular electroporation with
pVAX1, HPV16, HPV16/wtISG15 or HPV16/mutISG15 and boosted on days 11, 18, and
25. Tumor size was measured twice a week using electronic calipers and tumor volume
calculated as described previously [½(length x width2)]. Mice were monitored twice a
week for tumor growth and were measured as described previously (5,12). Under Penn
Institutional Animal Care guidelines, mice were sacrificed when tumor size reached 1820mm.
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In vivo CD8 T cell depletion study
During therapeutic vaccination, B6 mice were injected intraperitoneal with 200 µg of antiCD8 (53-6.72, Bio X cell) one day before tumor inoculation and repeated every three
days thereafter. Successful T cell depletion was confirmed by flow cytometric analysis of
peripheral blood mononuclear cells.

T-cell purification and adoptive transfer
CD8 T cells were isolated from splenocytes of vaccinated B6 mice 1 week after final
immunization in non-bearing tumor mice (Fig 2A). CD8+ T cells were purified from
splenocytes using negative selection to deplete CD4+ T cells, B cells, and myeloid cells.
Briefly, following RBC lysis, splenocytes were incubated with rat IgG anti-CD4 (GK1.5),
anti-B220 (RA3), anti-CD11b (M170.13), anti-MHC-II (M5/114), and anti-CD16/32
(2.4G2). Antibody-bound cells were removed using anti-rat IgG magnetic beads (18). For
adoptive transfer, ~4 x 106 CD8 T cells in 200 µl PBS were injected intravenously via tail
vein into each H2b B6.129S7-Rag1tm1Mom/J mouse.

Statistical Analysis
Group analyses were completed by matched, two-tailed, unpaired student’s t-tests to
analyze statistical significance of all quantitative data produced in this study. A P-value
<0.05 was considered statistically significant. Error bars indicate SEM and all tests were
performed using the Prism Software (*, P < 0.05; **, P < 0.01; ***, P < 0.001 compared
with HPV16 immunization).
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RESULTS
Design and expression of ISG15 constructs
The wild-type ISG15 (wtISG15) adjuvant construct was generated using the
mouse ISG15 sequence retrieved from GenBank (accession number: Q64339) with
several modifications (Figure 5.1A). ISG15 contains a C-terminal LRLRGG motif that is
necessary for its conjugation to a variety of target proteins in a process referred to as
ISGylation (19-21). In order to determine if conjugation was necessary for ISG15mediated immunomodulation, the ISG15 conjugation sequence site was mutated
(LRLRGG to AAAAGG) to generate the mutant ISG15 (mutISG15), incapable of
conjugation (Figure 5.1A). Both ISG15 constructs were genetically optimized and
subcloned into a modified pVAX1 mammalian expression vector (Figure 5.1B). To verify
the expression of both ISG15 encoding constructs, human rhabdomyosarcoma (RD)
cells were transfected separately with each vector and examined by WB. As shown in
Figure 5.1C, an ~15kDa free ISG15 was observed for each in cell lysates harvested 48
hours after transfection using anti-ISG15 monoclonal antibody (mAb) for detection.
ISG15 expression was not detected in the negative control pVAX1 group. Next, via an
enzyme-linked immunosorbent assay (ELISA) the secretion of free ISG15 was
monitored from the cell supernatants that were obtained 48 hours after transfection of
RD cells. As projected, supernatants from mutISG15 transfected RD cells had a higher
concentration of detectable secreted free ISG15 (7.2 ng/ml), compared to wtISG15 (4.4
ng/ml) (Figure 5.1D). This supported our notion that by mutating ISG15’s conjugation
motif, more unconjugated ISG15 would be available and secreted to the extracellular
environment.
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Immunization with ISG15 adjuvant induced strong HPV E7-specific CD8 T cell
immune responses.
To assess the immunogenic properties of ISG15, an IFNγ ELISpot assay was
performed to determine the number of vaccine-induced E7-specific IFNγ secreting cells
in response to E7 pooled peptides containing the immunodominant CTL epitope H-2DbE749-57 (E7). The immunization regimen is shown in Figure 5.2A. Briefly, groups of B6
mice (n = 4-5/group) were vaccinated twice at two-week intervals as follows: (i) HPV16
DNA/EP; (ii) HPV16/wtISG15 DNA/EP; (iii) HPV16/mutISG15 DNA/EP; and (iv)
pVAX1/EP. The co-administration of HPV16 with wtISG15 resulted in a 3.5-fold increase
in E7-specific IFNγ responses (~230 SFC/million splenocytes) compared with HPV16
alone-immunized group (~66 SFC/million splenocytes). ISG15 is an ubiquitin-like protein
that conjugates to target proteins and is critical for control of certain viral and bacterial
infections (6). In addition to the conjugated form of ISG15, it is known, that ISG15 is
present in an unconjugated form (free ISG15) and can also play an important role in
immunomodulation or during infection (6). Thus, in the same experiment, we examined if
vaccine-induced responses were independent of conjugation by immunizing mice with a
mutated form of ISG15 lacking a functional C-terminal LRLRGG conjugating motif.
Interestingly, similar to wtISG15, the mutISG15 vaccinated group demonstrated an
increase (~4-fold) in total E7-specific cells compared with HPV16-only group, suggesting
ISG15 can induce its effects independent of conjugation. We did not find relatively higher
induced levels of E6-specific vaccine-induced responses (data not shown). Together,
these data suggest the ubiquitin-like molecule ISG15 can act as an adjuvant to enhance
and stimulate E7-specific TH1-mediated CD8 T cell responses. Moreover, this data
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demonstrated that the elevated antigen (Ag)-specific responses were most likely
attributed to free ISG15.

ISG15-mediated augmentation of polyfunctional HPV E7-specific cell-mediated
responses
Considering that CD8+ T cell immune responses are essential in prevention of
tumorigenesis and elimination of tumors (1,22-25), we further examined the functional
profile of E7-specific CD8 T cell populations from vaccinated mice to secrete IFNγ, TNFα
and IL-2 in response to DbE749-57 peptide stimulation. Our gating strategy for intracellular
cytokine multiparametric flow cytometry analysis is shown in Figure 5.3A. One week
after final vaccination all tested vaccination regimens induced detectable CD8 T cell
responses producing all three effector cytokines (Figure 5.3). Compared to the antigen
alone group, both ISG15 vaccine regimens induced significant E7-specific CD8 T cells
producing total IFNγ (wtISG15, 0.68%; mutISG15, 0.92%) (Figure 5.3B) and total TNFα
(wtISG15, 0.42%; mutISG15, 0.54%) (Figure 5.3C). However, ISG15 only induced a
minor increase of Ag-specific CD8 T cells secreting IL-2 (Figure 5.3D) Importantly, a
significant number of the E7-specific CD8 T cells were polyfunctional, with ISG15immunized groups eliciting significantly higher frequencies of CD8 T cells producing
either IFNγ alone or dual IFNγ+TNFα+ in the spleens 7 days post vaccinations (Figure
5.3E). There was also a modest increase in the triple-positive IFNγ+TNFα+IL-2+ CD8
secreting cells in the ISG15-treated groups. Since ISG15 can have an effect on NK cells,
we monitored vaccine-induced NK responses, but no significant changes were seen
after vaccination with ISG15 (Figure 5.4A) (9). Furthermore, the administration of ISG15
did not increase vaccine-induced CD4 T cell responses as measured by ex vivo E7
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pooled peptide stimulation (Figure 5.4B).
Given that cytotoxic CD8 T lymphocytes (CTL) are critical components in
protection (1,5,24,25), we assessed the cytolytic properties of the adjuvant-induced CTL
responses to undergo degranulation and secrete effector cytokines simultaneously
(Figure 5.5). The groups vaccinated with immunoadjuvant ISG15 showed higher
percentages of the degranulation marker, CD107a (wtISG15, 2.4%; mutISG15, 3.1%),
compared with HPV16-alone group (Figure 5.5A). More interestingly, the ISG15adjuvanted vaccines elicited substantially higher frequencies of polyfunctional CTLs, with
a substantial representation of cells showing one, two, and three immunological
functions (Figure 5.5B-C). Notably, compared to HPV16 administered alone, the ISG15treated groups showed significantly higher frequencies of CD8 T cells co-expressing
CD107a+IFNγ+TNFα+ (wtISG15, 0.35%; mutISG15, 0.43%) (Figure 5.5C). Collectively,
the high frequencies of effector cells secreting proinflammatory cytokines are indicative
of the ISG15 cytokine-like properties and its adjuvant effects to enhance vaccine
potency by diving potent functional effector CTL immunity. Overall, an important
observation here was that a DNA plasmid expressing the mutISG15, incapable of
conjugation, maintained the adjuvant effects displayed by wild-type form, suggesting that
ISGylation is likely not required for immunomodulation of CD8 T cells.

ISG15 adjuvant amplifies robust Ag-specific effector-memory CD8 T cell
responses
Since it has been demonstrated that magnitude and quality of E7-specific CD8 T
cell responses correlates with the therapeutic efficacy of HPV vaccine against
established tumors (24,26), we investigated the HPV tetramer-specific CD8 T responses
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that may correlate with vaccine-induced HPV-associated tumor control. To this end, nontumor-bearing B6 mice were immunized with the aforementioned vaccination
formulations and schedule in Figure 5.2A. One week after final immunization, the
magnitude and subset differentiation of Ag-specific CD8 T cell responses were
examined using the CD8 epitope specificity of HPV16 E749-57 H2-Db-RAHYNIVTF
tetramer in the spleen and blood (Figure 5.6). Both wtISG15 and mutISG15 constructs
were able to significantly increase the DbE7 tetramer-specific CD8 T cell responses in
the spleen compared to HPV16 group alone (Figure 5.6A and B). In addition, the
delivery of both ISG15 plasmids also significantly amplified the number of DbE7
tetramer-specific CD8 T cells in the peripheral blood, suggesting trafficking of tumor
target-specific CTL’s into the periphery (Figure 5.6E) (26). The frequency of E7-tetramer
T cells in the blood within the wtISG15 and mutISG15 groups were 4 and 5.5-fold higher
compared with the nonadjuvanted group, respectively. This data confirmed that
immunoadjuvant ISG15 could amplify the Ag-specific CD8 T cells.
It has been suggested that effector-memory CD8 T cells are optimal subsets for
protective immunity and may predict therapeutic efficacy against tumors (4,5,27,28).
Effector memory T cells are the focus of cancer vaccines as they can initiate rapid
effector function and migrate quickly to the infected- or tumor-site (1,29-31). In this
study, we measured the DbE7 MHC class I tetramer vaccine-induced effector/effectormemory CD8 T cell subset based on expression marker of KLRG1 (effector memory Teff) (5,14,27) (Figure 5.6). The administration of wtISG15 resulted in a ~3-fold increase
in the percentages of Teff cells in the spleen, compared with the HPV16-only vaccinated
group (Figure 5.6C and D). Similarly, the inclusion of mutISG15 also significantly
enhanced the Teff responses in the spleen (Figure 5.6D). In addition, as shown in Figure
5.6F, the percentages of Teff cells in the blood were significantly higher in the adjuvant
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groups. These data suggest that immunoadjuvant ISG15 can enhance the magnitude
and quality of E7-specific CD8 T cell responses.

ISG15 acted as an effective CD8 T cell immunoadjuvant inducing antitumor
immunity
We next determined the therapeutic efficacy of ISG15 in a TC-1 tumor-bearing
mice model. Naïve recipient B6 mice (n = 10/group) were first inoculated subcutaneously
with TC-1 tumor (5x104) cells followed by HPV16, HPV16/wtISG15, HPV16/mutISG15 or
pVAX1 vaccination four days after tumor implantation (tumors had reached an average
size of 2 mm), followed with three boosts at 1-week intervals (Figure 5.7A). Tumors in
mice immunized with the mixture of HPV16/wtISG15 grew significantly slower than
HPV16 vaccinated group alone (Figure 5.7B). In contrast, pVAX1 control group failed to
show any therapeutic effect with all mice dying by day 35. Interestingly, mice given the
HPV16/mutISG15

had

significantly

better

tumor

control

than

mice

given

HPV16/wtISG15, likely due to greater induction of tumor-specific CTL responses. In
addition, compared to HPV16/wtISG15, the HPV16/mutISG15 combination rapidly
induced regression of more established TC-1 tumors (Figure 5.8). At day 42 post tumor
implantation, 6/10 mice in the HPV16-mutISG15 were tumor free, compared with either
HPV16 (1/10) or HPV16-wtISG15 (2/10) (Figure 5.8). Taken together, the adjuvant
properties of ISG15 demonstrated effective control and therapeutic cure of HPVassociated tumor-bearing mice.
Given ISG15 adjuvant properties to enhance E7-specific-CTL responses that are
essential to target established preexisting HPV infections (22,23), we investigated the
role of ISG15-elicited CD8 T cells for HPV-associated tumor elimination. Therefore, in a
therapeutic setting, CD8 T cells were depleted by intraperitoneal injection of anti-CD8
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antibody, beginning 1 day post-tumor inoculation and repeated every three days
subsequently (Figure 5.7C). Our results revealed that CD8 depletion significantly
abrogates the therapeutic effects of ISG15 adjuvancy as no mice survived to 30 days
post-implantation (Figure 5.7D). To confirm these findings, we performed CD8 T cell
adoptive transfer experiments in T cell immunodeficient B6 Rag1 KO mice (32). 4 x 106
CD8

T

cells

purified

from

splenocytes

of

HPV16,

HPV16/wtISG15,

and

HPV16/mutISG15 immunized mice (Figure 5.2A) were injected intravenously 4 days
post-inoculation of TC-1 cells (Figure 5.7E). As compared to HPV16 and naive controls,
mice that received either wtISG15 or mutISG15 vaccine-induced CD8 T cells had
significantly slower tumor growth (Figure 5.7F), likely owing to their functional CTL
phenotype (Figure 5.3 and 5.5). Taken together, the results suggest that ISG15-elicited
CD8 T cells are essential to prolonging survival and controlling tumor growth in the TC-1
therapeutic tumor model.
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FIGURES

Figure 5.1. Generation and expression of ISG15 encoding DNA vaccine plasmids.
(A) Schematic illustration of ISG15 protein and the amino acid sequences of wild-type
ISG15 (wtISG15) and mutated ISG15 (mutISG15). The IgE leader sequences are
underlined. The C-terminal ubiquitin-like conjugation site is bold and underlined. The
mutation sites introduced into the conjugation motif for mutISG15 (unconjugated form)
are in red. (B) map of ISG15 constructs. (C) Expression of ISG15 constructs examined
by Western blot analysis. The lowest band represents free ISG15. (D) Detection of
secreted wtISG15 and mutISG15 from transfected RD cells were confirmed via ELISA.
Data represents the means with SEM for two replicate assays.
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Figure 5.2. Co-delivery of ISG15 DNA vaccination promoted E7-specific CD8 T cell
immune responses secreting IFNγ production. (A) Immunization schedule for DNA
vaccine adjuvant study. C57BL/6 mice (n = 4-5/group) were immunized twice at twoweek intervals with HPV16 construct with or without wtISG15 or mutISG15 adjuvant
constructs via IM/EP delivery. One week after last vaccination, spleens were harvested
to analyze the Ag-specific CD8 T cell responses. (B) The frequency of E7-specific IFNγ
(spot forming cells/106 splenocytes) responses induced after each vaccination was
determined by IFNγ ELISpot assay in response to E7 pooled peptide containing the
specific CD8 HPV16 E7 epitope (RAHYNIVTF). Data represent 2 independent
experiments with 4-5 mice per group. *, P < 0.05; **, P < 0.01. Error bars indicate SEM.
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Figure 5.3. ISG15 induces polyfunctional HPV16 E7-specific CD8 T cells. (A)
Schematic diagram of gating strategy used to identify Ag-specific CD8 T cell
populations. (B-D). Column graphs show the percentages of HPV16 E7-specific CD8 T
cells releasing total cytokines IFNγ (B), TNFα (C), and IL-2 (D) after stimulation with
DbE749-57-specific peptide. (E) Column chart show polyfunctional subpopulations of
single-, double-, or triple-positive CD8 T cells releasing effector cytokines: IFNγ, TNFα,
and IL-2 to E749-57-specific stimulation. Pie charts represent proportion of each cytokine
population. Experiments were performed at least two times with similar results with 4-5
mice per group. *, P < 0.05 compared with HPV16 group. Error bars indicate SEM.
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Figure 5.4. ISG15 had no profound influence on the NK or CD4 T cells. (A) Dot plot
graphs show the percentages of NK cells in the spleens 1 week after final immunization
with HPV16, HPV16/wtISG15 or HPV16/mutISG15 groups. (B) Dot graphs show HPV
E7-specific CD4 T cells releasing IFNγ in response to ex vivo E7 pooled peptide
stimulation in the spleens. Data was not significant. Experiments were performed at least
two times (N = 4-5 mice/group). *, P < 0.05; **, P < 0.01. Error bars indicate SEM.
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Figure 5.5. ISG15 induces HPV16 E7-specific CD8 T cells undergoing cytotoxic
degranulation following immunization. E7-specific CD8 T cell responses measured
by intracellular cytokine and CD107a staining after stimulation of splenocytes with
DbE749-57 restricted (CD8) peptide were examined in all groups of animals 1 wk after final
immunization. (A) Ag-specific cytolytic degranulation of CD8 T cells measured by
staining for degranulation marker expression, CD107a. (B and C) Column graph shows
the frequency of cytolytic CD8 T cells simultaneously expressing only IFNγ (B) or the
frequency of polyfunctional cytokine producing and/or CD107a expressing CD8 T cells
(C). Experiments were performed at least twice with similar results with 4-5 mice per
group. *, P < 0.05; **, P < 0.01 compared with HPV16 group. Error bars indicate SEM
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Figure 5.6. ISG15 augments the formation of the effector-memory E7-specific CD8
T cell population. Groups B6 mice (n = 4-5) were immunized twice with HPV16,
HPV16/wtISG15 or HPV16/mutISG15 at two-week intervals. One week after last
immunization, both splenocytes and peripheral blood mononuclear cells were strained
for CD8, DbE749-57 tetramer, and the effector memory KLRG1 marker. (A) Representative
flow plot showing H2-Db-RAHYNIVTF-restrticted HPV16 E7-specific CD8 T cells in the
spleen one week after final immunization, or (B) in data represented as a scatter plot
graph. (C-D) Representative dot plots (C) and compiled data of the percentages of E7
tetramer-specific KLRG1+CD8+ effector memory phenotype population in the spleen
(D). (E-F) The percentages of total DbE749-57 tetramer-binding CD8 T cells from the
peripheral blood (E) and tetramer-specific effector memory CD8 T cells (F). Data is
representative of at least 2 experiments. *, P < 0.05; **, P < 0.01. Error bars indicate
SEM.
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Figure 5.7. The therapeutic effects induced by ISG15 in tumor-bearing mice. (A)
Schematic representation for therapeutic study. (B) Tumor growth measurement
after therapeutic DNA/EP vaccination (n = 10). (C) Schematic representation for CD8 T
cell depletion with therapeutic vaccination. (D) Tumor growth curve of vaccinated groups
(n = 5) without CD8 T cells. (E and F) schematic representation for T cell adoptive
transfer study (E). Approximately 4 x 106 CD8 T cells from vaccinated mice were purified
from splenocytes and adoptively transferred into tumor-bearing T cell immunodeficient
B6 Rag1 KO mice (n = 5) and assessed for tumor growth (F). All tumor-bearing mice
were injected subcutaneously with 5x104 TC-1 cells. *, P < 0.05; **, P < 0.01; ***, P <
0.001. Error bars indicate SEM.
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Figure 5.8. Inclusion of ISG15 as a vaccine adjuvant improves both tumor control
and regression in tumor-bearing mice. Groups of C57Bl/6 mice (n = 10/group) were
injected subcutaneously with 5x104 TC-1 cells. Starting on day 4 after tumor
implantation, all groups of mice were immunized followed with three boosts at weekly
intervals. Immunization with ISG15 constructs delayed tumor growth or led to tumor
regression in tumor-bearing mice. Tumor measurements (average values for each
individual mice) for each time point are shown only for surviving mice. Mice were
sacrificed when tumor diameter reached approximately 18-20 mm. Images are
representative examples of tumor size at day 42 after tumor implantation.
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DISCUSSION
ISG15 is known to play a major role in antiviral defense. In addition, it has also
been reported to function as an immunoregulatory molecule (6). The existence of a
secreted unconjugated form of ISG15 has been reported to have cytokine-like activity,
with evidence supporting its ability to induce IFNγ responses (9-13). Thus, this study
builds on these findings and extends ISG15 research in a therapeutic tumor model
system.
Herein, we first report the therapeutic efficacy of ISG15 immunoadjuvant
properties to augment Ag-specific CD8 T cell tumor immunity. We used a wellestablished preclinical HPV therapeutic challenge model to test the adjuvant effects of
ISG15 in a DNA vaccine setting. The main results of this study are that inclusion of
ISG15 can (i) increase the polyfunctional Ag-specific CTL responses; (ii) induce effectorlike memory CD8 T cell subset differentiation; (iii) have antitumor therapeutic effects;
and (iv) elicit vaccine-induced protective immunity independent of conjugation, further
establishing free ISG15 immunomodulatory properties.
In this study, we report that the inclusion of ISG15-induced robust Ag-specific
IFNγ responses. We find this in accordance with previous studies indicating that ISG15
can induce IFNγ secretion by lymphocytes (7-10). However, we include new evidence
that ISG15 delivered as a separate molecule in an adjuvant function, can drive CD8 T
cells to enhance their secretion of IFNγ and TNFα, further adding to the pool of
information regarding ISG15 immunomodulatory properties on T cells. It is noteworthy to
report that in this model or approach, ISG15 was not involved in induction of NK cells, as
previously shown (8). Furthermore, given that CTL functionality represents an important
correlate of protective capacity against HPV16 established tumors (24,25,33), we report
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that ISG15 promoted the expansion and Ag-specific cytolytic function of CD8 T cells by
augmenting the expression of IFNγ, TNFα and the degranulation maker CD107a in
various combinations. We also demonstrated that ISG15 delivered as an vaccine
adjuvant, amplified E7 tetramer-specific CD8 vaccine-induced T cell responses. The
reasons behind ISG15 ability to enhance the frequency of Ag-specific CD8 T cell
responses are unknown. However, an study by Casanova and colleagues have shown
that ISG15 may work in synergy with IL-12, suggesting that ISG15 likely promoted
enhanced CD8 T cells induction and expansion synergistically with IL-12 (10). In
addition, the ability of ISG15 to induce IFNγ secretion by lymphocytes, may also suggest
that ISG15 might bind to a cell surface receptor to modulate immune responses (6). The
identity of a cell surface receptor for ISG15 has yet to be discovered. Further studies will
be needed to elucidate the mechanism(s) underlying the adjuvant effects of ISG15
including soluble ISG15.
The administration of immunoadjuvants in vaccines has long been a studied as
an important method of improving their efficacy, or potency. Here we explored the
antitumor role of ISG15. Prior work in the TC-1 tumor challenge model, has
demonstrated that this model is CD8 T cell dependent for protection (12,33-35). As
expected, the results revealed that accordant with the enhance polyfunctional CTL
responses, administration of ISG15 led to strong inhibition of tumor growth, regression
and prolonged survival. Moreover, depletion of CD8 T cells in mice nullified the antitumor
effects of ISG15 and supported the tumors to grow larger compared to the non-treated
CD8 mAb HPV16 group. These data support that the antitumor activity of ISG15 was
dependent on CD8 T cells. Subsequently, as demonstrated in our adoptive transfer
experiments, CD8 T cells alone can reduce tumor volume, suggesting that the ISG15
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vaccine-induced CD8 T cell responses must be more functional at clearing HPV-infected
cells. In this experiment setting, the enhanced induction of E7-specific effector memorylike T cells may have correlated with the therapeutic efficacy of ISG15-treated groups
against established tumors. This notion is supported by the enhanced CTL activity
(Figure 5.4) and E7 tetramer-positive Teff cells in both the spleen and blood of mice
vaccinated with ISG15 (Figure 5.5). Notably, there were more detectable CD8 Teff cells
responses in the periphery, suggesting trafficking of target specific CD8 T cells to the
site of malignancy and initiating immediate effector function (26,31). Our studies appear
to be supportive of previous work demonstrating that vaccines eliciting higher Teff
correlated with superior protective immunity against inhibiting tumor growth (1,5,14).
Therefore, the magnitude and quality of E7-specific CD8 T cell memory population
correlated with the efficacy of ISG15 treated groups to control or resolve tumors during
the first 3 weeks of treatment. These potential correlates of immunity may represent a
major tool for continued development of future tumor vaccines. Consistent with this is
recent reports indicating that vaccine-induced effector memory may be the best
prognostic factor for therapeutic vaccines targeting established tumors or latently
infected pathogens (1,5,27,28). Central memory CD8 T cells elicited by ISG15 may have
also been important, as central memory T cells are essential features by which vaccines
can mediate protective immunity (29-31,36). This is an area of further investigation.
Overall, on the basis of these findings, the improved therapeutic effect by ISG15 is
associated with Ag-specific CTL responses.
In the same experimental setting, a highlight of this study was demonstrating that
the protection afforded by ISG15 was most likely not dependent on its conjugated form,
but rather on free ISG15. Our results indicated that mutISG15 was able to induce a
similar trend of robust Ag-specific antitumor T cell responses compared to wtISG15,
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suggesting that this activity was independent of ISGylation. The immunomodulatory
property of soluble free ISG15 is in agreement with several studies suggesting that
ISG15 acts as an immune activating cytokine (37). Both ISG15 constructs did not differ
enormously in their effectiveness at eliciting E7-specific tumor immunity. Thus, given that
both forms of the ISG15 constructs exerted similar immunostimulatory effects, the
phenotypes in CD8 T cells were not dependent on the motif (38). Interestingly,
mutISG15 was significantly better able to control the progression of established tumors
compared to wtISG15-adjuvanted treated mice. As more mutant-ISG15 is secreted from
transfected cells in our experiments (Figure 5.1D), it may orchestrate a more effective
adaptive response; thus, leading to better control of tumor growth and pathogen
clearance. However, the manner in which unconjugated secreted form of ISG15
(mutISG15) is able to induce better antitumor responses compared to wtISG15 is still not
yet clear. Nevertheless, the ability of the mutISG15 form to induce superior antitumor
responses highlights its potential to serve as an alternative potent ISG15 adjuvant. In
addition, it emphasizes that developing new ways to increase the levels of free ISG15
may be a novel approach to treat cancer and other infectious diseases.
In summary, the results of the current preclinical study provide more insight into
the immunomodulatory properties of free ISG15 and its potential to serve as a promising
vaccine adjuvant in cancer immunotherapy. The results also confirm the notion that
ISG15 can function as an immunomodulatory molecule. Moreover, the evidence that
ISG15 can be an effective adjuvant to drive potent CD8 T cell responses, support future
studies to evaluate its application in TB- or HIV-infection models.
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CHAPTER 6
ISG15 IS AN INFLAMMATORY MEDIATOR AND IMMUNOADJUVANT FOR
INFECTIOUS DISEASE

156

ABSTRACT

The significance of the ubiquitin-like protein, interferon-stimulated gene 15 (ISG15), in
human disease has gained considerably with studies that found ISG15 deficiency
increases susceptibility to mycobacterial infection among other pathologies. However,
the role of ISG15 in the cellular response to intracellular bacterial pathogens and the
translation of its immunomodulatory properties to novel immunotherapies have not yet
been explored. To accomplish this task, we employed the use of ISG15-deficient mice
and in vivo expression vector to augment expression of murine ISG15 in wild-type mice.
As with mycobacteria, ISG15-/- mice are highly susceptible to infection with the model
pathogen, Listeria monocytogenes (LM), and display significantly reduced production of
IFNγ. Tissue-specific defects in adaptive immunity to LM were also observed in ISG15-/mice along with impaired dendritic cell maturation suggesting a possible role for ISG15
in T cell activation and memory formation. In fact, use of ISG15 as an immunoadjuvant
enhances virus-specific CD8 T cells responses and provides protective immunity against
lethal intracranial lymphocytic choriomeningitis virus (LCMV) challenge infection. This
work elucidates the role of ISG15 as a critical mediator of innate anti-bacterial immunity
and a potent activator of adaptive immunity, a finding with significant implications in
immunotherapy development.
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INTRODUCTION
Ubiquitin and ubiquitin-like proteins (UBLs) have essential roles in the
development of functional immune responses (1).

One ubiquitin-like protein, in

particular, Interferon-stimulated gene 15 (ISG15), is gaining prominence due to its
specific induction during infection and relevance in human disease (2,3). ISG15 is highly
induced during viral infection and mediates protection against influenza, HIV, and
Sindbis virus infection among others (4,5). Type I Interferon produced during an infection
induces expression of ISG15, leading to its secretion and, like ubiquitin, conjugation to
intracellular substrates through the action of a unique enzymatic cascade (6,7). While
the molecular consequences of ISGylation are yet to be fully elucidated, it can inhibit
protein ubiquitylation and, therefore, block viral particle release (8-15).
Recent studies, however, expand the scope of ISG15 function beyond innate
antiviral defense (16,17). Bogunovic, et al. discovered that individuals with mutations in
Isg15 are more susceptible to infection by the intracellular bacterium Mycobacterium
tuberculosis (Mtb). The increased susceptibility due to ISG15 deficiency in these patients
correlated with impaired induction of pro-inflammatory cytokines by leukocytes (16,18).
Interestingly, these data agree with in vitro studies previously performed over twenty
years ago (19,20). In these studies, recombinant human ISG15 was found to activate
leukocytes in vitro when added to culture media and induce production of
proinflammatory cytokines (19). The use of a soluble form of ISG15 to induce these
immune activating effects is relevant as several studies suggest that ISG15 may have
immunomodulatory properties in its secreted form (18). Therefore, questions remain
regarding the immunological functions of ISG15 beyond innate anti-viral immunity. This
study endeavors to further elucidate this expanded role for ISG15 in immunity and
translate its immunomodulatory properties to a novel therapeutic strategy.
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METHODS
Mice
ISG15-/- mice and their syngeneic wild-type strain C57BL/6J were obtained from
Jackson Laboratory (Bar Harbor, ME) and bred and housed in the University of
Pennsylvania Hill Pavilion Animal Facility and in the TTUHSC Abilene LARC. Mice were
kept on a 12-hour light/dark cycle with sterile water and UV-treated or autoclaved
standard rodent diet. All mouse experiments were performed in accordance with the
regulations of the Institutional Animal Care and Use Committee of the TTUHSC and
University of Pennsylvania according to the guidelines of the National Institute of Health.

Bacterial strains
LM strains were cultured in BHI (Brain-heart infusion, CM1135, Oxoid LTD, Hampshire,
England) media supplemented with 50 ug/mL of streptomycin, harvested at mid-log
growth phase (0.6-0.8 at O.D. 600), aliquots flash-frozen in liquid N2, and stored at 80oC. LM stock titers were determined by serial dilution of a thawed stock vial, plating of
dilutions onto BHI-streptomycin agar plates, and counting the colony-forming units
(CFUs) after 18-24 hrs. at 37oC. For each infection experiment, a frozen stock vial was
freshly thawed, bacteria pelleted by centrifugation, and the pellet washed twice with 1X
phosphate-buffered saline (PBS).

In vitro LM Infection
Infection of bone marrow-derived macrophage (BMM) was performed as described
previously (61). For mRNA analysis, BMMs were seeded onto tissue culture-treated
dishes, incubated overnight, and infected with LM at a multiplicity of infection (MOI) of
10. The infected cells were washed, gentamicin was added 30 min after infection, and
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cells processed for RNA isolation using the RNeasy Mini kit (QIAGEN) according to the
manufacturer's instructions.

In vivo LM Infection
For primary infection studies to determine cytokine responses by qPCR and ELISA, 6-8
week old C57BL/6 and ISG15-/- mice were euthanized three days after intraperitoneal
(i.p.) injection with 105 CFU of LM in 200μl of sterile 1x PBS. To determine the role of
ISG15 in poly(I:C)-exacerbated listeriosis, C57BL/6J and ISG15-/- mice were infected
i.p. with 104 CFUs of LM alone or administered 150μg of poly(I:C) i.p. two days after LM
infection. All mice were euthanized on day 4 post-infection and spleens extracted.
Spleens were processed into single-cell suspensions, serially diluted, plated onto BHIagar plates supplemented with 50ug/mL streptomycin and colony-forming units counted
after overnight growth at 37oC. For longitudinal infection studies, 6-8 week old C57BL/6J
and ISG15-/- mice were i.p. injected with 104 CFUs of LM in 200μl of sterile 1x PBS. At
experiment end, mice were euthanized and processed for bacterial load. LM CFUs in
the spleen and liver were determined as described previously (61). In Figure 6.1, mice
were injected with 103, 104, and 105 CFU LM in 200µl of 1x PBS i.p. and euthanized at
day 4-post infection. Spleens and livers of the infected mice were harvested and LM
bacterial load determined by serial dilution of single cell suspensions and colony-forming
units counted after overnight growth on BHI-agar supplemented with 50ug/mL
streptomycin. In Figure 6.2, 6-8 week old C57BL/6 and ISG15-/- mice were infected
with 103 CFU of the attenuated Δacta LM strain, DPL-4029 or virulent LM. These mice
along with naïve WT and ISG15-/- mice were subsequently challenged with
intraperitoneal injection of 105 CFUs LM.
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Five days after challenge, mice were

euthanized and organs processed for flow cytometric analyses and bacterial load
determination.

Quantitative PCR
RNA was isolated from splenocytes and bone marrow-derived macrophages using an
RNeasy

plus

mini

kit

(Qiagen).

RNA

was

quantified

using

a

Nanodrop

spectrophotometer and 1ug of RNA was converted to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). The Step One Plus Real Time
system from Life Technologies was used for qPCR analysis in combination with FAST
SYBR Green (Applied Biosystems). To determine relative quantity of target genes
between groups,18S rRNA was used as a reference.

ELISA
In Figure 6.1, serum was collected by post-euthanasia heart puncture bleeds and blood
clots removed after incubation at 4°C for 30 minutes followed by centrifugation. Serum
samples were diluted 1:40 and assayed for levels of IFN-γ using the mouse ELISA
Ready-SET-Go! kit (eBiosciences, San Diego, CA, USA) according to the manufacturer's
instructions. In Figure 6.2, splenocytes were stimulated with 5 ug/mL of H2-Kb-restricted
LLO epitope peptide (62), MHC Class I-restricted HIV gag epitope peptide (63), or platebound anti-CD3/CD28 along with 50 U/mL of rhIL-2 overnight and media collected the
following day. Undiluted conditioned media was assessed for IFNγ and TNFα using the
mouse ELISA Ready-SET-Go! kit. Results were obtained at O.D. 450 using a Microplate reader (SynergyHT, BioTek) and analyzed on Gen5 (Ver1.08).
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Flow cytometric analysis
In Figure 6.1-6.2, spleens were extracted from mice and placed in 5 mL complete media
(Corning Cellgro; DMEM 1X; Cat no. 15-013-CM).

Spleens were mechanically

macerated and passed through 40 um cell strainers (Fisher, Cat no. 22363549,
22363547) to produce single-cell suspensions. Cells were treated with ACK lysis buffer
for 3-5 minutes at room temperature and washed three times in 1x PBS. Cells were
suspended in complete media and cell counts determined using a Beckman Coulter ViCell XR. For T cell stimulation, 2 x 106 cells were plated in 96-well round-bottom plates
and stimulated with 5ug/mL of MHC Class II-restricted LLO epitope peptide
(NEKYAQAYPNVS) (64), MHC Class II-restricted E7 epitope peptide (DRAHYNI) (65),
or PMA/ionomycin for 6 hours at 37°C, 5% CO2 in the presence of monensin and 50
U/mL of rhIL-2.

For cell surface staining, splenocytes were stained for various cell

surface markers after Fc-blockade with anti-CD16/CD32(Clone 93; 14-0161-85) using
fluorochrome-labeled mAbs (Supplementary information). All samples were acquired on
an LSRII or LSRFortessa flow cytometer (Becton Dickinson Biosciences, San Jose,
CA,USA), and data was analyzed using FlowJo software (v10, Tree Star). In Figure 6.3,
splenocytes were added to a 96-well plate (1x106/well) and were stimulated with the
immunodominant LCMV CTL epitope (NP396-404) (66) (Invitrogen) for 5-6 hours at
37C/5% CO2 in the presence of Protein Transport Inhibitor Cocktail (Brefeldin A and
Monensin) (eBioscience) according to the manufacturer’s instructions. The Cell
Stimulation Cocktail (plus protein transport inhibitors) (phorbol 12- myristate 13-acetate
(PMA), ionomycin, brefeldin A and monensin) (eBioscience) was used as a positive
control and R10 media as negative control. All cells were then stained for surface and
intracellular proteins as described by the manufacturer’s instructions (BD, San Diego,
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CA). Briefly, the cells were washed in FACS buffer (PBS containing 0.1% sodium azide
and 1% FCS) before surface staining with flourochrome-conjugated antibodies. Cells
were washed with FACS buffer, fixed and permeabilized using the BD Cytofix/Cytoperm
TM (BD, San Diego, CA, USA) according to the manufacturer’s protocol followed by
intracellular staining. Antibodies and reagents for staining are listed in Supplementary
information. All data was collected using a LSRII flow cytometer (BD Biosciences) and
analyzed using FlowJo software (Tree Star, Ashland, OR) and SPICE v5.2 (free
available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed using
FlowJo software to examine the polyfunctionality of the T cells from vaccinated animals.
Dead cells were removed by gating on a LIVE/DEAD fixable violet dead cell stain kit
(Invitrogen) versus forward scatter (FSC-A).

Plasmid construction
The GenBank accession no. Q64339.4 for mouse ISG15 was used to synthesize the
ISG15 plasmid DNA construct. The ISG15 plasmid DNA construct has a highly efficient
immunoglobulin E (IgE) leader sequence inserted at the 5′end of the gene. The construct
was commercially synthesized and genetically optimized (codon- and RNA-optimization)
for expression in mice and then subcloned (all by GenScript, Piscataway, NJ) into a
modified pVAX1 mammalian expression vector (Invitrogen, Carlsbad, CA).

Plasmid

expressing pLCMV-NP (NP) was prepared as previously described (34).

Transfection and expression of plasmids
In vitro ISG15 was confirmed by western blot (WB) analysis. 293T cells were cultured in
a 6-well plate and transfected with construct using Neofectin transfection reagent
(NeoBiolab) following manufacture’s protocol. Forty-eight hours later, cells were lysed
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using modified cell lysis buffer (Cell Signaling) with complete protease inhibitor cocktail
tablets (Roche) and cell lysate was collected. WB analysis was performed with an antiISG15 antibody (Cell Signaling) and visualized with IRDye 800CW goat anti-rabbit
antibody (Li-Cor) using the Odyssey imagining system (Li-Cor). β-actin served as a
loading control and visualized with IRDye 680 goat anti-mouse antibody (Li-Cor). In
addition, an indirect immunofluorescence microscopy assay was also executed to
confirm expression of ISG15 DNA construct. Rhabdomyosarcoma (RD) cells were plated
on two-well chamber slides (BD Biosciences) and grown to 70% confluence overnight in
a 37oC incubator with 5% CO2. The cells were transfected with 1 μg of ISG15 constructs
and the control plasmid pVAX (1 μg/well) using TurboFectinTM8.0 Transfection Reagent
(OriGene) according to the manufacturer’s instructions. Forty-eight hours later the cells
were fixed on slides using ice cold methanol for 10 min. The cells were stained with antiISG15 mouse monoclonal antibody (Cell Signaling) and subsequently incubated with
Alexa 555-conjugated anti-rat secondary antibody (Cell Signaling). Slides were mounted
using Fluoromount G with DAPI (Southern Biotechnology). Images were analyzed by
florescence microscopy (Leica DM4000B, Leica Microsystems Inc, USA) and
quantification was conducted using SPOT Advanced software program (SPOTTM
Diagnostic Instruments, Inc). Secretion of ISG15 was examined by using a CircuLex
mouse ISG15 ELISA kit (MBL International), according to manufacturer’s protocol.

Vaccinations and LCMV challenge
Mice were immunized once intramuscularly (i.m.) in the tibialis anterior muscle as
previously described (29,67). In vivo electroporation was delivered, with the
CELLECTRA adaptive constant current electroporation device (Inovio Pharmaceuticals),
at the same site immediately following vaccination as described (67). The mice (n = 5)
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were immunized with either 10 μg pVAX1 or 10 μg pLCMV-NP with or without 11 μg of
ISG15 construct. All studies were repeated at least three times. For lethal challenge
studies, mice were challenged i.c. with 40xLD50 of LCMV Armstrong as previously
described [34] in 30 μl of virus diluent (PBS with 20% FBS and 1X Anti-Anti (Invitrogen,
Carlsbad,CA). All mice LCMV challenged were housed in a BSL-2 facility and were
observed daily for 21 days.

ELISpot assays
Spleens were harvested 21 days following immunization to monitor vaccine-induced
responses as previously described (29,67). After spleens were harvested and
processed, IFNγ ELISpot assays were performed to determine the antigen-specific
cytokine secretion from immunized mice as described previously (29,67). The LCMVspecific T cell responses were assessed by stimulating splenocytes with the
immunodominant H2-Db LCMV CTL epitope (NP396-404 ) (66).

Statistical analysis
The one-tailed student t test was applied for comparison of the quantitative data of the
cellular immune responses induced by infection or vaccination. Statistically significant
outliers were removed from datasets by the ROUT method. All error bars indicate SEM
and all tests were performed using the Prism Software (La Jolla, CA) (*, P < 0.05; **, P <
0.01; ***, P < 0.001). Survival curves were analyzed by log-rank (Mantel-Cox) test.
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RESULTS
To determine the relevance of ISG15 in the innate immune response to the
model pathogen, Listeria monocytogenes (LM), ISG15 gene expression was inspected
after LM infection in wild-type C57/BL6 mice. Isg15 mRNA expression was significantly
induced at the peak of infection on day 3, with 100-fold higher expression of Isg15 in the
spleen, a major site of infection, compared to uninfected control mice (Figure 6.1A).
Infection of bone marrow-derived macrophages (BMM) with LM also resulted in a timedependent induction of Isg15 and the gene encoding the ISG15 E1 conjugating enzyme,
Ube1L (Figure 6.1B). Furthermore, secreted ISG15 protein could be detected in the
serum of infected WT mice at the peak of LM infection but not in ISG15-/- controls
(Figure 6.1C). Expression of Isg15 during LM infection was Type I IFN-dependent as
antibody-mediated blockade of IFN-β significantly blunted the Isg15 induction in LMinfected BMMs (Figure 6.1D). These data suggest the ISG15 pathway is induced during
LM infection and is dependent on production of Type I IFN. In contrast to viral infection,
Type I IFN exacerbates certain bacterial infections including listeriosis by impairing both
innate and adaptive responses to LM (21-23).
To determine if ISG15 mediates Type I IFN exacerbation of listeriosis, WT and
ISG15-/- mice were infected with LM and Type I IFN was induced by administering a
dsRNA mimetic molecule, poly (I:C) (21,24). Surprisingly, ISG15 is not necessary for
Type I IFN-mediated exacerbation of listeriosis and two independent experiments
suggested that ISG15-/- mice may even be more susceptible to LM infection (Figure
6.1E). The role of ISG15 in innate immunity to LM was further explored with a timecourse infection. On day 1 post-infection, ISG15-/- mice were more resistant to acute
infection with LM as evidenced by significantly reduced bacterial burden (Figure 6.1F).
However, bacterial burden was significantly elevated in ISG15-/- mice at the peak of
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infection on day 3 and continued to rise subsequently in contrast to their wild-type
counterparts.

We next sought to determine if this result was only relevant at the initial

infection dose, 104 CFUs, as previous studies have shown dose-dependent susceptibility
to LM (25). WT and ISG15-/- mice were infected with a log range of infection doses from
103 CFUs to 105 CFUs of LM. In the spleens of WT mice receiving the lowest dose of LM
(103 CFUs), only 40% of mice had evidence of listeriosis (Figure 6.1G). However, 80%
of ISG15-/- mice had detectable levels of LM in their spleen (Figure 6.1G). Similar
results were observed in the livers of WT and ISG15-/- mice after receiving the lowest
dose with 20% and 100% of mice demonstrating listeriosis, respectively (Figure 6.1H).
Significantly increased listeriosis was also observed at higher starting doses in both the
spleens and livers of ISG15-/- mice (Figures 6.1G-H). While NK cell numbers were
similar (Figure 6.1I), the increased susceptibility to acute LM infection in ISG15-/- mice
did correlate with significantly reduced expression of splenic ifng and serum levels of
IFNγ (Figure 6.1J-K), an essential proinflammatory cytokine in the clearance of LM
infection (26,27).
As LM virulence has previously been reported to inversely correlate with adaptive
immunity to LM (23), we sought to determine if ISG15 deficiency also compromised
adaptive immune responses to LM. After prior vaccination with an attenuated strain of
LM (DPL-4029), with reduced ability to undergo ActA mediated cell-to-cell spread, WT
and ISG15-/- mice were challenged with the virulent 10403S strain of LM and
development of adaptive immunity assessed on day 5 post-infection (Figure 6.2A). Both
WT and ISG15-/- demonstrated similar induction of LM-specific CD8 T cell immunity in
the spleen as evidenced by specific production of IFNγ and TNFα after H2-Kb LLOepitope296-304 peptide stimulation (Figure 6.2B). In addition, ISG15-/- mice generated
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similar numbers of LLO-specific splenic CD4 T cells after LM challenge and stimulation
with LLO190-201 epitope peptide (Figure 6.2C). Furthermore, no deficiencies were
observed in overall splenic CD4 and CD8 T cell populations of ISG15-/- mice during
primary and secondary responses to LM (Figure 6.2D-E). As expected, splenic LM
bacterial load in previously infected mice was comparable between ISG15-/- and WT
mice (Figure 6.2F). However, liver bacterial load in previously infected ISG15-/- mice
was approximately 100-fold greater than in previously infected WT mice (Figure 6.2G).
Similar liver-specific defects in adaptive immunity were observed when WT and ISG15-/mice were first infected with a low dose of virulent LM (103 CFUs) prior to high-dose
challenge (Figure 6.2H-J). While these results suggest ISG15 may be involved in liver
immune-privilege (28), the altered adaptive immune response to LM may be due to
defects in the myeloid compartment. In fact, greater numbers of myeloid cells were
observed in the spleens of ISG15-/- mice during LM infection, but there were significantly
fewer conventional dendritic cells to facilitate induction of a robust T cell response to
control infection in the liver (Figure 6.2K-M).

Furthermore, stimulation of splenic

dendritic cells with LPS revealed that ISG15 deficiency impairs dendritic cell maturation
as evidenced by reduced surface levels of costimulatory molecules CD80 and CD86
(Figure 6.2N-P). Collectively, these results would suggest that ISGylation facilitates T
cell priming, a function that has not yet been attributed to it. Therefore, ISG15 may be
important in fostering cell-mediated adaptive immunity by augmenting antigenpresenting cell number and function.
The observed results, that ISG15 deficiency impairs IFNγ responses during LM
infection, led us to determine if these observed immunoregulatory properties of ISG15
could be leveraged to enhance responses to immune-privileged sites. Therefore, we
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induced overproduction of ISG15 in wild-type mice by delivering it as a DNA vaccine
adjuvant to augment T cell-mediated immunity. This in vivo mammalian ISG15
expression DNA plasmid was developed as previously described (29) (Figure 6.3A).
Briefly, the mouse ISG15 gene was cloned into the pVAX mammalian expression vector
under the control of a CMV promoter and with an IgE leader sequence to allow for
secretion (Figure 6.3A). After transfection of 293T cells with pVAX-mISG15, cells
proficiently expressed intracellular murine ISG15 as determined by Western Blot
analysis and fluorescent microscopy (Figures 6.3B and 6.3C, respectively). As shown in
Figure 6.3C, ISG15 expression was found in the cytoplasm as determined by
colocalization with the nuclear stain, DAPI (30,31) (Figure 6.3C). Due to the inclusion of
an IgE leader sequence, transfection with pVAX-mISG15 also resulted in proficient
secretion of soluble mouse ISG15 into the culture supernatants from pVAX-mISG15
transfected 3T3 cells in comparison to empty vector transfected cells (Figure 6.3D). To
determine if ISG15 could augment CD8 T cell-mediated immunity in vivo, further studies
were performed with an infection model in which ISG15 is not relevant, the intracranial
(i.c.) lymphocytic choriomeningitis virus (LMCV) infection model (32,33). The LCMV
infection model is an established model to study CD8 T cell responses to the brain of
infected mice (34). Therefore, to characterize the CD8 T cell responses driven by ISG15,
groups of mice were intramuscularly administered plasmid expressing LCMV structural
protein, NP, with or without plasmid expressing mISG15. Mice receiving the NP vaccine
administered with mISG15 generated significantly more DbNP396-40 (NP396)-specific IFNγ spot-forming cells (SFCs) than mice receiving pVAX-NP or empty pVAX plasmid alone
(Figure 6.3E). Furthermore, the NP vaccine administered with mISG15 induced
significantly higher percentages of NP-specific polyfunctional CD8 T cells compared to
mice receiving vector expressing antigen alone (Figure 6.3F). To determine if the
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observed adjuvant effect of mISG15 impacted survival, mice were challenged 21 days
after vaccination with a lethal intracranial dose (40xLD50) of the LCMV Armstrong strain
(34). Dramatically increased survival to lethal LCMV infection was observed in the
mISG15 and NP vaccine group compared to the group-receiving NP antigen alone
(Figure 6.3G). Taken together, these data demonstrate that mISG15 can act as an
immunoadjuvant to activate highly effective antigen-specific CD8+ T-cell responses to
even immune-privileged sites.
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FIGURES
FIGURE 6.1
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FIGURE 6.1 CONT.

Figure 6.1. ISG15 deficiency impairs innate immune responses to LM (A) Mice (n=3/group) were infected with 105
LM CFUs and euthanized at the peak of infection on day 3 along with a group of uninfected mice. Spleens were excised,
processed into a single-cell suspension, and RNA extracted. After conversion to cDNA, spleens were assessed for
expression of Isg15 by qPCR analysis. Bar graphs depict induction of Isg15 expression after LM infection. (B) Bone
marrow-derived macrophage (BMM) were differentiated with M-CSF and infected with LM (n=3/group). BMM were lysed
after 8 and 16 hours post-infection along with uninfected controls and processed for RNA extraction. After cDNA
conversion, BMMs were assessed for Isg15 gene expression along with the gene for its E1-activating enzyme, Ube1l. (C)
WT (n=4) and ISG15-/- mice (n=5) infected with 105 LM CFUs were euthanized on day 3 post-infection and serum
collected to assess levels of secreted ISG15 protein by ISG15 ELISA. (D) BMMs were infected with LM followed by
treatment with isotype control or IFN-beta blockading antibody one hour post-infection (n=3/group). At experiment end,
BMMs were lysed, mRNA extracted, converted to cDNA, and Isg15 gene expression assessed by qPCR analysis. (E) WT
(n=4) and ISG15-/- (n=5) mice were infected i.p. with 104 CFUs of LM alone or administered 150μg of poly(I:C) i.p. two
days after LM infection (n=3/group). All mice were euthanized on day 4 post-infection and spleens excised and
processed into single-cell suspensions. Suspensions were serially diluted and plated out on BHI-streptomycin agar plates
in order to determine colony-forming units (CFUs) per spleen. (F) WT and ISG15-/- mice (n=3/group) were infected i.p.
with 104 CFUs of LM and euthanized on day 1, 3, and 5 post-infection. Spleens and livers from infected mice were
excised and processed into single-cell suspensions. Suspensions were serially diluted and plated out on BHIstreptomycin agar plates in order to determine colony-forming units (CFUs) per organ. Total bacterial load was
determined by adding LM CFUs from the spleen and liver of each mouse. In order to determine if susceptibility to LM
infection is dose-dependent, WT and ISG15-/- mice (n=5/group) were infected i.p. with a log range of doses of LM CFUs.
At day 4 post-infection, spleens and livers were extracted, processed into single-cell suspensions, serially diluted, and
plated out on BHI-streptomycin agar plates. (G) Scatter plots depicting LM CFUs in the spleens of WT and ISG15-/- after
infection with a log range of doses. (H) Scatter plots depicting LM CFUs in the livers of WT and ISG15-/- after infection
with a log range of doses. (I) Scatter plot depicting NK1.1+ splenocytes in WT and USP18-/- mice during primary LM
infection with 105 CFUs. (J) WT (n=5/group) and ISG15-/- mice (n=3/group) were infected i.p. with 105 CFUs of LM and
euthanized at the peak of infection on day 3 post-infection. Spleens were excised, processed into single-cell
suspensions, and RNA extracted. After conversion to cDNA, spleens were assessed for expression of the
proinflammatory cytokine gene Ifng. (K) Production and secretion of IFN-γ was confirmed by ELISA analysis of serum
from WT and ISG15-/- mice (n=5/group) infected with 105 CFUs LM at peak of infection on day 3 post-infection. Amount
of IFN-γ protein in serum was calculated with a protein standard. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 6.2
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FIGURE 6.2 CONT.

Figure 6.2. ISG15 deficiency alters adaptive immune response to LM and impairs
DC maturation. (A), Schematic depicting the experimental procedure to determine the
role of ISG15 in adaptive immunity to LM. Briefly, WT and ISG15-/- mice were infected
i.p. with 105 CFUs of LM with or without prior infection with 103 CFUs of the attenuated
LM strain, DPL-4029 (B), Production of IFNγ and TNFα by LLO-specific CD8+ T cells
after stimulation with MHC Class I-restricted LLO epitope peptide, control peptide, or
anti-CD3/CD28 as measured by ELISA after prior infection with DPL-4029 and challenge
with LM. (C), LLO-specific IFNγ-producing splenic CD4+ T cells from LM-infected WT
and ISG15-/- mice with stimulation by phorbol 12-myristate 13-acetate (PMA) (50ng/mL)
and ionomycin (800ng/mL), control peptide or MHC Class II-restricted LLO epitope
peptide. (D), Splenic CD8+ T cell and (E), splenic CD4+ T cell percentages during innate
and adaptive response to LM. (F), LM bacterial burden in the spleen and (G), liver of
WT and ISG15-/- mice. (H), Schematic depicting alternate experimental procedure to
determine the role of ISG15 in adaptive immunity to LM. Briefly, WT and ISG15-/- mice
were infected i.p. with 105 CFUs of LM with or without prior infection with 103 CFUs of
the virulent LM strain, 10403S. (I) LM bacterial burden in the spleen and (J), liver of WT
and ISG15-/- mice from experiment depicted in H. (K), Splenic myeloid cells during
innate and adaptive response to LM from experiment depicted in Fig. 2A. (I),
Percentage of myeloid cells that are CD11chi and (J), overall percentage of splenocytes
that are conventional DCs during LM infection. (K), WT and ISG15-/- spleens were
stimulated with 1ug of LPS for 6 hrs. and surface expression of markers associated with
DC maturation were assessed by flow cytometry for expression of CD86, (L), CD80 and
(M), co-expression of CD80 and CD86. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P <
0.0001.
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FIGURE 6.3
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FIGURE 6.3 CONT.

Figure 6.3. Elevated ISG15 expression augments virus-specific CD8 T cell
responses and increases survival against lethal LCMV challenge. (A), Depiction of
ISG15 protein adjuvant constructs. (B), expression of ISG15 in 293 T cells as examined
by Western blot analysis. Labeled panels show protein detected by anti-ISG15 mAb. (C),
Detection of expression of ISG15 via immunofluorescence microscopy. (D), secretion of
ISG15 after transfection of empty pVAX and pVAX-mISG15 in 3T3 cells (n=3/group) was
confirmed via ELISA of conditioned media. (E), B6 mice (n=5/group) where immunized
once with or without ISG15 and 21 days later mice where sacrificed and spleens where
processed to monitor the vaccine induced immune responses. IFNγ ELISpot was
performed to detect antigen specific immune responses to the LCMV DbNP396-404
antigen (NP396) in combination with ISG15 when used in IM immunization via
electroporation. (F) Multiparameter flow cytometry was used to determine the
percentages of polyfunctional CD8+ T cell cytokine profile. The bar chart shows the
percentage of NP-specific CD8+ T cells displayed as triple, double of single positive
CD8+ T cells secreting cytokines. (G) Mice (n=10/group) were immunized one time IM
using EP with 10ug of empty vector control plasmid (pVAX) or 10ug of LCMV-NP with or
without ISG15 adjuvant. At day 21 post-vaccination, mice were challenged intracranial
with 40xLD50 LCMV and animal survival is displayed in the graph. Experiments were
performed at least three times in independent experiments and data are representative
of the results. *, P < 0.05; **, P < 0.01, ****, P < 0.0001.
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DISCUSSION
ISG15 has a well-established role in innate antiviral responses, but recent
studies have shed light on further functions in immunity for this small ubiquitin-like
protein (3,16,17). Our studies support this expanded role of ISG15 in immunity, as we
find it is essential for innate immunity to the bacterial pathogen, LM (Figure 6.1).
Furthermore, while ISG15 deficiency does not hinder formation of splenic LM-specific T
cell responses, protective adaptive immunity is not evident in the liver of ISG15-/- mice
after subsequent LM challenge (Figure 6.2). Additionally, splenic DCs from ISG15-/mice have reduced expression of maturation markers and overexpression of ISG15 by
WT mice was able to augment pathogen-specific CD8 T cell responses and increase
survival to lethal intracranial LCMV challenge (Figure 6.3). These results confirm a
growing consensus that the role of ISG15 is likely more pleiotropic than just directing
anti-viral innate immunity and prompt further questions regarding its mechanisms in
immunity and promise in immunotherapy development (18).
In regard to innate defense against LM infection, previous studies suggest ISG15
may impact several stages of the bacterium’s lifecycle. Once LM invades a phagocytic
cell, autophagy activates and facilitates clearance and processing of the pathogen
(35,36). ISG15 deficiency has previously been reported to impair autophagy and,
therefore, may exacerbate listeriosis and hinder presentation of LM-derived epitopes
(37). However, LM has evolved strategies to evade autophagic destruction and escape
into the host cell cytosol (38-40). Once LM invades the cytosol of an infected cell, it
rapidly polymerizes actin and propels itself into the cell membrane, forming protrusions
into surrounding cells and propagating the infection (41-44). ISG15 may also hinder this
process as it covalently binds actin and regulates its polymerization, possibly hindering
LM virulence at this stage (45,46). Lastly, protrusion formation by LM, a necessary step
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in its cell-to-cell spread, is carried out through exploitation of the ezrin/radixin/moesin
(ERM) complex, an interface between the cytoskeleton and the cell membrane (47,48).
ISG15 conjugates components of the ERM complex and, while the consequence of this
ISGylation is unclear, it may hinder its usefulness for LM cell-to-cell spread (30).
More broadly, our findings in ISG15-/- mice provide support for recent studies
demonstrating that individuals with mutations in Isg15 are at increased risk for
intracellular facultative bacterial infection (16,49). This susceptibility is likely due, in part,
to reduced IFNγ production in ISG15-/- mice and leukocytes from ISG15-deficient
patients leading to impaired macrophage activation (16). In fact, reduced activation of
ISG15-/- macrophage has previously been reported in the context of viral infection (50).
One possible explanation for the role of ISG15 in IFNγ production could be that it
contains alarmin-like activity (51). Over two decades ago, a pair of studies found that
recombinant ISG15 alone, when added to culture with PBMCs, could stimulate IFNγ
production (19,20). Further credence to this alarmin hypothesis is that ISG15 is
expressed and secreted to a high degree during disease states such as infection and
cancer (10,52-56). Alternatively, recent studies suggest that ISG15 may augment the
ability of a cell to produce IFNγ in response to stimulus (16,17). This may be the
consequence of a recently proposed mechanism for ISG15, stabilization of the negative
regulator of Type I IFN signaling, USP18 (17). In response to intracellular bacterial
infection, USP18 facilitates robust STAT4-dependent IFNγ production and bacterial
clearance (17,57). Interestingly, mutation of the LRGG repeat in ISG15 did not impair
ISG15-mediated stabilization of USP18 suggesting conjugation is not necessary for
some ISG15 functions (17). Further studies to inspect the dependence of ISG15
immunomodulation on USP18 status and conjugation potential are ongoing.
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In addition to an expanded role in innate anti-bacterial immunity, our study also
provides evidence for a novel role for ISG15 as a powerful immunoadjuvant for T-cell
mediated immunity (Figure 6.2-6.3). While ISG15 deficiency appeared to have a limited
impact on T-cell responses to LM, overexpression of ISG15 significantly augmented
polyfunctional LCMV-specific CD8 T cell responses, which are essential to survival
against LCMV challenge (58). An explanation for this discrepancy could be that
endogenous ISG15 is not essential for intrinsic T cell function, as there could be
redundancy within the Type I IFN-induced responses. Thus, there could be other
mechanisms by which the T cells are still able to get activated even if it is to a lesser
extent. This needs to be further investigated. On the contrary, in the case of the LCMV
model, ISG15 clearly had an effect on augmenting CD8 T cells when delivered as an
immunoadjuvant. This suggested that CD8 T cells, on the other hand, could respond to
soluble ISG15. We find this in accordance with previous data demonstrating that free
soluble ISG15 can induce lymphocytes to induce IFNγ responses (16,17). However,
evidence is still lacking as to whether ISG15 binds a receptor to mediate these
immunomodulatory CD8 T cell effects or if intracellular uptake and conjugation is
required. Further work is required to elucidate the mechanism of action between
secreted vs. non-secreted ISG15. We are currently investigating this approach.
Alternatively, our results provide strong evidence that ISG15 may facilitate or orchestrate
the adaptive responses through enhanced dendritic cell maturation (Figure 6.2). One
possible hypothesis is that ISG15 is acting as a DAMP much like HMGB1 that binds a
pattern-recognition receptor (PRR) to induce inflammation (59,60). A previous study by
Padovan, et al. in 2002 suggested a similar DC stimulatory property for ISG15 secreted
from melanoma cells (54). More recently, ISG15 was found to synergize with IL-12 to
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enhance activation of Mtb-specific T cell responses (16). The summation of this
evidence suggests that ISG15 is a powerful immunoadjuvant for CTL-mediated
immunotherapy.

Therefore, further studies are warranted to determine the possibly

broad applicability of ISG15 as an immunoadjuvant for other diseases and to explore the
relevance of ISG15 conjugation and secretion in this novel role.
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CHAPTER 7
DISCUSSION, IMPLICATIONS, AND FUTURE STUDIES

“The reward for work well done is the opportunity to do more.”
– Jonas Salk
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Vaccines represent one of the greatest medical interventions against diseases.
However, there is still a great need for effective vaccines against cancers and many
chronic infectious such as HIV, tuberculosis and malaria. For these pathogens, it is
known that CD4 T helper 1 (TH1) and CD8 T cell-mediated immunity is critical in
preventing or controlling the onset of disease (1). These challenging diseases have
shifted vaccine focus in generating T cell-mediated immune responses and adjuvants
that specifically drive this preferred effects (1). Adjuvants are critical components of most
clinical vaccines which are used to shape the quantity and quality of immune responses.
Currently available U.S. Food and Drug Administration (FDA)–licensed adjuvants are
poor inducers of TH1 and even worse at treating CD8 T-cell responses (2,3). Therefore,
it is important to identify a new generation of potent vaccine adjuvant(s) that can induce
potent and durable T cell immunity.
Different vaccine platforms have been studied, but the development of DNAbased vaccines in conjunction with molecular adjuvants has emerged as particularly
promising for enhancing effective T cell induced viral and tumor immunity (4). It is
becoming increasingly well recognized that the administration of immunostimulatory
molecules, such as cytokines or cytokine-like molecules, to modulate immune responses
has great potential in medicine (4,5). Thus, by harnessing the power of our own immune
system, cytokines are promising vaccine adjuvants for enhancing the immune responses
against an array of infectious diseases. Several studies into the biology of IL-33 and
ISG15 suggest that they might serve as effective vaccine adjuvants (6,7). In this thesis,
we show for the first time the efficacy of both IL-33 and ISG15 as DNA vaccine
adjuvants in varies models of infection. We show new insight into the biological
properties of both IL-33 and ISG15, and highlight their potential as new promising
adjuvants at improving the magnitude and function of effector CD8 T cell responses.
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Therefore, both IL-33 and ISG15 are new players in the immunoadjuvant arena, with the
potential to improve effectiveness of future immunotherapies for cancer and chronic
diseases. Collectively, our results provide strong evidence for their future role as potent
novel adjuvants in vaccines designed to boost CD8 T cell immunity

IL-33 as a Vaccine Adjuvant
IL-33, a member of the IL-1 cytokine family is released by necrotic cells or by
activated innate immune cells during tissue damage or infection (6,8). It is considered to
serve as the first line of defense against pathogens, in other words, to serve as an
alarmin, by providing an endogenous danger signal that triggers inflammation and
promotes cell-mediated immune response. For many years IL-33 has been studied in
the context of T helper type 2 (TH2)-driven inflammatory disorders (9). Interestingly, IL-33
has now emerged as a cytokine with a plethora of pleiotropic properties. Depending on
the immune cells targeted by IL-33, it is reported to not only promote TH2 immunity, but
evidence has begun to unveil IL-33’s unappreciated role to induce both TH1 and CD8 T
cell–mediated immunity (6,10). Therefore, in this study we investigated the potential role
of IL-33 to act as an immunoadjuvant to elicit effective CD8 T cell-mediated tumor and
viral immunity.
Herein, we first demonstrate that both biologically active forms of IL-33, fulllength (proIL-33) and mature IL-33 (mtrIL-33) when combined with a HPV16 E6/E7
encoded DNA vaccine, enhanced the Ag-specific effector memory CD8 T cell immune
responses. Their adjuvant activities skewed toward the TH1 axis, and not to the TH2 axis.
We reported that both isoforms drove IFNγ responses, but neither form drove high
secretion of IL-4 or any elevation of IgE levels as previously reported (11,12). Finally,
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both proIL-33 and mtrIL-33 adjuvants induced potent anti-tumor CD8 T cell immunity
which facilitated successful tumor regression of established TC-1 tumor-bearing mice.
Given these significant findings that IL-33 can augment bonafide Ag-specific CD8
protective tumor immunity, we expanded the scope of these studies to access its
efficacy in a LCMV viral challenge model. The LCMV model is known to require CD8 T
cell responses for protective immunity (13-18). For these studies I utilized mtrIL-33,
instead of proIL-33, given proIL-33 alternative action as a nuclear transcription factor
which still needs to be further elucidated (6,8,9). Thus, I only focused on IL-33’s cytokine
activity and noted that mtrIL-33 delivered as an adjuvant significantly enhanced the
LCMV-specific antiviral immunity and provided complete or significant protection against
a high-dose lethal LCMV intracranial challenge. Collectively, these studies validated IL33’s role as a potent vaccine adjuvant for future T cell vaccine studies.
The specific role in the protective responses against HPV-associated cancers
and LCMV infection have been attributed to CD8+ T cell immune responses, and
therefore, are the focus for achieving effective immunity against such diseases (13-21).
Our results showed that the cytokine secreting T cell responses induced by proIL-33 and
mtrIL-33 were mainly mediated by polyfunctional Ag-specific CD8 T populations
secreting IFNγ+TNFα+IL-2+, IFNγ+TNFα+ and IFNγ+, while a large proportion of CD8 T
cells having a cytolytic phenotype. Although we found this data in accordance with
Bonilla et al. demonstrating that IL-33 can drive plurifunctional CD8 T cell responses in a
viral infection model (10), we further demonstrated that the delivery of IL-33 isoforms as
immunoadjuvants can indeed enhance plurifunctional CD8 T cell responses, further
expanding the pool of information we now know about IL-33. In addition, we reported
that both IL-33 isoforms could significantly amplify and increase the magnitude of
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tetramer-specific effector CD8 T cell responses in the periphery in a vaccine setting,
which correlated with superior viral protection and tumor regression (Chapters 2 & 3).
The reasons behind the role of IL-33 to expand the frequency of CD8 T cells are not yet
entirely clear (10,22,23). Recently, Luzina et al. demonstrated in a vaccine delivery
approach that mtrIL-33’s effect is ST2-dependent (11). Moreover, substantial research
has shown (i) that activated CD8 T cells can express ST2 receptor and (ii) that ST2 is
important for IL-33 action, as mice deficient in ST2 are entirely unresponsive to IL-33
(24). Therefore, the ability of ST2+CD8 T cells to respond to immunoadjuvant proIL-33
and mtrIL-33 is a possible explanation for the vaccine-induced augmentation (10,22). On
the other hand, although one might assume that proIL-33 should induce similar effects to
mtrIL-33 because they bind to the same ST2 receptor, Luzina et al. also reported that
they have differences in their specific activities. Luzina et al. demonstrated that proIL-33
promotes inflammation differently from mtrIL-33 in an ST2-independent fashion (11).
Additional studies that involve IL-33 receptor knockout mice will help confirm whether
our proIL-33 TH1 adjuvant properties are dependent or independent of ST2 receptor. We
are currently pursuing these studies. These data demonstrate the overall superiority of
immunoadjuvant IL-33 in enhancing the Ag-specific CD8+ T cells in a DNA vaccine
setting.
Another mechanism behind IL-33’s potential to drive the formation and
differentiation of effector memory CD8+ T cells is likely due to its ability to significantly
increase T-bet expression in CD8+ T cells in vivo (Chapters 2 & 3). Joshi and colleagues
have shown that overexpression of T-bet is enough to induce the formation of KLRG1+
effector cells and that CD8+ T cells lacking T-bet are impaired in forming these cytolytic
effector cells (25). Therefore, my data presented in this thesis supports the notion that
an increase in T-bet is associated with effector CD8+ T cell differentiation and their ability
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to have CTL phenotype. This finding also supports previous data showing by Yang et al.
demonstrating that CD8 T cells treated with IL-33 in the presence of IL-12 result in T-betdependent expression of ST2 in vivo (22). Furthermore, it is also possible that our
selected vaccine antigens, which are potent TH1 antigens, may have facilitated the
induction of TH1 cytokines IL-12 and IFNγ secretion by APCs. Therefore, this induced
favored TH1 cytokine milieu perpetuated by our selected antigen may have induced a
favorable immune environment that allowed IL-33 to foster a greater TH1 cell-mediated
immune response. Further studies are needed to understand exactly how IL-33 induces
TH1 IFNγ responses in the context of an in vivo immune setting.
Overall, my studies conclude that IL-33 can act as an immunoadjuvant to
increase the potency of DNA vaccines. We established that some of the preclinical
beneficial effects of IL-33 as an adjuvant are: (i) IL-33 can increase the seroconversion
rate; (ii) facilitate the use of smaller doses of antigen to induce protective immunity; (iii)
reduce the number of doses required to achieve protection; (iv) provide an appropriate
desired immune response (TH1 and CD8 T cells); (v) increase the generation of effector
memory T cells; and (vi) increase the speed of initial response. In the future, we hope to
determine if IL-33 can also improve weak immune responses, where it will be beneficial
for the elderly or immunocompromised individuals. Taken together, the improved
efficacy of our DNA vaccines offered by IL-33 in this thesis highlights its potential utility
as a future vaccine adjuvant in the treatment of a variety of chronic diseases, including in
the context of cancer vaccine therapies.
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IL-33: TH2 vs TH1 Route of Immunization
Although IL-33 originally has been associated with TH2 immunity, our IL-33
studies report that IL-33 delivered as a vaccine adjuvant could modulate immune
responses toward a TH1/CD8+ T cell response. Under different conditions it appears that
IL-33 can have different functions either associated in driving TH2- or TH1-immune
responses when delivered in vivo (10,11,26,27). How one method elicits TH2 responses
and another TH1 response is unclear. The reasons for the differences may be attributed
to variations in the routes of immunization in which the surrounding microenvironment
(targeting cells and cytokine network) potentiate different outcomes. For instance,
delivery into the mucosal sites which is normally rich with TH2-driven cells (T regulatory
cells, mast cells, basophils, eosinophils and innate lymphoid cells) may favor a TH2
response, while it is likely that residential and local immune cells in the muscle may favor
a TH1 response during DNA vaccination. However, the key cell types in the muscle site
that could be expressing ST2 and responsible for mediating the vaccine-induced
responses have not been investigated. Furthermore, the TH1-driven nature of the
adjuvant properties could have also been perpetuated because of the selected vaccine
target antigen activating APCs to trigger IL-12, which will support IL-33’s IFNγ-inducing
activity (22), and without it, a TH1 response will dominate. Therefore, further testing is
needed to determine if IL-33 is dependent on IL-12 to favor a TH1 response in vivo.
Overall, this supports the theory that the immunomodulatory functions of IL-33 might
actually be more complex than initially assumed. Therefore, the route of delivery should
be carefully studied to maximize the desired T cell phenotype in a particular immune
setting to better target a particular disease
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IL-33 Isoforms as Future Vaccine Adjuvants
Along with all the different established cytokines, there has recently been an
appreciation for alternative splicing or processing of cytokine genes (eg. IL-1, IL-2, IL-7,
IL-18), which result in multiple cytokine isoforms with different functional activities (28).
Cytokine isoforms can provide additional diversity to their complex biological effects that
participate in control and protection against different foreign pathogens. Indeed, IL-33
has emerged as a cytokine containing several different isoforms that can play a role in
facilitating protective immunity (11,27-31). Tsuda et al. demonstrated the existence of
multiple splice variants of IL-33 dependent on the cell type expressing IL-33 (30).
Furthermore, Lefrancais et al. reported that neutrophil-specific proteases in neutrophils
could cleave full-length human IL-33 to generate several mature processed variants with
enhanced biological activity (tenfold) compared with proIL-33 (28). They also
demonstrated that murine IL-33 can be similarly cleaved by these same neutrophil
proteases (cathepsin G and elastase), generating two isoforms of mtrIL-33 (28). In our
studies, in chapter 3, two bands of IL-33 were detected after transfection with proIL-33 in
human rhabdomyosarcoma cells (27). Therefore, the observed humoral responses
elicited by our proIL-33 adjuvant, may not have been driven solely by proIL-33, but also
by either spliced variants of proIL-33 or processed forms of proIL-33 (aka mtrIL-33), as
processing of the adjuvant did occur in vitro. These alternatively spliced or processed IL33 cytokine isoforms represent attractive candidates for further study as possible
vaccine adjuvants or immune modulating therapeutics. For future studies we plan to
compare the immune modulation induced by these different identified isoforms of proIL33 (splice variants) and mtrIL-33 (processed forms). This will provide insight into their
potential to be properly utilized for different vaccination systems. Thus, fully
understanding the IL-33 signaling system, especially its cytokine contributions as a
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nuclear modulator versus extracellular molecule, will open new chapters on how to
harness the power of all IL-33 isoforms in future vaccines and cancer therapies. The
accessibility and continued study of both ST2 and IL-33 knockout mice will help enhance
our understanding of IL-33’s ability to influence adoptive immunity and its power to
protect against disease.

ISG15 as a Vaccine Adjuvant
Given our success with IL-33 as vaccine molecular adjuvant to induce potent T
cell immunity, we decided to continue this successful approach to identify additional
adjuvants capable of amplifying CD8 T cell antitumor and antiviral immunity. I therefore,
employed a DNA vaccination approach to investigate the inclusion of ISG15 to also
enhance Ag-specific CD8 T cell responses.
ISG15 is an ubiquitin-like protein induced by type I interferon and is associated
with antiviral activity (32). For decades, free ISG15 has been implicated in the production
of IFNγ, thus functioning as an immunomodulatory molecule (33-35). More recently, a
study by Casanova and colleagues confirmed this cytokine-like role for ISG15 by
demonstrating that ISG15-deficiency was associated with a loss of IFNγ, which in turn
led to increased susceptibility to mycobacterial disease in both mice and humans (36).
However, ISG15’s role to influence CD8 T cell responses and act as a vaccine adjuvant
has not yet been explored. In this study, we showed for the first time the efficacy of
ISG15 as a molecular adjuvant to augment Ag-specific CD8 T cell viral and tumor
immunity. We used the well-established preclinical LCMV intracranial and HPVassociated therapeutic challenge models to test the adjuvant effects of ISG15 in a DNA
vaccine setting. The main results of this study are that inclusion of ISG15 can (i)
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increase the polyfunctional Ag-specific CTL responses secreting IFNγ+TNFα+IL-2+; (ii)
induce effector-like memory CD8 T cell differentiation; (iii) have antitumor therapeutic
effects; (iv) induce significant LCMV protective immunity; (v) elicit vaccine-induced
protective immunity independent of conjugation, further establishing free ISG15 perhaps
functions as a cytokine; (vi) increase the magnitude and phenotype of tetramer-specific
CD8 T cell responses, which correlated with tumor regression; and finally that (vii) CD8
T cell depletion and adoptive transfer experiments revealed that ISG15 protective
efficacy was CD8 T cell-mediated. Collectively, my work provides more insight into the
immunomodulatory properties of ISG15 and its potential to serve as an effective CD8 T
cell vaccine adjuvant in a therapeutic tumor or infectious setting.
The reasons behind ISG15 ability to enhance the frequency of Ag-specific CD8 T
cell responses are unknown. However, a recent study by Casanova and colleagues
have shown that ISG15 may work in synergy with IL-12, suggesting that ISG15 likely
promoted enhanced CD8 T cells synergistically with IL-12 (36). In addition, the ability of
ISG15 to induce IFNγ secretion by lymphocytes, may also suggest that ISG15 might bind
to a cell surface receptor to modulate immune responses (32). The identity of a cell
surface receptor for ISG15 has yet to be discovered. Nevertheless, the actions of
extracellular ISG15 have been most clearly tied to the induction of IFNγ secretion by
lymphocytes (31-35). Our findings in Chapter 6, demonstrated that susceptibility to acute
LM infection in ISG15-/- mice correlated with the significantly reduced expression of IFNγ
responses both in the spleen and in the blood. Although ISG15 deficient mice seemed to
have limited impact of T cell responses to LM overtime, we did see that delivery of
ISG15 as an adjuvant augmented LCMV-specific CD8 T cell protective immunity. We
find this in accordance with previous data demonstrating that free soluble ISG15 can
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induce lymphocytes to induce IFNγ responses (31-35). An explanation for this
discrepancy could be that endogenous ISG15 is not essential for intrinsic T cell function,
as there could be redundancy within the Type I IFN-induced responses. Therefore, by
other unknown mechanisms the T cells are still able to get activated even if it is to a
lesser extent. Alternatively, by using ISG15 deficient mice, our results provided evidence
that ISG15 may facilitate or orchestrate the adaptive responses through enhanced
dendritic cell maturation. Therefore, ISG15 may not only modulate T cells directly as a
“cytokine-like” molecule, but may also foster cell-mediated adaptive immune response
by augmenting APC functions. Further studies will be needed to elucidate the
mechanism(s) underlying the adjuvant effects of ISG15. The evidence that ISG15 can be
an effective adjuvant to drive potent CD8 T cell responses, support future studies to test
its application in other infection models that require T cell immunity.
A major highlight of our study in Chapter 5 was demonstrating that ISG15
delivered as an immunoadjuvant generates responses independent of conjugation as an
LRLRGG-mutant ISG15 also induced potent CD8 T cell responses. This suggested that
the protection afforded by ISG15 was most likely not dependent on its conjugated form,
but rather on free ISG15. However, we cannot exclude the functional properties of
intracellular free ISG15 or conjugated ISG15 as it has been shown to also be biologically
functional (32,37). We are currently pursuing their different association with modulating
immunogenicity. Overall, the ability of free ISG15 (mutISG15) to induce superior
antitumor responses (Chapter 5) highlights its potential to serve as an alternative potent
ISG15 adjuvant. In addition, it emphasizes that developing new ways to increase the
levels of free ISG15 may be a novel approach to treat cancer and other infectious
diseases.
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Free ISG15
To date, there are two mechanisms of action by which ISG15 contributes to the
host response to infection: (i) conjugation dependent actions of ISG15 and (ii) the
biological properties of ISG15 that are mediated by free ISG15. In this thesis, we
demonstrate that the protection afforded by ISG15 can be independent on its conjugated
form, free ISG15, supporting the notion that ISG15 perhaps functions as a cytokine.
However, while this study provides the first in vivo evidence that free ISG15 delivered as
an adjuvant contributes to host response during a tumor therapeutic or viral challenge
model, it does not distinguish between the actions of extracellular and intracellular free
ISG15. Therefore, further testing is needed to distinguish between the activity of
intracellular and extracellular free ISG15. The identification of an ISG15 receptor(s) and
in vivo blocking antibodies for ISG15 would be essential tools in defining whether the
protection mediated by ISG15 in any infectious or tumor model is through the action of
extracellular free ISG15. The availability of recombinant mouse ISG15 would also be a
valuable tool to further establish a proof of concept. Overall, fully understanding the
biological function of free ISG15 would allow us to fully harness its power to treat a
variety of infectious diseases and cancers.

197

IL-33’s and ISG15’s Role on CD8 T Cell Memory Subsets
The establishment of immunological memory means that the immune system is
able to respond with greater strength upon re-encounter with a same pathogen and is
the basis for effective vaccination (38). The CD8 memory T cell population is
heterogeneous, but perhaps the best characterized CD8 memory T cell subsets is the
paradigm of central and effector memory cells (39-42). Central memory T (Tcm) cells
localize to the lymphoid tissues and are capable of robust recall proliferation, whereas
effector-memory T (Tem) cells, are predominately located in the peripheral sites and can
quickly become cytolytic, but with limited proliferative capacity. There is still a
controversy about which subset of memory CD8 T cells are most optimal for protective
immunity. However, from a therapeutic point of view, the goal of successful vaccination
might best be the induction of effector-like memory CD8 T cells to rapidly control
infection and/or tumor growth. Recently, reports have begun to show that the effectormemory KLRG1+CD8+ T cell population can mediate potent protective immunity against
certain pathogens (43-45) and might be optimal for immediate regression of established
subcutaneous (s.c.) tumors (46). Our results showed that mice immunized with IL-33
and/or ISG15 induced robust expansion of Ag-specific effector memory CD8 T cells in
the periphery, suggesting trafficking of activated CD8 T cells to the site of Ag stimulation.
The high frequency of Ag-specific effector-memory cells in the periphery is consistent
with the observation that effector-memory T cells can migrate to the site of infection and
initiate immediate effector function (39). Our findings support the concept that vaccineinduced effector-memory CD8 T cell responses might be important memory CD8 T cell
subsets for an effective therapeutic vaccine against tumors and other chronic infections
(46). Furthermore, the quantity and quality of the effector memory T cells amplified by
both our molecular adjuvants (IL-33 and ISG15) seemed to correlate with their efficacy in
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the tumor or viral challenge models. Therefore, these potential correlates of immunity
may suggest a different focus for vaccination strategies.
We are currently investigating the ability of IL-33 and ISG15 to generate Tcm
immunity, since Tcm cells are important subsets that also mediate optimal protective
immunity against pathogens and constitute the basis for vaccination (39-42,47,48).
However, given that Murali-krishna et al. have reported that the initial magnitude (burst
size or peak) of the CD8 effector T cell responses correlates to the long-term memory
responses, suggest that IL-33 and ISG15 most likely can induce long-term immunity
(49). Moreover, because preventative vaccines should induce long-lasting Ag-specific
responses, we are further investigating the efficacy of these immunostimulatory
adjuvants in the context of prophylactic vaccines and its establishment of long-lasting
memory responses. Overall, understanding the mechanism of action by which either
both IL-33 and/or ISG15 influences the expansion, or development of heterogeneous
CD8 T cell populations in vaccines is an important area for further investigation.

IL-33’s and ISG15’s Role on the Humoral Responses
Antibodies are an important part of the host immune system to identify and
neutralize infectious agents and have been the correlate of immunity for all currently
successful licensed vaccines. Although CD8 T cells responses were important in our IL33 study, we also examined the effects of IL-33 on B cell responses. The major
significant difference between proIL-33 and mtrIL-33 was that proIL-33 was able to
increase the HPV E7-antigen specific IgG binding levels. Full length IL-33’s dual function
property, to act not only as a cytokine, but also as a nuclear transcription factor, may
explain the increase in antibody responses by proIL-33. Its nuclear localization may have
effects on modulating the humoral immune responses. Thus, the specific transcriptional
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targets of nuclear IL-33 are still unknown and must be further investigated. Another
possibility for this outcome could have been due to the ability of proIL-33 to modulate the
immune responses independent of its cognate ST2 receptor (11). We are currently
pursuing understanding full-lengths association with modulating immunogenicity using
ST2 knockout mice. Moreover, just recently published, Zhao et al. demonstrated that IL33 promoted humoral responses to HBV during the pathogenic progress (48). They
reported that IL-33 activated humoral immunity against HBV in vivo and in vitro by
activating T follicular helper cells. This recent report confirms our findings that IL-33 can
modulate humoral immune responses. Although the importance of our findings are not
yet clear, these data suggests that IL-33 could also be useful in vaccine strategies
aiming to achieve enhanced antibody responses and cellular immunity. In regards to
ISG15, to the best of our knowledge, ISG15’s role on the effect of antibody responses
has never been examined and is an area of further investigation. In the future, in parallel
with IL-33, we hope to study their immunoadjuvant properties on humoral responses
using an influenza challenge model, a model which antibodies are known to be essential
for protection.

IL-33’s and ISG15’s Effects Other Immune Cells (DCs, NK and CD4 T Cells)
It is well known that antigen presented by activated DCs and the type of
production of polarizing cytokines they secrete can promote different fates on T cell
development (50). First, we demonstrated that IL-33 could induce DC maturation by
assessing the up-regulation of certain surface expression markers and their induction of
proinflammatory cytokines, all of which may influence adaptive immunity. Mouse bone
marrow derived dendritic cells (BMDCs) in vitro incubated with recombinant IL-33 upregulated the DC maturation markers, CD80, CD86 and CD83 and secreted pro200

inflammatory TH1 cytokines. The ability of IL-33 to induce phenotypic maturation of DCs
in vitro, may explain IL-33’s functional role on the impact of CD8 T cells observed in our
study, recruiting the right type of immune cell infiltration necessary to facilitate both
effective viral and tumor immunity. Regarding ISG15’s effects on DC maturation, we
observed that in ISG15-/- mice, their DCs were impaired and unable to undergo DC
maturation, suggesting a possible role for ISG15 in T cell activation and memory
formation. Therefore, we are currently investigating both IL-33 and ISG15 roles on DC
maturation and function during vaccination in vivo.
Considering that CD4 T cells play an important role in facilitating an effective
adaptive immune response, by helping the activity of other immune cells (e.g. B cell
antibody class switching, maximizing bactericidal and cytotoxic T cell activity) by
releasing cytokines, we evaluated if our adjuvants can augment CD4 TH1 cell responses.
While ISG15 did not enhance Ag-specific CD4 T cells responses, IL-33, however did
significantly increase the TH1 CD4 T cell responses against HPV, HIV, and TB (Chapters
2,3,4). Although for years it was assumed that IL-33 mainly played a role in CD4 TH2
immunity (given the early findings of the selective expression of ST2 by TH2 but not Th1
cells) (6), our results intimated that mtrIL-33 in vivo might directly enhance TH1 CD4 T
cell responses. IL-33 as a DNA adjuvant can broadly expand T cell responses. An
explanation for this could most likely be that only activated TH1 CD4 T cells can express
ST2 receptor, and in synergy with IL-12, local IL-33 will significantly augment a TH1
response (22). This aspect requires further study. Taken together, our data shows that
IL-33 can be both an effective CD4 and CD8 T cell vaccine adjuvant, while ISG15 seems
to only enhance CD8 T cell-mediated responses. Nevertheless, it still needs to be
completely determined whether ISG15 can modulate CD4 T cell responses, given that
the models I used are mainly CD8 T cell-mediated. We plan to test ISG15 CD4 T effects
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using other pathogen targets such as TB, where CD4 TH1 responses are known to be
critical for protective immunity. Although CD4 T cell help is not crucial for CD8 T cell
priming, it is believed to be essential in the expansion of secondary responses of
memory CD8 T cells (39,51,52). Thus, we are currently determining if IL-33 or ISG15
can induce effective CD8 T cell responses independent of CD4 responses during the
course of homologous prime-boost vaccination.
Finally, it is likely that other immune cells may have accounted for the observed
enhancement in TH1 immunity. For instance, both IL-33 and ISG15 have been shown to
activate Natural Killer (NK) cells to secrete IFNγ (8,23). Nevertheless, further studies will
be needed to elucidate under what conditions both IL-33 and ISG15 promotes TH1 and
CD8 T cell immunity; to determine their regulatory networks bridging the innate with the
adaptive immune responses.

IL-33’s and ISG15’s Application for Other Disease Targets and Cancer
Given these significant findings, we went on to observe in a preclinical setting,
that IL-33 would also increase the Ag-specific CD4 and CD8 T cell responses when codelivered with a DNA vaccine encoding either a HIV, flu, malaria or TB target antigens
(Chapters 2,3,4 and unpublished data). We are currently examining the efficacy of IL-33
in a malaria, influenza, and TB challenge models. On the other hand, we reported that
ISG15-/- mice are highly susceptible to infection with the model pathogen, Listeria
monocytogenes (LM), and display significantly reduced production of IFNγ. Therefore,
with the recent finding observed by Bogunovic et al, that individuals with mutations in
Isg15 are more susceptible to infection by the intracellular bacterium Mycobacterium
tuberculosis (Mtb) (36), we are next evaluating ISG15’s application in a TB-infection
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model. Overall, these findings significantly highlight the important role for both IL-33 and
ISG15 as effective adjuvants to be incorporated into future vaccines targeting an array of
microbial infections.
The important roles IL-33 and ISG15 may play in cancer is only beginning to
surface. For instance, three recent studies have highlighted the important role of IL-33 in
human cancer and tumor mouse models (Lung, melanoma, cervical, breast and
carcinoma) and have shown that IL-33 can drive antitumor CD8 T cell responses (27,5358). For ISG15, its role in protective tumor immunity has only begun to be appreciated
(57). In accordance with our data, Burks et al just recently demonstrated that free ISG15
could induce an antitumor immune response in vivo and in vitro against breast cancer
(58). They reported that extracellular free ISG15 suppresses breast tumor growth and
increased NK cell infiltration into xenografted breast tumors in nude mice. Clearly, my
studies provided stronger evidence for IL-33’s and ISG15’s beneficial role in tumor
immunity and their utility to be used as cancer immunotherapies. My studies showed that
a HPV DNA vaccine plus our adjuvant combinations (IL-33 and/or ISG15) induced great
control or complete tumor regression in a therapeutic HPV-associated murine tumor
challenge model. More studies using ISG15-/-, UBE1L-/-, ST2-/- and IL-33-/- mice will
help further elucidate the significant roles ISG15 and IL-33 play in the host antitumor
responses. Given the recent studies (as mentioned above) showing that IL-33 and
ISG15 as immunoadjuvants can augment Ag-specific TH1 and CD8 T cell immune
responses, its role in enhancing tumor surveillance and antitumor immunity is worth
continued investigation. In the future, we plan to study both IL-33’s and ISG15’s specific
role in the tumor microenvironment and surveillance process.
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Similarities and Differences Between IL-33 and ISG15 Adjuvant Properties
Both IL-33 and ISG15 delivered as vaccine adjuvants enhanced potent Agspecific polyfunctional CD8 T cell tumor and viral immunity. Both adjuvants induced high
frequencies of effector CD8 T cells responses compared to the non-treated adjuvant
DNA vaccine groups. In contrast to IL-33, ISG15 did not significantly enhance the CD4 T
cell responses. Therefore, IL-33 is capable of augmenting broader T cell responses.
However, given ISG15’s ability to modulate the adaptive responses (increasing vaccineinduced IFNγ responses), suggests that ISG15 can potentially function like a cytokine
similar to IL-33. In addition, besides their effects on CD8 T cells, our results may
propose that the adjuvants effects of IL-33 and ISG15 may also be through DC
activation and maturation. Further studies are warranted to determine how IL-33 and
ISG15 orchestrate the adaptive responses through enhanced DC maturation. Overall, I
have provided evidence of their potential relevance for the design of future T-cell based
vaccines against cancers and infections requiring such desired responses. Since both
IL-33 and ISG15 adjuvants can affect the immune responses in different ways, such as
eliciting a broad range of immunological responses (humoral vs. cellular immunity or
both), it is important to choose a candidate adjuvant for future specific vaccine
formulations. The results of the similarities and differences between IL-33 and ISG15 are
summarized in Table 7.1.
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Combination of Adjuvants
Adjuvants are critical components of many vaccines and will continue to be
essential components for the development of future vaccines for the treatment of
infectious diseases and cancers. However, deciding how to select to the best vaccine
adjuvant for enhancing protective immunity will depend on the disease in question.
Consequently, no single adjuvant is capable of stimulating broad and robust protective
immune responses required to fight chronic infectious diseases and cancers. Therefore,
it is believe that a future design of vaccines will focus on incorporating multiple adjuvants
as a way to enhance multiple immunological parameters and improve vaccine efficacy.
Recent studies have shown that using multiple adjuvants in combination can
synergistically enhance or improve the immune responses to vaccines. For example, the
combination of toll-like receptor agonists can enhance DC function, the induction of CD8
T cell responses, and antibody responses (59,60). The literature has even shown
evidence of combination adjuvants containing cytokines like IL-12, IL-2 and GM-CSF
increasing specific CTL and IFNγ-secreting T cell responses (4,59-61). Therefore, with
this knowledge, in the future, we hope to coadminister IL-33 and ISG15 in combination
or simultaneously in a vaccine setting. We also plan to compare their efficacy individually
or in combination to other TH1 inducing cytokines, such as IL-12 and IL-18. In addition,
we plan to test both IL-33 and ISG15 in combination with other licensed adjuvants (alum,
ASO4, or MF59) as a goal to enhance effective antibody and cellular responses required
to induce protective immunity in each particular disease.
Although the combination of adjuvants may be the way forward in vaccine design
to elicit robust and broad protective immune responses, such an approach might not be
enough to treat cancer or chronically infected patients, where overcoming the well205

established immunosuppressive environment can be challenging. Therefore, an
alternative, will be to administer vaccines in combination with other therapeutic
interventions (e.g. immunotherapy), such as monoclonal antibody immune checkpoint
inhibitors (e.g. PD1, PDL1, LAG-3, and/or TIM-3). Identifying the appropriate
combination of adjuvants (double combination therapy) plus therapeutic treatments
(triple combination therapy) may offer tremendous opportunities for improving the
efficacy of future vaccines to treat against complex chronic diseases and cancer.

Clinical Application
It may be an investing effort into harnessing the power of IL-33 and ISG15 in the
clinical setting. For instance, a recent study examining the expression of IL-33 in cervical
tissue of patients with different stages of HPV cervical disease showed that lower levels
of IL-33 in cervical tissue were associated with more severe stages of HPV-induced
dysplastic change (55). Furthermore, an important study by Casanova and colleagues,
have shown that humans lacking ISG15 develop mycobacterial diseases (35).
Therefore, it is conceivable to suggest that delivery of IL-33 or ISG15, like other
cytokines IL-2 or IFNγ, could be used to help fight viral and bacterial infections, as well
as cancer in the general population. However, this hypothesis remains to be tested. In
order to move these adjuvants into clinical studies, their immunogenicity and efficacy
must be tested in other animal models. In the future, we to hope to immunize non-human
primates with our adjuvants along with selected target antigens (e.g. HPV or HIV) study
to determine immunogenicity.
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Closing Remarks
In this thesis, I exclusively show for the first time that IL-33 and ISG15 can be
promising molecular adjuvants at improving CD8 T cell immunity in a vaccine setting.
The exciting evidence that IL-33 and ISG15 can induce protective immunity in both
infectious and cancer models, supports their development as immunoadjuvant
candidates for enhancing the potency of both prophylactic and therapeutic DNA
vaccines (Figure 7.1). This knowledge opens new avenues for harnessing the power of
IL-33 and ISG15 as immunostimulatory adjuvants for future novel vaccines against
diseases that require TH1/CD8 T cell protective immunity such as TB, malaria, HIV, and
even cancers. In the end, although the immune system may never win the war against
disease, but with effective adjuvants like IL-33 and ISG15, it might just avoid some
mortal battles.
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FIGURES
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Figure 7.1. The potential biological mechanisms of the adjuvant properties of IL-33 and ISG15 on immune cells to
induce viral, bacterial, and tumor immunity. These observed effects are determined by the specific cells targeted and
the associated cytokine network. (a) IL-33 as a cytokine has dual-function: acting as a cytokine and localizing in the
nucleus which functions are unclear. The administration of both full-length IL-33 (proIL-33) and mature IL-33 (mtrIL-33)
can have cellular activities on NK/NKT, CD4 and effector CD8 T cells which produce Th1-associated protective immunity.
Also potentially accompanying, APCs produce and secrete IL-12, which then induces expression of ST2 on NK/NKT cells
and CD8+ T cells, permitting IL-33 to induce Th1-associated cytokine production. It is unclear whether Th1 CD4+ T cells
are able to upregulate ST2, however, IFNγ production by other activated immune cells likely leads to their amplification
which then can help activate antiviral and tumoricidal immunity. Interestingly, recent evidence hints at a new activity for
proIL-33 to activate cells independent of the ST2 receptor. Does proIL-33 bind to another unknown receptor? Or is proIL33 taken up by cells by apoptotic bodies caused from necrotic cells, which in turn, allows proIL-33 to migrate into the
nucleus of the new cell and facilitating an immune response? These mechanisms are unknown. Moreover, data has
demonstrated that proIL-33 can elicit antigen-specific antibodies, yet its role in protection against infectious pathogens
remains to be determined. (b) Type I IFNs stimulates the production of ISG15 usually after infection or by tissue damage.
Normally, ISG15 conjugates to target proteins by a method known as ISGylation to control viral infection. However, ISG15
can also exist into other forms: free intracellular ISG15 and free extracellular ISG15 which are depicted here. Little is still
known about the properties of conjugated ISG15 form, but even less is known about the free forms of ISG15.
Interestingly, recent evidence (along with what is presented in this thesis) highlights that free extracellular ISG15 may
potentially act as a cytokine and induce Th1 immune responses. Free soluble ISG15 has now been described as having
cellular activities (adjuvant properties) on NK cells and CD8 T cells. ISG15’s immunological properties suggest it might
have a receptor, however, no ISG15 receptor has been discovered. It is believe that in synergy with IL-12, ISG15 can
further augment Th1 immunity. It is unclear if ISG15 works as a DAMP-associated molecule (increasing DC function or
maturation) or if it is engulfed by the cells through unknown process to modulate adaptive immune responses. It is known
that free intracellular ISG15 has immunomodulatory properties, but the molecular mechanisms behind it are still unknown.
Notes: DAMP, damaged-associated molecular pattern molecule; NK, natural killer cells; INF, interferon; Alt, alternative;
Rc, receptor; Teff, effector memory CD8 T cells; Tfh, CD4 T follicular helper cells
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